
<html lang="en"     class="pb-page"  data-request-id="bd7d9db7-813e-46f5-94e9-649a7f09afd0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-1;article:article:10.1021/acs.jmedchem.5b01498;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent" /></meta><meta name="dc.Creator" content="Bing  Wang" /></meta><meta name="dc.Creator" content="Daniel  Chu" /></meta><meta name="dc.Creator" content="Ying  Feng" /></meta><meta name="dc.Creator" content="Yuqiao  Shen" /></meta><meta name="dc.Creator" content="Mika  Aoyagi-Scharber" /></meta><meta name="dc.Creator" content="Leonard E.  Post" /></meta><meta name="dc.Description" content="We discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. Lead optimization led to the identification of (8S,9R)-47 (tala..." /></meta><meta name="Description" content="We discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. Lead optimization led to the identification of (8S,9R)-47 (tala..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 23, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01498" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01498" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01498" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01498" /></link>
        
    
    

<title>Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01498" /></meta><meta property="og:title" content="Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0013.jpeg" /></meta><meta property="og:description" content="We discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. Lead optimization led to the identification of (8S,9R)-47 (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one). The novel stereospecific dual chiral-center-embedded structure of this compound has enabled extensive and unique binding interactions with PARP1/2 proteins. (8S,9R)-47 demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, respectively. It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), respectively. (8S,9R)-47 is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. (8S,9R)-47 has completed phase 1 clinical trial and is currently being studied in phase 2 and 3 clinical trials for the treatment of locally advanced and/or metastatic breast cancer with germline BRCA1/2 deleterious mutations." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01498"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01498">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01498&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01498&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01498&amp;href=/doi/10.1021/acs.jmedchem.5b01498" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 335-357</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01465" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01522" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Characterization of (8<i>S</i>,9<i>R</i>)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bing++Wang">Bing Wang</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Chu">Daniel Chu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Feng">Ying Feng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuqiao++Shen">Yuqiao Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mika++Aoyagi-Scharber">Mika Aoyagi-Scharber</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leonard+E.++Post">Leonard E. Post</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, California 94949, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 1-415-506-3319. E-mail: <a href="/cdn-cgi/l/email-protection#197b6e78777e597b746b77377a7674"><span class="__cf_email__" data-cfemail="620015030c0522000f100c4c010d0f">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01498&amp;href=/doi/10.1021%2Facs.jmedchem.5b01498" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 335–357</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 10, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 September 2015</li><li><span class="item_label"><b>Published</b> online</span>23 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01498" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01498</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D335%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBing%2BWang%252C%2BDaniel%2BChu%252C%2BYing%2BFeng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D1%26contentID%3Dacs.jmedchem.5b01498%26title%3DDiscovery%2Band%2BCharacterization%2Bof%2B%25288S%252C9R%2529-5-Fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1H-1%252C2%252C4-triazol-5-yl%2529-2%252C7%252C8%252C9-tetrahydro-3H-pyrido%255B4%252C3%252C2-de%255Dphthalazin-3-one%2B%2528BMN%2B673%252C%2BTalazoparib%2529%252C%2Ba%2BNovel%252C%2BHighly%2BPotent%252C%2Band%2BOrally%2BEfficacious%2BPoly%2528ADP-ribose%2529%2BPolymerase-1%252F2%2BInhibitor%252C%2Bas%2Ban%2BAnticancer%2BAgent%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D357%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01498"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4513</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">67</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01498" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Chu&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Yuqiao&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Mika&quot;,&quot;last_name&quot;:&quot;Aoyagi-Scharber&quot;},{&quot;first_name&quot;:&quot;Leonard&quot;,&quot;last_name&quot;:&quot;E. Post&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;335-357&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01498&quot;},&quot;abstract&quot;:&quot;We discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. Lead optimization led to the identification of (8S,9R)-47 (talazoparib; BMN 673; (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one). The novel stereospecific dual chiral-center-embedded structure of this compound has enabled extensive and unique binding interactions with PARP1/2 proteins. (8S,9R)-47 demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with Ki = 1.2 and 0.87 nM, respectively. It inhibits PARP-mediated PARylation in a whole-cell assay with an EC50 of 2.51 nM and prevents proliferation of cancer cells carrying mutant BRCA1/2, with EC50 = 0.3 nM (MX-1) and 5 nM (Capan-1), respectively. (8S,9R)-47 is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following or&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01498&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01498" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01498&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01498" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01498&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01498" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01498&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01498&amp;href=/doi/10.1021/acs.jmedchem.5b01498" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01498" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01498" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26pmid%3D26652717%26genre%3Darticle%26aulast%3DWang%26date%3D2016%26atitle%3DDiscovery%2Band%2BCharacterization%2Bof%2B%25288S%252C9R%2529-5-Fluoro-8-%25284-fluorophenyl%2529-9-%25281-methyl-1H-1%252C2%252C4-triazol-5-yl%2529-2%252C7%252C8%252C9-tetrahydro-3H-pyrido%255B4%252C3%252C2-de%255Dphthalazin-3-one%2B%2528BMN%2B673%252C%2BTalazoparib%2529%252C%2Ba%2BNovel%252C%2BHighly%2BPotent%252C%2Band%2BOrally%2BEfficacious%2BPoly%2528ADP-ribose%2529%2BPolymerase-1%252F2%2BInhibitor%252C%2Bas%2Ban%2BAnticancer%2BAgent%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D1%26spage%3D335%26epage%3D357%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/jmcmar.2016.59.issue-1/20160114/jmcmar.2016.59.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We discovered and developed a novel series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. Lead optimization led to the identification of (8<i>S</i>,9<i>R</i>)-<b>47</b> (talazoparib; BMN 673; (8<i>S</i>,9<i>R</i>)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one). The novel stereospecific dual chiral-center-embedded structure of this compound has enabled extensive and unique binding interactions with PARP1/2 proteins. (8<i>S</i>,9<i>R</i>)-<b>47</b> demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity with <i>K</i><sub>i</sub> = 1.2 and 0.87 nM, respectively. It inhibits PARP-mediated PARylation in a whole-cell assay with an EC<sub>50</sub> of 2.51 nM and prevents proliferation of cancer cells carrying mutant <i>BRCA1</i>/<i>2</i>, with EC<sub>50</sub> = 0.3 nM (MX-1) and 5 nM (Capan-1), respectively. (8<i>S</i>,9<i>R</i>)-<b>47</b> is orally available, displaying favorable pharmacokinetic (PK) properties and remarkable antitumor efficacy in the <i>BRCA1</i> mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. (8<i>S</i>,9<i>R</i>)-<b>47</b> has completed phase 1 clinical trial and is currently being studied in phase 2 and 3 clinical trials for the treatment of locally advanced and/or metastatic breast cancer with germline <i>BRCA1</i>/<i>2</i> deleterious mutations.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Poly(ADP-ribose) polymerases (PARPs) catalyze the formation of poly(ADP-ribose) (PAR), a post-translational modification that is involved in a number of important biological processes, such as surveillance of genome integrity, cell cycle progression, initiation of the DNA damage response, apoptosis, and regulation of transcription.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Among the PARP family members, PARP1 and its close relative PARP2 play essential roles in the repair of DNA single-strand breaks (SSBs).<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> PARP1 is an abundant nuclear protein that detects broken DNA strands and binds damaged DNA through its N-terminal zinc-finger domain, leading to activation of the C-terminal catalytic domain that hydrolyzes NAD<sup>+</sup> to produce PAR polymers that extend hundreds of ADP-ribose units.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> This post-translational modification, referred to as PARylation, promotes the recruitment of DNA repair proteins to the site of SSBs, allowing subsequent repair of damaged DNA via a repair pathway termed base excision repair.<a onclick="showRef(event, 'ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref6">(3, 6)</a> PARP2 also resides in the nucleus and functions in a similar manner to PARP1, but it is comparatively less abundant, contributing only 5–10% of the total PARP activity.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a></div><div class="NLM_p">Small-molecule inhibitors of PARP1 and PARP2 are emerging as an exciting class of anticancer agents.<a onclick="showRef(event, 'ref3 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref9">(3, 9)</a> Several PARP inhibitors have been reported (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), all of which are analogues of nicotinamide.<a onclick="showRef(event, 'ref3 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref10 ref11">(3, 10, 11)</a> These include olaparib (AZD-2281; AstraZeneca/Kudos),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> rucaparib (AG-014699; Clovis/Pfizer),<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> niraparib (MK-4827; Tesaro/Merck),<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> veliparib (ABT-888; AbbVie),<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17-19)</a> and talazoparib (BMN 673; BioMarin/LEAD/Medivation),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> all of which are commercially available or in late-phase (phases 2 and 3) clinical trials. In addition, several new PARP inhibitors were recently reported and are in preclinical or early stage clinical evaluation.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PARP inhibitors currently undergoing clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Not only do these PARP inhibitors show antitumor activity in combination with DNA damaging agents such as temozolomide and topoisomerase inhibitors<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> but many of them also demonstrate the ability to work as stand-alone treatment to kills cancer cells that harbor homologous recombination (HR) DNA repair deficiency, such as those that carry loss-of-function mutations in either the <i>BRCA1</i> or <i>BRCA2</i> tumor suppressor gene.<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29">(25-29)</a> In addition to inhibiting the catalytic activity of PARP1 and PARP2, some PARP inhibitors were shown to “trap” PARP proteins on DNA and subsequently interfere with DNA repair and replication, resulting in remarkable single-agent cytotoxicity.<a onclick="showRef(event, 'ref30 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref32">(30, 32)</a> It was demonstrated that PARP trapping is the dominant mechanism by which these PARP inhibitors kill cancer cells.<a onclick="showRef(event, 'ref30 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref32">(30, 32)</a> Not all PARP inhibitors are equivalent in their PARP trapping capacity. In fact, the capacity to trap PARP varies significantly among several clinical-stage PARP inhibitors and correlates well with their ability to kill cancer cells.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a></div><div class="NLM_p last">In this article, we report the discovery, characterization, and development of a novel series of tetrahydropyridophthalazinones that led to the identification of (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673, talazoparib), a novel and highly potent PARP1/2 inhibitor. Compound (8<i>S</i>,9<i>R</i>)-<b>47</b> inhibits PARP1 and PARP2 enzyme activity with <i>K</i><sub>i</sub> = 1.2 and 0.87 nM, respectively. What’s unique about (8<i>S</i>,9<i>R</i>)-<b>47</b> is that it achieves antitumor responses at much lower concentrations compared to those of previous-generation PARP inhibitors. For example, its EC<sub>50</sub>’s in <i>BRCA1</i>-deficient MX-1 cells and <i>BRCA2</i>-deficient Capan-1 cells are >50× lower than the EC<sub>50</sub>’s of olaparib and >2000× lower than those of veliparib.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Analysis by Murai et al. indicated that (8<i>S</i>,9<i>R</i>)-<b>47</b> is a highly potent PARP-trapping agent,<a onclick="showRef(event, 'ref30 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref32">(30, 32)</a> providing a mechanistic explanation for the remarkable antitumor potency of this molecule compared to that of other PARP inhibitors. (8<i>S</i>,9<i>R</i>)-<b>47</b> has excellent liver microsome stability, good oral bioavailability, and pharmacokinetic properties that support oral, once-daily administration. These properties have enabled this compound to show remarkable antitumor efficacy at low doses in xenograft models following oral dosing, making it a promising anticancer agent.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Discovery of the Tetrahydropyridophthalazinone Scaffold</h3><div class="NLM_p">We initiated a PARP inhibitor program to generate prototype compounds to potentially serve as new and more potent PARP inhibitors. Compound <b>5</b> was one of the early prototype PARP inhibitors planned for our program (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, part A). The original synthesis plan was to begin with 4-nitroisobenzofuranone <b>6</b> through the intermediates <b>7</b> and <b>8</b> to prepare a phthalazinone intermediate <b>9</b> and, after bromination and subsequent cyclization, to generate compound <b>5</b>. However, after multiple attempts at converting 4-aminoisobenzofuran-1(3<i>H</i>)-one <b>7</b> to intermediate <b>8</b> using adopted literature reaction conditions,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> we were unable to obtain the desired product. Careful structure elucidation based on 2D NMR and mass spectra suggested that the major product was, in fact, a bicyclic methyl 4-oxo-2,3-diphenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>12</b>), an unexpected and previously unknown compound in the literature. The two phenyl groups were found to be <i>trans</i> to each other on the newly formed ring (as a racemate). It was confounding at first as to how a simple compound such as <b>7</b> could be converted into a more complex compound <b>12</b> in just one step of our synthesis plan (planned conversion from intermediate <b>7</b> to <b>8</b>). One of the possible reaction mechanisms for this transformation under the given conditions is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, part B. We speculated that it involved three unanticipated cascade reaction steps. Specifically, the formation of benzylideneamino intermediate <b>11a</b> from <b>7</b>, followed by further condensation of <b>11a</b> with benzaldehyde resulting in <b>11b</b>. Then, sodium methoxide opened the lactone ring of <b>11b</b>, which in turn sequentially led to the formation of an ester and a ketone as well as the ring closure observed in <b>12</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Planned Synthetic Route to <b>5</b> and the Synthesis of <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) EA, 10% Pd/C, H<sub>2</sub>, 1 atm, rt, 2 h; (ii) PhCHO, MeONa, ethyl propionate, reflux, 18 h; (iii) H<sub>2</sub>NNH<sub>2</sub>, H<sub>2</sub>O, reflux, 3 h; (iv) NBS; (v) deprotection–cyclization–oxidation.</p></p></figure><div class="NLM_p">Although unexpected, it was recognized that there was still a possibility that this compound could be converted to a potential PARP inhibitor by cyclizing the keto-ester moiety with hydrazine. This would create a tricyclic tetrahydropyridophthalazinone core that could provide hydrogen-bonding and π-stacking interactions to the nicotinamide-binding site of the enzyme, like other existing PARP inhibitors.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref17 ref18 ref19 ref34'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref17 ref18 ref19 ref34">(12-15, 17-19, 34)</a> It was not clear, though, how the two rigidly and spatially substituted phenyl groups on the tetrahydropyrido ring would impact the binding to the enzyme. Nonetheless, treating <b>12</b> with hydrazine indeed gave rise to compound <b>13</b> (mostly in the <i>trans</i> form and as a racemate) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, part B). This compound was first tested in a PARP1 enzymatic inhibitory assay and showed an impressive IC<sub>50</sub> of 6.1 nM. However, the weak cellular activity of this compound (GI<sub>50</sub> > 300 μM) clearly indicated that further optimization was needed.</div><div class="NLM_p last">Given the good enzymatic inhibitory potency and the structural novelty of compound <b>13</b>, it was quite desirable to expand it into a series and build a medicinal chemistry optimization program on the scaffold. Assuming that the conversion of <b>7</b> to the key intermediate <b>12</b> works through the formation of the intermediates <b>11a</b> and <b>11b</b>, this synthetic utility could be employed to create more structurally diverse derivatives. For example, one could still synthesize <b>12</b>-like compounds that have two of the same substituents on the tetrahydropyrido ring in the same manner as in <b>12</b> by using different aldehydes in the reaction. More importantly, one could also first prepare an <b>11a</b> derivative by using an aldehyde and then react it with a second, structurally different aldehyde to make a derivative of <b>12</b> with two different substituents on the ring. Potentially, one or both of these substituents could be further derivatized. Together, the biological activity, the structural novelty, and the synthetic feasibility of this tetrahydropyridophthalazinone scaffold could constitute a promising and viable medicinal chemistry platform for a PARP inhibitor program.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Compound Synthesis</h3><div class="NLM_p">The synthesis of a small set of compounds (<b>13</b>, <b>15</b>–<b>19</b>) that bear two identical substituents on the 8- and 9-positions on the tetrahydropyridophthalazinone core was carried out according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Reacting 4-aminoisobenzofuran-1(3<i>H</i>)-one <b>7</b> with the corresponding aldehydes in the presence of sodium methoxide in ethyl propionate at a reflux for 18 h led to 2- and 3-bisubstituted methyl 4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylates <b>14a</b>–<b>e</b> in 16–67% yields. Further treatment of <b>14a</b>–<b>e</b> with hydrazine hydrate gave rise to compounds <b>15</b>–<b>19</b> in 21–70% yields (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). A selective reduction of 9-pyridyl over 8-pyridyl in compounds <b>15</b>–<b>17</b> could then be performed via a hydrogenation conditions using PtO<sub>2</sub> as a catalyst at 50 °C for 24 h to prepare compounds such as <b>20</b> (prepared from <b>17</b>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b>–<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) RCHO, MeONa, ethyl propionate, reflux, 18 h; (ii) H<sub>2</sub>NNH<sub>2</sub>, H<sub>2</sub>O, reflux, 3 h; (iii) PtO<sub>2</sub>, 20 atm H<sub>2</sub>, MeOH, 50 °C, 24 h.</p></p></figure><div class="NLM_p">The vast majority of compounds in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> (<b>24</b>–<b>57</b>) that have different substituents on the 8- and 9-positions on the tetrahydropyridophthalazinone core were synthesized according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Condensation of 4-aminoisobenzofuran-1(3<i>H</i>)-ones <b>7</b>, <b>7a</b>, or <b>7b</b> with aldehydes in methanol in the presence of MgSO<sub>4</sub> gave corresponding (<i>E</i>)-4-(benzylideneamino)isobenzofuran-1(3<i>H</i>)-one intermediates <b>21a</b>–<b>l</b>, with yields ranging from 32 to 98%. These intermediates were converted to ethyl 4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylates with the 2- and 3-positions bearing different substituents (<b>22a</b>–<b>t</b> and <b>23a</b>–<b>g</b>) by reacting with a second aldehyde in the presence of either sodium methoxide or sodium ethoxide in ethyl propionate (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, steps i and ii). The yields ranged from 5 to 59%. The low yield conversions were mainly observed when the second aldehyde was the more electrophilic triazole carbaldehydes or when benzylideneamino-6-fluoroisobenzofuranones were used. This suggests that a more scalable process or synthetic route might be needed when these compounds become important for the program. It was found that the predominant products at this step possessed a <i>trans</i> configuration for the 2,3-substituted ethyl 4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylates; their <i>cis</i> counterparts were either not detectable or too little was produced to be isolated in the reaction mixture. Further treatment of these intermediates with hydrazine monohydrate afforded a group of tetradropyridophthalazinone derivatives (<b>24</b> and <b>28</b>–<b>51</b>) that have different substituents on the 8- and 9-positions with a typical yield range from 15 to 80%. Compounds <b>48</b>–<b>51</b> that have a dimethoxymethyl or diethoxymethyl either on the 8-phenyl or 9-phenyl moiety were hydrolyzed to give the corresponding aldehyde derivatives <b>48a</b>, <b>49a</b>, <b>50a</b>, and <b>51a</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, steps iii and iv). Subsequent reductive amination of these four compounds using various amines in the presence of sodium borohydride then allowed introduction of either a <i>N</i>,<i>N</i>-dimethyl methyl moiety (<b>25</b>–<b>27</b>) or a cyclic (4–6 membered ring) aminomethyl moiety (<b>51</b>–<b>57</b>) to the 8- or 9-phenyl group (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, step v).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>24</b>–<b>57</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) R<sub>1</sub>CHO, MgSO<sub>4</sub>, MeOH, reflux, 24 h; (ii) R<sub>2</sub>CHO, R<sub>3</sub>ONa = EtONa (except for <b>22a</b>–<b>c</b>, <b>22m</b>, and <b>23e</b>, wherein R<sub>3</sub>ONa = MeONa), ethyl propionate, rt, 18 h; (iii) H<sub>2</sub>NNH<sub>2</sub>, H<sub>2</sub>O, MeOH, rt to reflux, 3–18 h; (iv) 3 <i>N</i> HCl, rt; (v) amine, NaBH<sub>4</sub>.</p></p></figure><div class="NLM_p">The low synthetic yield of a number of the biologically interesting compounds at the ethyl 4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylates (<b>22</b> and <b>23</b>) formation step in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> severely hampered the further medicinal chemistry optimization and biological evaluation of those compounds. The lack of synthetic scalability would also present a significant barrier for these compounds to advance to a developmental stage. To address the issue, a new route was designed and developed (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). A condensation reaction between 6-fluoro-4-nitroisobenzofuran-1(3<i>H</i>)-one <b>7c</b> and 2-methyl-2<i>H</i>-1,2,4-triazole-3-carbaldehyde in the presence of Et<sub>3</sub>N and Ac<sub>2</sub>O in 2-Me-THF gave compound <b>58</b> in 78% yield. The ring opening of the lactone in <b>58</b> by MeOH using AcOH as a catalyst led to the formation of a keto-ester intermediate <b>59</b> in a quantitative manner. Isolation and purification of the products for both steps were achieved via precipitation and filtration. Transforming <b>59</b> to methyl 7-fluoro-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate derivatives (<b>60a</b>–<b>e</b>) was accomplished in yields of 73–98% (except for <b>60c</b>). Again, the <i>trans</i> configuration isomers were found to be the predominant products, and occasionally a low level of <i>cis</i> isomers could be detected in the reaction mixture by LC-MS. The tetrahydropyridophthalazinones <b>47</b> and <b>61</b>–<b>64</b> were prepared from <b>60a</b>–<b>e</b>, respectively, by treating with hydrazine monohydrate in a mixture solvent of water and methanol. The products could be collected by direct filtration of the reaction mixture, giving yields from about 30 to 80%. The trace amount of the residual <i>cis</i> isomers formed from the carried-over <i>cis</i> isomers in the previous step could be effectively removed by filtration due to their solubility in methanol. The <i>cis</i>-<b>47</b> compound was enriched and isolated by combining the filtrate mother liquid from multiple large-scale batches of <b>47</b>. Up to this point, all synthetic steps in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> required no column chromatography purifications.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>47</b>, <b>61</b>–<b>64</b>, and (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) 1-methyl-1<i>H</i>-1,2,4-triazole-5-carbaldehyde, Et<sub>3</sub>N, Ac<sub>2</sub>O, 2-Me-THF, rt to 80 °C, 2 h; (ii) MeOH, rt, overnight; (iii) R<sub>1</sub>CHO, TiCl<sub>3</sub>, THF, MeOH, 0 °C to rt, (iv) H<sub>2</sub>NNH<sub>2</sub>, MeOH, rt, overnight; (v) <b>47</b>, SFC chiral separation.</p></p></figure><div class="NLM_p">Chiral resolutions of a number of biologically interesting compounds, including <b>36</b>, <b>42</b>, <b>46</b>, <b>47</b>, and <b>57</b>, were performed by employing supercritical fluid chromatography (SFC) using a CHIRALPAK IA or OJ-H column and CO<sub>2</sub>/MeOH as the eluents. As such, enantiomers (8<i>R</i>,9<i>S</i>)-<b>36</b> and (8<i>S</i>,9<i>R</i>)-<b>36</b>, (<i>8R</i>,<i>9S</i>)-<b>42</b> and (8<i>S</i>,9<i>R</i>)-<b>42</b>, (8<i>S</i>,9<i>R</i>)-<b>46</b> and (8<i>R</i>,9<i>S</i>)-<b>46</b>, (8<i>R</i>,9<i>S</i>)-<b>47</b> and (8<i>S</i>,9<i>R</i>)-<b>47</b>, as well as (8<i>R</i>,9<i>S</i>)-<b>57</b> and (8<i>S</i>,9<i>R</i>)-<b>57</b> were obtained in yields of 63, 79, 90, 80, and 95%, respectively, and generally with >99% ee. The low solubility of compound <b>47</b> in methanol (ca. 9 mg/mL) caused the chiral separation efficiency and scalability of this compound to be less than optimal. We later found that both separation efficiency and scalability could be drastically improved by performing SFC separation for the much more soluble precursor <b>60a</b> (solubility of ca. 100 mg/mL in MeOH) on a CHIRALPAK IC stationary phase using CO<sub>2</sub>/MeOH as the mobile phase. The obtained enantiomers (2<i>S</i>,3<i>R</i>)-<b>60a</b> and (2<i>R</i>,3<i>S</i>)-<b>60a</b> could be further converted to compounds (8<i>S</i>,9<i>R</i>)-<b>47</b> and (8<i>R</i>,9<i>S</i>)-<b>47</b> by treating with hydrazine hydrate without compromising the chiral purity of the final compounds (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, step v).</div><div class="NLM_p">The absolute configuration of the active enantiomer for <b>47</b> was determined by analysis of anomalous X-ray scattering by the crystal made from the active enantiomer of <b>47</b> tosylate salt. An ORTEP diagram of the crystal is shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. The single-crystal structure not only confirmed the proposed tetrahydropyridophthalazinone core structure but also showed an absolute configuration of <i>R</i> and <i>S</i> at C1 (9-position) and C2 (8-position), respectively. On the basis of this information, the absolute stereo configuration of the active enantiomer of <b>47</b> can be assigned as (8<i>S</i>,9<i>R</i>)-<b>47</b>. The inactive enantiomer of <b>47</b>, with the (8<i>R</i>,9<i>S</i>) configuration, was named LT-00674.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. ORTEP diagram of BMN 673 ((8<i>S</i>,9<i>R</i>)-<b>47</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Structure–Activity Relationship (SAR) and Lead Optimization</h3><div class="NLM_p">All synthesized analogues were evaluated for PARP-1 enzymatic inhibitory activity using rucaparib (AG-014699) as the reference standard in the assay.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition to the PARP-1 inhibition assay, many compounds were tested in three additional functional assays: a cellular PARylation assay to assess their ability to inhibit intracellular PARP1/2 activity, a TMZ sensitization assay to examine their ability to potentiate cell killing by temozolomide, and a Capan-1 cytotoxicity assay to measure the single-agent anticancer activity in <i>BRCA2</i>-mutation background. A number of the selected compounds were also assessed for their metabolic stability in rat liver microsomes. Our initial efforts to generate analogues attempted to replace the 8- and 9-phenyl groups of the early intermediate <b>13</b> with a pair of identical heteroaryl moieties for better solubility and cellular activities (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Unfortunately, it was found that <b>15</b>–<b>18</b>, wherein the heteroaryls are pyridyls or imidazole, displayed much reduced inhibitory activities, with IC<sub>50</sub>’s ranging from ∼20 to ∼100 nM (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) compared to 6.1 nM for <b>13</b>. To examine whether the aromatic moieties at the 8- or 9-position could be replaced by nonaromatic ones, compounds <b>20</b> and <b>33</b> were prepared and assayed. The data indicate that such a replacement is not well-tolerated (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). For example, generation of compound <b>20</b> from <b>17</b> resulted in a roughly 6-fold drop in its enzymatic potency, from IC<sub>50</sub> = 17.7 to 105 nM. More drastically, changing the 9-phenyl in <b>13</b> to 9-isopropyl in <b>33</b> resulted in a virtually inactive IC<sub>50</sub> of 4.139 μM of the latter. Similar replacements at the 8-position also led to a similar activity loss (data not shown).</div><div class="NLM_p">We thus turned our attention to exploring SAR by incorporating various substituents onto the phenyl groups of compound <b>13</b>. First, a small set of compounds having identical substitutions of an <i>N</i>,<i>N</i>-dialkylamino methyl or <i>N</i>-methylamino methyl group on both the 8- and 9-phenyl was examined. Compound <b>19</b> was one of the examples, in which <i>N</i>,<i>N</i>-dimethylamino methyl was placed on the <i>para</i> position of the two phenyls. As a result, compound <b>19</b> not only displayed good enzymatic inhibitory activity (IC<sub>50</sub> = 3.89 nM) but also elicited cellular activities including a single-agent EC<sub>50</sub> of 0.979 μM in the Capan-1 cytotoxicity assay (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Encouraged by this finding, we next explored compounds <b>24</b>–<b>27</b> in which just one <i>N</i>,<i>N</i>-dimethylamino methyl group was substituted at either the 8- or 9-phenyl group on the tetrahydropyridophthalazinone core. Compound <b>25</b> with <i>N</i>,<i>N</i>-dimethylamino methyl substituted at the <i>para</i> position of 8-phenyl demonstrated a rather attractive in vitro activity profile, with an IC<sub>50</sub> = 2.36 nM in PARP1 inhibition, EC<sub>50</sub> = 6 nM in a PARylation assay, GI<sub>50</sub> = 59 μM in a TMZ potentiation assay, and EC<sub>50</sub> = 0.387 μM as a single agent in the Capan-1 assay, which are comparable to those from the reference compound rucaparib (AG-014699) (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Interestingly, when the same substitution was swapped to a 9-phenyl group to give <b>24</b>, reduced enzyme inhibitory potency and potentiation activity with TMZ were observed (IC<sub>50</sub> = 5.85 nM and GI<sub>50</sub> = 112 μM). Likewise, another similar pair of compounds, <b>26</b> and <b>27</b> (with IC<sub>50</sub> = 3.65, 2.63 and GI<sub>50</sub> = 204, 128 nM, respectively), in which the same substitution was switched to the <i>meta</i> position of 9- and 8-phenyls, respectively, also seemed to suggest that the substitution at 8-phenyl could provide more favorable activities.</div><div class="NLM_p">Compound <b>25</b> showed interesting biological activities, but its metabolic stability was less than optimal, with a half-life of 12 min in rat liver microsomes (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>; rLM). In order to improve its metabolic stability, two subsets of compounds were synthesized and evaluated. The examples of the first set consisted of <b>28</b>, <b>29</b>, <b>30</b>, and <b>52</b>, in which 8-(4-dimethylamino methyl)phenyl was kept for every compound, and the substitution of isopropyl, methyl, trifluoromethyl, and fluoro was introduced, respectively, to the <i>para</i> position of 9-phenyl (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The substitution of isopropyl and trifluoromethyl on the 9-phenyl appeared to be slightly detrimental, as evidenced by the reduced enzymatic inhibitory activity for <b>28</b> (IC<sub>50</sub> = 9.59 nM) and <b>30</b> (IC<sub>50</sub> = 6.29 nM). While enzymatic activity was quite comparable among <b>25</b>, <b>29</b>, and <b>52</b>, certain metabolic stability improvements were noticed for methyl-substituted <b>29</b> (rLM <i>t</i><sub>1/2</sub> = 35 min) and fluoro-substituted <b>52</b> (rLM <i>t</i><sub>1/2</sub> = 44 min) over the original lead <b>25</b> (rLM <i>t</i><sub>1/2</sub> = 12 min). It is speculated that such enhancement of metabolic stability is probably achieved by blocking a potential <i>para</i>-hydroxylation on the 9-phenyl. This was further confirmed by another matched molecular pair, <b>31</b> and <b>32</b>, in which the only structural difference is 9-phenyl for <b>31</b> vs 9-fluorophenyl for <b>32</b>, with half-lives of 5 vs 82 min, respectively, in rat liver microsomes. It was also noted that <b>31</b> and <b>32</b> both bear a 5-fluoro substitution on the tricyclic core and yielded a more favorable single-agent activity in the Capan-1 assay than the other 5-desfluoro compounds within the set despite their comparable enzymatic activities. The second subset of compounds, <b>53</b>–<b>57</b>, was made to exploit the replacement of <i>N</i>,<i>N</i>-dimethylamino methyl with the cyclic amino methyl moieties on the <i>para</i> position of the 8-phenyl (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Specifically, 4-(4-methylpiperazin-1-yl)methyl for <b>53</b>, 4-(pyrrolidin-1-yl)methyl for <b>54</b>, and 4-(azetidin-1-yl)methyl for <b>55</b> replaced the dimethylaminomethyl moiety in <b>25</b>; compounds <b>56</b> and <b>57</b> were derived from <b>54</b> and <b>55</b> by replacing the 9-phenyl with 9-fluorophenyl. Overall, such modifications did not affect the in vitro potency and metabolic stability very much for <b>53</b>–<b>56</b>. However, compound <b>57</b> (rLM <i>t</i><sub>1/2</sub> = 89 min), structurally similar to <b>32</b>, also achieved a similar degree of metabolic stability improvement from <b>25</b> while retaining the excellent in vitro potency. Altogether, those compounds, including <b>19</b>, <b>29</b>, <b>32</b>, <b>52</b>, and <b>57</b>, in which the <i>para</i> position of 9-phenyl is blocked by groups such as fluoro, methyl, or dimethylamino methyl, all demonstrated an improved metabolic stability over the unsubstituted 9-phenyl analogue <b>25</b>, suggesting that the <i>para</i> position of the 9-phenyl might be a metabolic soft spot, presumably for hydroxylation (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Activity and Metabolic Stability of 8,9-Diphenyl Derived Tetrahydropyridophthalazinone Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0011.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center" char=".">PARP-1 enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cellular PAR inhibition EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">TMZ chemosensitization<a class="ref internalNav" href="#t1fn3" aria-label="d">d</a> GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">Capan-1 (BRCA2 mutant) EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rLM <i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="left">58.4</td><td class="colsep0 rowsep0" align="left">324</td><td class="colsep0 rowsep0" align="char" char=".">2.97</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">5.85</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">112</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.36</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="char" char=".">0.387</td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">3.65</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">204</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">128</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">3.89</td><td class="colsep0 rowsep0" align="left">18.6</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="char" char=".">0.979</td><td class="colsep0 rowsep0" align="left">>120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-isopropyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">9.59</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">123</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-methyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.95</td><td class="colsep0 rowsep0" align="left">10.8</td><td class="colsep0 rowsep0" align="left">123</td><td class="colsep0 rowsep0" align="char" char=".">0.514</td><td class="colsep0 rowsep0" align="left">35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">6.29</td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char=".">0.818</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.48</td><td class="colsep0 rowsep0" align="left">18.5</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="char" char=".">1.73</td><td class="colsep0 rowsep0" align="left">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3.29</td><td class="colsep0 rowsep0" align="left">8.48</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="char" char=".">0.146</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="char" char=".">0.134</td><td class="colsep0 rowsep0" align="left">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">4-(4-methylpiperazin-1-yl)methyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td><td class="colsep0 rowsep0" align="left">40.6</td><td class="colsep0 rowsep0" align="left">54.6</td><td class="colsep0 rowsep0" align="char" char=".">0.603</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">4-(pyrrolidin-1-ylmethyl)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">4.02</td><td class="colsep0 rowsep0" align="left">9.47</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="char" char=".">0.298</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">4-(azetidin-1-ylmethyl)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">3.63</td><td class="colsep0 rowsep0" align="left">9.7</td><td class="colsep0 rowsep0" align="left">89</td><td class="colsep0 rowsep0" align="char" char=".">0.434</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">4-(pyrrolidin-1-ylmethyl)</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">134</td><td class="colsep0 rowsep0" align="char" char=".">0.454</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">4-(azetidin-1-ylmethyl)</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">3.09</td><td class="colsep0 rowsep0" align="left">3.81</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="char" char=".">0.276</td><td class="colsep0 rowsep0" align="left">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (rucaparib)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">1.98</td><td class="colsep0 rowsep0" align="left">4.74</td><td class="colsep0 rowsep0" align="left">144</td><td class="colsep0 rowsep0" align="char" char=".">0.609</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Mean of duplicate determinations.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Mean of triplicate determinations.</p></div><div class="footnote" id="t1fn3"><sup>d</sup><p class="last">TMZ sensitization conditions: the concentration (μM) of TMZ that kills 50% of the treated cells (GI<sub>50</sub>) in the presence of 0.4 μM PARP inhibitors</p></div></div></div><div class="NLM_p">In light of this finding and in order to further enhance metabolic stability, we designed and synthesized another series of compounds in which a few, presumably metabolically less labile, azole moieties were introduced to the 9-position (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compound <b>35</b> was derived from <b>13</b> by using a 1-methyl-imidazol-2-yl moiety in lieu of 9-phenyl. As the first compound in the series, it displayed a rather promising biological profile (comparable to that of the reference compound rucaparib (AG-014699)). This included excellent enzymatic activity (IC<sub>50</sub> = 2.35 nM), moderate to good cellular activities in PARylation (EC<sub>50</sub> = 16.9 nM), TMZ potentiation (GI<sub>50</sub> = 97 μM), single-agent Capan-1 cytotoxicity (EC<sub>50</sub> = 0.36 μM), and good metabolic stability (rLM <i>t</i><sub>1/2</sub> = 89 min) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Recognizing that the <i>para</i> position of the 8-phenyl might also be a potential metabolic soft spot, we next introduced a fluorine to block this position in compound <b>36</b>. As a result, the metabolic stability, indeed, was further enhanced (rLM <i>t</i><sub>1/2</sub> > 120 min) without compromising other biological activities. Further incorporating 5-fluoro onto <b>36</b> generated compound <b>42</b>, which was as potent as <b>36</b> in enzymatic inhibition (IC<sub>50</sub> = 1.87 nM), cellular PARylation (EC<sub>50</sub> = 17 nM), and chemosensitization (GI<sub>50</sub> = 35.7 μM). However, as in the cases of <b>31</b> and <b>32</b>, the 5-fluoro-substituted compound <b>42</b> again demonstrated an evident enhancement of single-agent activity in Capan-1 cancer cells (EC<sub>50</sub> = 0.056 μM), showing about a 7-fold potency increase over <b>36</b>. In contrast, 5-position modifications with a substitution other than fluorine, such as chlorine, bromine, methyl, and methoxy, all led to a certain degree of activity reduction. For example, <b>41</b>, a 5-chloro-substituted derivative of <b>37</b>, displayed an activity profile of PARP1 IC<sub>50</sub> = 6.18 nM, cellular PARylation EC<sub>50</sub> = 121 nM, TMZ sensitization GI<sub>50</sub> = 111 μM, and single-agent Capan-1 EC<sub>50</sub> = 0.785 μM. The 5-fluoro-substituted <b>37</b> yielded an enzymatic inhibition IC<sub>50</sub> of 2.14 nM, PARylation EC<sub>50</sub> of 18.1 nM, TMZ potentiation GI<sub>50</sub> of 36.3 μM, and single -agent activity EC<sub>50</sub> of 0.247 μM. Similar detrimental effects were reported for a 5-substitution that is bulkier than hydrogen and fluorine in other PARP inhibitors in the literature.<a onclick="showRef(event, 'ref19 ref35'); return false;" href="javascript:void(0);" class="ref ref19 ref35">(19, 35)</a></div><div class="NLM_p">Besides a 9-imidazole group, analogues with other 9-azoles were also exploited (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compound <b>38</b> bearing 9-(thiazol-2-yl) showed an enzymatic IC<sub>50</sub> of 7.35 nM, a slight reduction compared to that of <b>36</b> (IC<sub>50</sub> = 2.08 nM). Compound <b>39</b> having a 9-(1-methyl-pyrazol-5-yl) substitution demonstrated an equipotent enzymatic inhibitory activity compared to that of <b>36</b>, with an IC<sub>50</sub> of 1.84 nM. However, its single-agent activity in Capan-1 cells (EC<sub>50</sub> = 0.956 μM) was somewhat decreased from that of <b>36</b> (EC<sub>50</sub> = 0.418 μM). A similar trend but with a more amplified effect was also observed for compound <b>45</b>, in which the tetrahydropyridophthalazinone core was substituted with 8-phenyl and 9-(4-methyl-1,2,4-triazol-3-yl) groups. It displayed a potent enzymatic inhibitory activity (IC<sub>50</sub> = 2.76 nM) but a much reduced single-agent activity in the Capan-1 assay (EC<sub>50</sub> = 4.34 μM). Interestingly, despite a subtle structural difference between <b>43</b> and <b>45</b>, 9-(1-methyl-1,2,4-triazol-5-yl) vs 9-(4-methyl-1,2,4-triazol-3-yl), their single-agent activity difference is rather significant, an EC<sub>50</sub> = 0.17 μM for <b>43</b> vs EC<sub>50</sub> = 4.34 μM for <b>45</b>, about a 25-fold difference. Compound <b>43</b> is also metabolically quite stable (rLM <i>t</i><sub>1/2</sub> = 414 min). With this newly identified lead, further structural refinements were performed by employing the previously gained SAR knowledge. First, replacing the 8-phenyl with 8-(4-fluorophenyl) in <b>43</b> resulted in compound <b>46</b> that elicited about the same enzymatic activity (IC<sub>50</sub> = 2.29 nM) as that of <b>43</b> but had improved cellular activities, including PARylation (EC<sub>50</sub> = 6.94 nM), chemosensitization (GI<sub>50</sub> = 44 μM), and single-agent cytotoxicity (EC<sub>50</sub> = 0.071 μM) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Moreover, when 5-fluoro was introduced to <b>43</b>, leading to compound <b>44</b>, the single-agent cytotoxicity was further reduced to a single-digit nanomolar range (EC<sub>50</sub> = 0.009 μM), representing about a 19-fold potency increase over that of lead compound <b>43</b>. In view of the excellent biological activities measured for <b>44</b> and <b>46</b>, the next logical extension was to make a compound in which the tetrahydropyridophthalazinone core was substituted with 5-fluoro, 8-(4-fluorophenyl), and 9-(1-methyl-1,2,4-triazol-5-yl) moieties. This substitution led to compound <b>47</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), which indeed retained the enzymatic (IC<sub>50</sub> = 2.14 nM) and cellular PARylation (EC<sub>50</sub> = 5.48 nM) activities as well as the metabolic stability (rLM <i>t</i><sub>1/2</sub> = 359 min), but, more importantly, it achieved a remarkable cytotoxicity either as a single agent in Capan-1 cells (EC<sub>50</sub> = 0.008 μM) or in combination with TMZ in the chemosensitization assay (GI<sub>50</sub> = 19 μM). It is the most potent compound that we have identified thus far in this series.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Activity and Metabolic Stability of 8,9-Aryl or Heteroaryl Derived Tetrahydropyridophthalazinone Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0012.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">PARP-1 enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cellular PAR inhibition EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">TMZ chemosensitization<a class="ref internalNav" href="#t2fn3" aria-label="d">d</a> GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Capan-1 (BRCA2 mutant) EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">rLM <i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">4-pyridyl</td><td class="colsep0 rowsep0" align="left">4-pyridyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">22.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>400</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">2-pyridyl</td><td class="colsep0 rowsep0" align="left">2-pyridyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">108</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">3-pyridyl</td><td class="colsep0 rowsep0" align="left">3-pyridyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">17.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">24.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">3-pyridyl</td><td class="colsep0 rowsep0" align="left">piperidin-3-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">105</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">isopropyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4139</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">9.45</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>400</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.35</td><td class="colsep0 rowsep0" align="left">16.9</td><td class="colsep0 rowsep0" align="left">97</td><td class="colsep0 rowsep0" align="left">0.36</td><td class="colsep0 rowsep0" align="left">89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.08</td><td class="colsep0 rowsep0" align="left">19.7</td><td class="colsep0 rowsep0" align="left">75.5</td><td class="colsep0 rowsep0" align="left">0.418</td><td class="colsep0 rowsep0" align="left">>120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">2.14</td><td class="colsep0 rowsep0" align="left">18.1</td><td class="colsep0 rowsep0" align="left">36.3</td><td class="colsep0 rowsep0" align="left">0.108</td><td class="colsep0 rowsep0" align="left">103</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">thiazol-2-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">7.35</td><td class="colsep0 rowsep0" align="left">24.4</td><td class="colsep0 rowsep0" align="left">106</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">1-Me-pyrazol-5-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1.84</td><td class="colsep0 rowsep0" align="left">9.33</td><td class="colsep0 rowsep0" align="left">>400</td><td class="colsep0 rowsep0" align="left">0.956</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub>-phenyl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5.27</td><td class="colsep0 rowsep0" align="left">27.2</td><td class="colsep0 rowsep0" align="left">192</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">6.18</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">111</td><td class="colsep0 rowsep0" align="left">0.785</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">1-Me-imidazol-2-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">1.87</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">35.7</td><td class="colsep0 rowsep0" align="left">0.056</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="left">>400</td><td class="colsep0 rowsep0" align="left">0.170</td><td class="colsep0 rowsep0" align="left">414</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">0.009</td><td class="colsep0 rowsep0" align="left">472</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">4-Me-1,2,4-triazol-3-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.76</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>400</td><td class="colsep0 rowsep0" align="left">4.34</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2.29</td><td class="colsep0 rowsep0" align="left">6.94</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">0.071</td><td class="colsep0 rowsep0" align="left">>120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">2.14</td><td class="colsep0 rowsep0" align="left">5.48</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">359</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">4-(acetamidophenyl)</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">2.08</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.146</td><td class="colsep0 rowsep0" align="left">>120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">pyrimidin-5-yl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">7.62</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">1-Me-pyrazol-5-yl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">2.88</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.92</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">4-cyanophenyl</td><td class="colsep0 rowsep0" align="left">1-Me-1,2,4-triazol-5-yl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.088</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (rucaparib)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.98</td><td class="colsep0 rowsep0" align="left">4.74</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">0.609</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Mean of duplicate determinations.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Mean of triplicate determinations.</p></div><div class="footnote" id="t2fn3"><sup>d</sup><p class="last">TMZ sensitization conditions: the concentration (μM) of TMZ that kills 50% of the treated cells (GI<sub>50</sub>) in the presence of 0.4 μM PARP inhibitors</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Stereospecific Inhibitory Activity</h3><div class="NLM_p">Disubstitution at the 8- and 9-positions on the tetrahydropyridophthalazinone core creates not only <i>trans</i> and <i>cis</i> isomers but also two chiral centers. Fortunately, the thermodynamically more favorable <i>trans</i> isomers are always the predominant products in the synthesis, and, importantly, the <i>cis</i> isomers are far less active than their <i>trans</i> counterparts. For example, the <i>cis</i> isomers (8<i>S</i>,9<i>S</i> and 8<i>R</i>,9<i>R</i> were not separated) of <b>47</b> showed a rather weak activity with PARP1 (IC<sub>50</sub> = 44.9 nM). All of the <i>trans</i> compounds made and evaluated up to this point are racemates. Given the activity differences between the <i>trans</i> and <i>cis</i> isomers, it is conceivable that one of the enantiomers in a <i>trans</i> racemate might yield a more favorable inhibition activity. We thus selected a set of leading racemate compounds, including <b>36</b>, <b>42</b>, <b>46</b>, <b>47</b>, and <b>57</b>, for chiral resolution. The in vitro activities from the resulting five pairs of enantiomers after the chiral resolutions are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Evidently, one of the two enantiomers in every pair demonstrated drastically better in vitro activities than its mirror image isomer. This indicated that the binding interactions of the tetrahydropyridophthalazinone derivatives to the PARP enzyme are indeed stereospecific. It was noted that the degree of the differential activities between the two enantiomers appeared to be compound-dependent, ranging from a few fold to a few hundred fold among the five pairs of the stereoisomers in both enzymatic and cellular activities. The largest activity separation was found for the enantiomer pair resolved from <b>47</b>, showing a strikingly more than 200-fold potency difference across the enzymatic, cellular PARylation, TMZ sensitization, and Capan-1 assays (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The absolute stereo configuration of the active enantiomer resolved from racemate <b>47</b> was determined by single-crystal X-ray diffraction to have an 8<i>S</i>,9<i>R</i> configuration and therefore was assigned as (8<i>S</i>,9<i>R</i>)-<b>47</b>. On the basis of this information, the same stereo configurations were assigned to other active enantiomers for the remaining four pairs. Compound (8<i>S</i>,9<i>R</i>)-<b>47</b>, the sole compound with single-digit nanomolar inhibitory activities in all assays, was the most potent compound in the set and was approximately 2-fold as active as the racemate <b>47</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). All other active enantiomers including (8<i>S</i>,9<i>R</i>)-<b>36</b>, (8<i>S</i>,9<i>R</i>)-<b>42</b>, (8<i>S</i>,9<i>R</i>)-<b>46</b>, and (8<i>S</i>,9<i>R</i>)-<b>57</b> have also shown comparable or better in vitro potency in comparison with that of known clinic PARP inhibitors. Furthermore, we found that (8<i>S</i>,9<i>R</i>)-<b>47</b> inhibits PARP1 and PARP2 with a similar potency (<i>K</i><sub>i</sub> = 1.2 nM for PARP1 and <i>K</i><sub><i>i</i></sub> = 0.85 nM for PARP2), which is likely due to the sequence similarity in the catalytic domains of the two enzymes.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Activity for the Selected Enantiomer Pairs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">enantiomeric purity (% ee)</th><th class="colsep0 rowsep0" align="center">PARP-1 enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cellular PAR inhibition EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">TMZ chemosensitization<a class="ref internalNav" href="#t3fn3" aria-label="d">d</a> GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Capan-1 (BRCA2 deficient) EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>R</i>,9<i>S</i>)-<b>36</b></td><td class="colsep0 rowsep0" align="left">98.7</td><td class="colsep0 rowsep0" align="left">136</td><td class="colsep0 rowsep0" align="left">285</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">6310</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>36</b></td><td class="colsep0 rowsep0" align="left">99.2</td><td class="colsep0 rowsep0" align="left">2.25</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">261</td><td class="colsep0 rowsep0" align="left">305</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>R</i>,9<i>S</i>)-<b>42</b></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">22.4</td><td class="colsep0 rowsep0" align="left">164</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">124</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>42</b></td><td class="colsep0 rowsep0" align="left">99.1</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">17.9</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>46</b></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">1.46</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">41</td><td class="colsep0 rowsep0" align="left">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>R</i>,9<i>S</i>)-<b>46</b></td><td class="colsep0 rowsep0" align="left">98.6</td><td class="colsep0 rowsep0" align="left">68.9</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="left">3263</td><td class="colsep0 rowsep0" align="left">1883</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>57</b></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">6.3</td><td class="colsep0 rowsep0" align="left">279</td><td class="colsep0 rowsep0" align="left">389</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>R</i>,9<i>S</i>)-<b>57</b></td><td class="colsep0 rowsep0" align="left">99.5</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">11.8</td><td class="colsep0 rowsep0" align="left">3572</td><td class="colsep0 rowsep0" align="left">2249</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>47</b></td><td class="colsep0 rowsep0" align="left">99.3</td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left">2.51</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>R</i>,9<i>S</i>)-<b>47</b></td><td class="colsep0 rowsep0" align="left">99.2</td><td class="colsep0 rowsep0" align="left">144</td><td class="colsep0 rowsep0" align="left">864</td><td class="colsep0 rowsep0" align="left">1807</td><td class="colsep0 rowsep0" align="left">1135</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Mean of duplicate determinations.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Mean of triplicate determinations.</p></div><div class="footnote" id="t3fn3"><sup>d</sup><p class="last">TMZ sensitization conditions: the concentration (nM) of a PARP inhibitor that kills 50% of the treated cells (GI50) in the presence of 200 μM TMZ is reported.</p></div></div></div><div class="NLM_p last">Intriguingly, the high sensitivity of enzyme inhibitory activity to the stereo configuration in our series was not observed in other PARP inhibitors in the clinic. For example, both veliparib (ABT-888) and niraparib (MK-4827) contain one chiral center, but their <i>R</i> and <i>S</i> enantiomers are virtually equipotent in inhibiting PARP1 enzyme.<a onclick="showRef(event, 'ref15 ref16 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref19">(15, 16, 19)</a> Such distinct stereo specificity in our PARP inhibitors might arise from the rigidly locked dual asymmetric configurations at the 8- and 9-positions, creating additional and/or unique interactive contacts outside the nicotinamide-binding pocket in the PARP protein. This notion was confirmed later in the co-crystal structural studies of (8<i>S</i>,9<i>R</i>)-<b>47</b> with PARP1 and PARP2, vide infra.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Cellular Cytotoxicity</h3><div class="NLM_p">Throughout the lead optimization process, another intriguing finding was that while many compounds in the 8- and 9-aryl-disubstituted tetrahydropyridophthalazinone series were similarly potent in PARP inhibition (in the enzyme assay and in the cellular PARylation assay), they behaved quite differently regarding cytotoxicity either as a single agent in the Capan-1 assay or as a chemosensitizer in the TMZ assay. Examples included the matched molecular pairs of <b>32</b> and <b>52</b>, <b>36</b> and <b>42</b>, <b>43</b> and <b>45</b>, and <b>46</b> and <b>47</b> (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). This phenomenon was also observed among other known PARP inhibitors in clinical development<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref17 ref18 ref19">(12-15, 17-19)</a> and becomes even more evident for (8<i>S</i>,9<i>R</i>)-<b>47</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> as shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Specifically, despite their quite comparable enzymatic and cellular PARylation inhibitory activities, (8<i>S</i>,9<i>R</i>)-<b>47</b> is 59-fold, 35-fold, and 1500-fold more effective in enhancing cytotoxicity with TMZ relative to olaparib (AZD-2281), rucaparib (AG-014699), and veliparib (ABT-888), respectively. Likewise, (8<i>S</i>,9<i>R</i>)-<b>47</b> also displayed activity as a single agent in <i>BRCA1</i> and <i>BRCA2</i> mutant cell-killing assays that was magnitudes greater when compared in parallel with that of other PARP inhibitors such as veliparib (ABT-888), rucaparib (AG-014699), niraparib (MK-4827), and olaparib (AZD-2281), making it the most cytotoxic PARP inhibitor in clinical development (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Activity Comparison of (8<i>S</i>,9<i>R</i>)-<b>47</b> with Other PARP Inhibitors in Clinical Development</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">PARP-1 enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cellular PAR inhibition EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">TMZ chemosensitization<a class="ref internalNav" href="#t4fn3" aria-label="d">d</a> GI<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MX-1 cell (<i>BRCA1</i> mutant) EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Capan-1 cell (<i>BRCA2</i> mutant) EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">MRC-5 (normal) EC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Veliparib</td><td class="colsep0 rowsep0" align="left">4.73</td><td class="colsep0 rowsep0" align="left">5.94</td><td class="colsep0 rowsep0" align="left">6203</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left"> > 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rucaparib</td><td class="colsep0 rowsep0" align="left">1.98</td><td class="colsep0 rowsep0" align="left">4.69</td><td class="colsep0 rowsep0" align="left">144</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">609</td><td class="colsep0 rowsep0" align="left">8.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Olaparib</td><td class="colsep0 rowsep0" align="left">1.94</td><td class="colsep0 rowsep0" align="left">3.57</td><td class="colsep0 rowsep0" align="left">237</td><td class="colsep0 rowsep0" align="left">23.2</td><td class="colsep0 rowsep0" align="left">259</td><td class="colsep0 rowsep0" align="left">5.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Nicaparib</td><td class="colsep0 rowsep0" align="left">8.05</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">650</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>47</b></td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left">2.51</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">0.31</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Mean of duplicate determinations.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Mean of triplicate determinations.</p></div><div class="footnote" id="t4fn3"><sup>d</sup><p class="last">TMZ sensitization conditions: the concentration (nM) of a PARP inhibitor that kills 50% of the treated cells (GI<sub>50</sub>) in the presence of 200 μM TMZ is reported.</p></div></div></div><div class="NLM_p last">It is extremely unlikely that such magnitudes of discrepancy in cytotoxicity are attributed to catalytic inhibition capabilities alone. Instead, a recently proposed PARP–DNA complex trapping hypothesis may offer a plausible explanation.<a onclick="showRef(event, 'ref30 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref32 ref33">(30, 32, 33)</a> This concept suggests that certain PARP inhibitor structures may induce allosteric conformational changes in the enzyme, thereby stabilizing its association with damaged DNA. This, in turn, prevents DNA replication and transcription, killing cancer cells more effectively than catalytic inhibition alone. Recent studies by others have revealed that the potency to trap PARP–DNA complexes varies widely across different PARP inhibitors but correlates quite well with the rank order of cytotoxicity. For example, while veliparib (ABT-888) exhibits little trapping activity, (8<i>S</i>,9<i>R</i>)-<b>47</b> displays a PARP–DNA complex trapping efficiency that is about 100-fold more than that of olaparib (AZD-2281), niraparib (MK-4827), and rucaparib (AG-014699), making it the most potent trapper known to date.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Structural Basis for Binding of Tetrahydropyridophthlazinones to PARP1</h3><div class="NLM_p">A recently published X-ray co-crystal structure of the PARP1 catalytic domain (<i>cat</i>PARP1) bound to (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673; talazoparib)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> provides insight into the differential inhibitory potencies among the series of tetrahydropyridophthlazinones described here. In particular, the observed dependence of inhibitory activity on distinct stereospecificity and heterocyclic structures of the novel tripartite chemical scaffold can be partly explained by unique binding interactions formed by the inhibitor’s 8<i>S</i>-(<i>p</i>-fluorophenyl) and 9<i>R</i>-triazole substituents in the NAD<sup>+</sup> site (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). As reported in the co-crystal structure<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and reproduced in the calculated docked model, the active <i>trans</i>-(8<i>S</i>,9<i>R</i>) configuration, as in (8<i>S</i>,9<i>R</i>)-<b>47</b>, allows the fluorophenyl and 1,2,4-triazole groups to form unprecedented π-stacking and water-mediated hydrogen-bonding interactions with Tyr889 and Tyr896, respectively (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). Molecular docking of the less potent enantiomer, <i>trans</i>-(8<i>R</i>,9<i>S</i>)-<b>47</b> or LT-00674 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), results in a noticeable displacement of the bound ligand within the NAD<sup>+</sup> site (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). While maintaining the conserved π-stacking and hydrogen-bonding interactions with key PARP1 residues (His862, Gly863, Ala898, Lys903, Ser904, Tyr907, and Glu988), the orientation and position of the 8<i>R</i>-fluorophenyl and 9<i>S</i>-triazole groups deviate significantly from that observed with (8<i>S</i>,9<i>R</i>)-<b>47</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). Such displacements would cause steric clashes, causing the repositioning of PARP1 residues, including the prominent π-stacking with Tyr907, as illustrated in the induced-fit docked model (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). Moreover, the 9<i>S</i>-triazole group in the predicted binding pose no longer participates in the water-mediated hydrogen-bonding interaction with the backbone of Tyr896 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). These marked structural changes, predicted by molecular docking, may be a plausible factor that contributes to the distinct (8<i>S</i>,9<i>R</i>) stereospecificity in these tetrahydropyridophthalazinone derivatives (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted ligand binding poses relative to <i>cat</i>PARP1: (8<i>S</i>,9<i>R</i>)-<b>47</b> (talazoparib; BMN 673) co-crystal structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT">4PJT</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (A) Overlay of the calculated (cyan) and co-crystallized (magenta) binding poses of (8<i>S</i>,9<i>R</i>)-<b>47</b> validates that the induced-fit docking protocol reproduces the inhibitor binding mode of the co-crystal structure. (B) Overlay of the binding poses of (8<i>R</i>,9<i>S</i>)-<b>47</b> calculated (cyan) and (8<i>S</i>,9<i>R</i>)-<b>47</b> co-crystallized (magenta) suggests that the (8<i>R</i>,9<i>S</i>) stereoconfiguration could impose steric strains to nearby PARP1 residues (arrows). (C) Overlay of the binding pose of (8<i>S</i>,9<i>R</i>)-<b>39</b> calculated (cyan) and (8<i>S</i>,9<i>R</i>)-<b>47</b> co-crystallized (magenta) suggests that inhibitor interactions with the NAD<sup>+</sup>-binding residues and/or ordered water molecule (arrow) could be affected by the absence of a hydrogen-bonding N atom on the 9<i>R</i>-substituent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ordered active-site water molecules contribute to an intricate network of hydrogen-bonding and π-stacking interactions formed between <i>cat</i>PARP1 and (8<i>S</i>,9<i>R</i>)-<b>47</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Nitrogen atoms on both the tricyclic tetrahydropyridophthalazinone core (N1 and N7) and 9<i>R</i>-heterocyclic 1,2,4-triazole group (N4) form hydrogen bonds with the ordered water molecules, which, in turn, can interact with the PARP1 active-site residues, such as Glu988 and Tyr896 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). Interestingly, nitrogen atoms at positions 1, 2, and 4 on the 9<i>R</i>-triazole ring appear to contribute to the distinct inhibitory and/or cytotoxicity potencies among (8<i>S</i>,9<i>R</i>)-<b>47</b> and its related compounds. For example, removal of the N4 atom alone, as in (8<i>S</i>,9<i>R</i>)-<b>39</b>, significantly reduces single-agent cancer cell-killing activity without affecting enzymatic inhibition potency (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Substitution of this hydrogen-bonding N4 atom by carbon in (8<i>S</i>,9<i>R</i>)-<b>39</b> would require displacement of its 9-substituent away from the ordered active-site water molecule or vice versa; the latter case was predicted in the docked model, in which the conserved active-site water molecule moved away from both the bound ligand and Tyr896 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>c). Elucidation of the functional consequences of the environmental changes around the 9<i>R</i>-triazole group, especially on the inhibitor’s cytotoxic potencies, awaits further studies. In aggregate, several critical aspects of SAR among these tetrahydropyridophthalazinone derivatives are likely directly related to the fine-tuned stereospecific packing and hydrogen-bonding network formed by the unique tripartite scaffold at the NAD<sup>+</sup>-binding site (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). Notably, the novel interactions formed by stereospecific, dibranched (8<i>S</i>,9<i>R</i>)-<b>47</b> at the outer borders of the inhibitor-binding pocket have been suggested to influence PARP1’s conformational flexibility, which is possibly involved in the interdomain communication, PARP1–DNA trapping activity, and cytotoxicity potency.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Pharmacokinetic and in Vitro Safety Properties</h3><div class="NLM_p">The excellent in vitro biological and metabolic profiles of the top lead compounds warranted further assessment of their PK properties. As shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, with the exception of the only nonazole derivative (8<i>S</i>,9<i>R</i>)-<b>57</b>, all other compounds demonstrated excellent oral bioavailability ranging from 47 to 91% after oral exposure in Sprague–Dawley rats. All compounds have a reasonable terminal elimination half-life of >2 h, and most compounds display low plasma clearance and volume distribution. Compound (8<i>S</i>,9<i>R</i>)-<b>47</b> has excellent oral exposure and a significantly superior overall PK profile compared to that of the reference compound olaparib (AZD-2281). In beagle dog PK studies, the free base and tosylate salt also behaved very well, showing excellent bioavailability and oral exposure and a long half-life that could support a once-daily dosing regimen (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Moreover, (8<i>S</i>,9<i>R</i>)-<b>47</b> demonstrated a favorable in vitro safety profile based on off-target, CYP450 isozyme, hERG, and Ames screenings (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). Given its favorable PK and in vitro safety profiles, (8<i>S</i>,9<i>R</i>)-<b>47</b> was further evaluated in in vivo xenograft tumor models.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters in Rat for Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">iv (5 mg/kg)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center">po (10 mg/kg)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC (ng·h/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>36</b></td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">10 530</td><td class="colsep0 rowsep0" align="left">36 500</td><td class="colsep0 rowsep0" align="left">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>42</b></td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0.73</td><td class="colsep0 rowsep0" align="left">3988</td><td class="colsep0 rowsep0" align="left">1810</td><td class="colsep0 rowsep0" align="left">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>46</b></td><td class="colsep0 rowsep0" align="left">2.44</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">7771</td><td class="colsep0 rowsep0" align="left">39 852</td><td class="colsep0 rowsep0" align="left">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>57</b></td><td class="colsep0 rowsep0" align="left">2.29</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">126</td><td class="colsep0 rowsep0" align="left">914</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(8<i>S</i>,9<i>R</i>)-<b>47</b></td><td class="colsep0 rowsep0" align="left">2.25</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">7948</td><td class="colsep0 rowsep0" align="left">56 134</td><td class="colsep0 rowsep0" align="left">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD-2281</td><td class="colsep0 rowsep0" align="left">0.53</td><td class="colsep0 rowsep0" align="left">34.3</td><td class="colsep0 rowsep0" align="left">0.83</td><td class="colsep0 rowsep0" align="left">437</td><td class="colsep0 rowsep0" align="left">559</td><td class="colsep0 rowsep0" align="left">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Formulation: 10% DMAc, 5% Solutol, 85% PBS buffer.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters in Dog for Free Base (8<i>S</i>,9<i>R</i>)-<b>47</b> and Its Tosylate Salt</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center" char="±">tosylate salt, iv (0.025 mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">tosylate salt oral (0.01 mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">free base oral (0.1 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char="±">129 ± 41.5</td><td class="colsep0 rowsep0" align="char" char="±">600 ± 88.2</td><td class="colsep0 rowsep0" align="char" char="±">619 ± 110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char="±">135 ± 44.5</td><td class="colsep0 rowsep0" align="char" char="±">611 ± 92.7</td><td class="colsep0 rowsep0" align="char" char="±">629 ± 115</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="±">18.9 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">68.0 ± 7.28</td><td class="colsep0 rowsep0" align="char" char="±">72.2 ± 7.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">26.7 ± 6.48</td><td class="colsep0 rowsep0" align="char" char="±">24.4 ± 1.42</td><td class="colsep0 rowsep0" align="char" char="±">17.9 ± 1.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>last</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="±">0.182 ± 0.111</td><td class="colsep0 rowsep0" align="char" char="±">0.313 ± 0.118</td><td class="colsep0 rowsep0" align="char" char="±">0.365 ± 0.188</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i>/<i>F</i> (mL/kg)</td><td class="colsep0 rowsep0" align="char" char="±">4666 ± 1940<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">5810 ± 619</td><td class="colsep0 rowsep0" align="char" char="±">4161 ± 575</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl/<i>F</i> (mL/h/kg)</td><td class="colsep0 rowsep0" align="char" char="±">198 ± 60.2<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">166 ± 24.6</td><td class="colsep0 rowsep0" align="char" char="±">162 ± 27.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">118.7 ± 29.7</td><td class="colsep0 rowsep0" align="char" char="±">120.9 ± 25.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>V</i><sub>ss</sub>.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Cl.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Absolute bioavailability.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Safety Profile of (8<i>S</i>,9<i>R</i>)-<b>47</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">off-target screening against 72 nontarget proteins at 10 μM</td><td class="colsep0 rowsep0" align="left">no significant responses</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">screening against CYP1A2, 3A4, 2D6, 2C9, and 2C19</td><td class="colsep0 rowsep0" align="left"><12% inhibition at 10 μM concentration</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG functional cellular assay</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> > 100 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ames test</td><td class="colsep0 rowsep0" align="left">no sign of mutagenicity at concentration of 5 mg/plate</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding</td><td class="colsep0 rowsep0" align="left">78.7% bound in human plasma</td></tr></tbody></table></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> In Vivo Antitumor Studies of (8<i>S</i>,9<i>R</i>)-<b>47</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></h3><div class="NLM_p">To assess the in vivo pharmacodynamics of (8<i>S</i>,9<i>R</i>)-<b>47</b>, MX-1 xenograft-bearing mice were given a single oral administration of 1 mg/kg (8<i>S</i>,9<i>R</i>)-<b>47</b>, and tumors were harvested at 2, 8, and 24 h post treatment. Intratumoral PAR levels were determined as described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Treatment with (8<i>S</i>,9<i>R</i>)-<b>47</b> drastically reduced intratumoral PAR levels at 2 and 8 h, followed by only a partial recovery at 24 h (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a). This is in contrast to oral dosing of 100 mg/kg olaparib (AZD-2281), which resulted in significant PAR reduction only at 2 h post treatment, with partial recovery at 8 h and full recovery at 24 h.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. BMN 673 ((8<i>S</i>,9<i>R</i>)-<b>47</b>) exhibits antitumor activity against a <i>BRCA1</i> mutant tumor model in mice.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (A) Pharmacodynamic activity in <i>BRCA1</i> mutant mouse xenograft model following a single dose (1 mg/kg, po) by measuring MX-1 tumor PAR levels using ELISA at 2, 8, and 24 h after treatment. (B) Antitumor efficacy in <i>BRCA1</i> mutant (MX-1) mouse xenograft model following once-daily (QD) oral dosing. (C) BMN 673 is more effective in mouse xenograft models with 0.165 mg/kg twice-daily (BID) dosing than 0.33 mg/kg once-daily (QD) dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To assess in vivo antitumor effects of (8<i>S</i>,9<i>R</i>)-<b>47</b> as a single agent, immunodeficient mice bearing established subcutaneous MX-1 tumor xenografts were treated with (8<i>S</i>,9<i>R</i>)-<b>47</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Once-daily (QD) oral administration of 0.33 mg/kg (8<i>S</i>,9<i>R</i>)-<b>47</b> for 28 consecutive days significantly inhibited xenograft MX-1 tumor growth, with four of six mice achieving a complete response (CR; tumor impalpable; <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b). The lower dose of 0.1 mg/kg (8<i>S</i>,9<i>R</i>)-<b>47</b> showed a limited and insignificant effect on tumor growth after extended treatment (>21 days; <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b), but it still appeared to be more effective than olaparib (AZD-2281) dosed orally at 100 mg/kg QD. (8<i>S</i>,9<i>R</i>)-<b>47</b> at these doses was well-tolerated, with no animal lethality or significant weight loss observed after 28 consecutive days of treatment.</div><div class="NLM_p">Because the PAR levels in mouse xenograft tumors started to recover between 8 and 24 h post administration of (8<i>S</i>,9<i>R</i>)-<b>47</b> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a), we tested whether twice-daily (BID) split-dosing may be more efficacious than QD dosing by comparing 0.33 mg/kg/dose QD vs 0.165 mg/kg/dose BID for 28 days in MX-1 xenogtraft mice.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Both dosing regimens were highly effective during the treatment period at inhibiting MX-1 tumor growth. However, while tumor growth in the QD cohort eventually reestablished after cessation of drug treatment, those in the BID cohort resulted in six of six CRs with no reestablishment of tumor growth even at 5 weeks after cessation of treatment (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>c). These data suggest that continuous suppression of PARP1/2 is required for a sustained antitumor effect in the context of single-agent treatment and that, in mice, BID dosing of (8<i>S</i>,9<i>R</i>)-<b>47</b> was preferred to achieve optimal therapeutic effects. It should be noted that half-life of (8<i>S</i>,9<i>R</i>)-<b>47</b> in humans (∼40 h) is considerably longer than that in mice; QD dosing is sufficient in human patients to continuously suppress PARP and reach anticancer effects.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a></div><div class="NLM_p">The ability of (8<i>S</i>,9<i>R</i>)-<b>47</b> to potentiate DNA-damaging anticancer agents was also assessed in xenograft tumor models.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> MX-1 tumor-bearing mice were treated with 8 consecutive daily oral doses of (8<i>S</i>,9<i>R</i>)-<b>47</b>, olaparib, or vehicle (days 1–8). Cisplatin was dosed intraperitoneally at 6 mg/kg on day 3. (8<i>S</i>,9<i>R</i>)-<b>47</b> at 0.1, 0.33, and 1 mg/kg demonstrated dose-dependent sensitization of cisplatin (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a). In a separate study, (8<i>S</i>,9<i>R</i>)-<b>47</b> showed significant potentiation of carboplatin antitumor effects in vivo without significant overall toxicity (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b). (8<i>S</i>,9<i>R</i>)-<b>47</b> also demonstrates extraordinary potentiation of alkylating agent temozolomide in a number of preclinical studies.<a onclick="showRef(event, 'ref20 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref20 ref39 ref40">(20, 39, 40)</a></div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. BMN 673 ((8<i>S</i>,9<i>R</i>)-<b>47</b>) potentiates the effects of DNA-damaging cytotoxic agents in a BRCA1 mutant MX-1 xenograft mouse model.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (A) BMN 673 in combination with cisplatin. BMN 673 and olaparib were dosed orally once-daily (QD) from days 1–8; cisplatin was dosed by intraperitoneal injection (ip) at 6 mg/kg on day 3. (B) BMN 673 in combination with carboplatin. BMN 673 was dosed orally QD at 0.33 mg/kg for 5 or 8 days starting from day 1. Carboplatin was dosed ip at a 35 mg/kg dosage on day 1 half of an hour after BMN 673 administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66824" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66824" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have described the discovery and characterization of a novel, highly selective, and potent PARP1/2 inhibitor, (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673; talazoparib). This compound represents a series of structurally unique, dual chiral-substituted tetrahydropyridophthalazinones that enable unique and extensive binding interactions with PARP1 and PARP2 proteins. Compound (8<i>S</i>,9<i>R</i>)-<b>47</b> has demonstrated exceptionally potent in vitro antitumor activities, especially as a single-agent in <i>BRCA1</i>/<i>2</i>-deficient cells. Mounting evidence indicates that the ability of (8<i>S</i>,9<i>R</i>)-<b>47</b> to strongly trap PARP proteins at least partially explains its exceptional tumor killing activity.<a onclick="showRef(event, 'ref30 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref32 ref33">(30, 32, 33)</a> (8<i>S</i>,9<i>R</i>)-<b>47</b> also displays favorable pharmacokinetic properties and in vitro safety profiles. The excellent potency and pharmacokinetic properties of this compound after oral administration translate into in vivo anticancer efficacy either as a single agent or as a chemosensitization agent in the <i>BRCA1</i>-deficient MX-1 breast cancer xenograft model and a number of other xenograft tumor models.</div><div class="NLM_p last">The biological and pharmacological properties of (8<i>S</i>,9<i>R</i>)-<b>47</b> warranted its further evaluation in clinical settings. In a phase 1 clinical trial in patients with solid tumors, (8<i>S</i>,9<i>R</i>)-<b>47</b> was shown to be generally well-tolerated with inhibition of PARP activity in peripheral blood mononuclear cells occurring at oral doses as low as 100 μg/day.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> Single-agent anticancer activity was demonstrated in ovarian and breast cancers with deleterious germline <i>BRCA1</i> or <i>BRCA2</i> mutation and in patients with small cell lung cancer.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> On the basis of these encouraging results, two late-phase clinical trials have been initiated using the recommended oral dose of 1 mg/day (8<i>S</i>,9<i>R</i>)-<b>47</b>: a phase 3 international, open-label, randomized, parallel, two-arm study in germline <i>BRCA</i> mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and a phase 2 study in heavily pretreated breast cancer patients with germline <i>BRCA</i> mutations (ABRAZO).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis General</h3><div class="NLM_p last">Solvents and reagents were obtained from commercial suppliers and were used without further purification. The reference compounds ABT-888, AG-014699, AZD-2281, and MK-4827 were synthesized according to literature procedures.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19">(15-19)</a> HPLC-MS analyses were performed on an Agilent 1200 together with a MS 6110 using electrospray ionization (ESI). Prep-HPLC separations were carried out either on a Waters 2545 or Gilson GX-281. Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker AVANCE III 400 spectrometer and are referenced in ppm relative to TMS. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Proton peak multiplicity is reported as s (singlet), d (doublet), t (triplet), q (quintet), dd (doublet of doublets), m (multiplet), and bs (broad singlet). All final compounds displayed ≥95% purity (otherwise as noted), as determined by analytical RP-HPLC on an Agilent 1200 UV wavelengths of 214 and 254 nm.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Chiral HPLC Separation and Analysis</h3><div class="NLM_p last">Chiral separation of racemic compounds was performed using preparative supercritical fluid chromatography (prep-SFC) on a Waters SFC-80 (Thar). Analytical SFC analyses were conducted on a Waters SFC method station (Thar). The chiral column used to resolve the enantiomers was either a CHIRALPACK IA, IC, or OJ-H. Retention times for the individual enantiomers are reported in minutes, whereas the ee (enantiomeric excess) values were calculated based on the UV absorption (at 254 nm) areas for the two enantiomers, respectively. Optical rotation of the chiral compounds was measured using a RUDOLPH (AUTOPOL V) automatic polarimeter.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis of 4-Aminoisobenzofuran-1(3<i>H</i>)-one (<b>7</b>)</h3><div class="NLM_p">A suspension of sodium borohydride (0.757 g, 20 mmol) in anhydrous tetrahydrofuran (THF) (120 mL) was cooled to 0 °C. A solution of 4-nitrobenzofuran-1,3-dione (6.18 g, 32 mmol) in anhydrous tetrahydrofuran (30 mL) was then added dropwise to the suspension. After the addition, the mixture was allowed to stir at this temperature for 3 h. The reaction was quenched with 3 N hydrochloric acid (to pH 1). Water (40 mL) was added to the mixture, which was then stirred for 1 h. THF was removed under reduced pressure. The residue was partitioned between water (150 mL) and ethyl acetate (150 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated to give a crude product. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 20:1 to 2:1) to give 4-nitroisobenzofuran-1(3<i>H</i>)-one (4.2 g, yield 73%) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 180 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 5.77 (s, 3H), 7.32–7.34 (d, <i>J</i> = 8.4 Hz, 1H), 7.81–7.85 (t, <i>J</i> = 8.0 Hz, 1H), 8.29 (d, <i>J</i> = 8.0 Hz, 1H), 8.55 (d, <i>J</i> = 8.0 Hz, 1H).</div><div class="NLM_p last">A suspension of 4-nitroisobenzofuran-1(3<i>H</i>)-one (1.0 g, 5.58 mmol) and 10% Pd/C (0.1 g) in ethyl acetate (30 mL) was purged in 1 atm hydrogen and stirred at 25 °C for 3 h. The mixture was filtered, and the filtrate was concentrated to give 4-aminoisobenzofuran-1(3<i>H</i>)-one (<b>7</b>) (0.8 g, yield 96%) as an off-white solid. MS (ESI) <i>m</i>/<i>z</i>: 150 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 3.82 (bs, 1H), 5.19 (s, 3H), 6.91–6.95 (m, 1H), 7.32–7.36 (m, 2H).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Synthesis of Methyl 4-Oxo-2,3-diaryl-1,2,3,4-tetrahydroquinoline-5-carboxylates (<b>12</b>, <b>14a</b>–<b>e</b>)</h3><div id="sec5_2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Methyl 4-Oxo-2,3-diaryl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>12</b>)</h4><div class="NLM_p last">A mixture of 4-aminoisobenzofuran-1(3<i>H</i>)-one (<b>7</b>) (0.4 g, 2.68 mmol) and benzaldehyde (0.72 g, 6.7 mmol) in ethyl propionate (20 mL) was cooled to 0 °C. Then, a solution of sodium methoxide in methanol [sodium (248 mg, 10.72 mmol) in methanol (20 mL)] was added dropwise. After the addition, the mixture was heated at reflux for 16 h. The mixture was quenched with water (10 mL) and the solvent was removed under reduced pressure. The residue was dissolved in water, acidified with 1 N hydrochloric acid to pH 6, and then extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated to give a crude product, which was purified by prep-HPLC to give methyl 4-oxo-2,3-diphenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>12</b>) (390 mg, yield 41%) as a light yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 358 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 3.86 (s, 3H), 3.95–3.98 (d, <i>J</i> = 16.4 Hz, 1H), 4.81–4.84 (d, <i>J</i> = 12.8 Hz, 1H), 4.89 (s, br 1H), 6.72–6.77 (m, 2H), 6.90–6.93 (m, 2H), 7.11–7.21 (m, 8H), 7.34–7.36 (t, <i>J</i> = 7.8 Hz, 1H).</div></div><div id="sec5_2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Methyl 4-Oxo-2,3-di(4-pyridyl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>14a</b>)</h4><div class="NLM_p last">Compound <b>14a</b> was synthesized by employing the procedure described for compound <b>12</b> using 4-pyridylaldehyde (268 mg, 2.5 mmol) in lieu of benzaldehyde and adjusting the other reagents proportionally to give <b>14a</b> as a light yellow solid (60 mg, yield 17%). MS (ESI) <i>m</i>/<i>z</i>: 360 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Methyl 4-Oxo-2,3-di(2-pyridyl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>14b</b>)</h4><div class="NLM_p last">Compound <b>14b</b> was synthesized by employing the procedure described for compound <b>12</b> using 2-pyridylaldehyde (268 mg, 2.5 mmol) in lieu of benzaldehyde and adjusting the other reagents proportionally to give <b>14b</b> as a light yellow solid (84 mg, yield 23%). MS (ESI) <i>m</i>/<i>z</i>: 360 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Methyl 4-Oxo-2,3-di(3-pyridyl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>14c</b>)</h4><div class="NLM_p last">Compound <b>14c</b> was synthesized by employing the procedure described for compound <b>12</b> using 3-pyridylaldehyde (535 mg, 5 mmol) in lieu of benzaldehyde and adjusting the other reagents proportionally. Purification was using column chromatography (silica gel, petroleum ether/ethyl acetate = 100:1 to 10:1) to give <b>14c</b> as a light yellow solid (480 mg, yield 67%). MS (ESI) <i>m</i>/<i>z</i>: 360 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Methyl 4-Oxo-2,3-di(1-methyl imidazol-2-yl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>14d</b>)</h4><div class="NLM_p last">Compound <b>14d</b> was synthesized by employing the procedure described for compound <b>12</b> using <b>7</b> (298 mg, 2 mmol) and 1-methyl-1<i>H</i>-imidazole-2-carbaldehyde (440 mg, 4 mmol) and adjusting the other reagents proportionally. Purification was using column chromatography (silica gel, petroleum ether/ethyl acetate = 5:1 to 1) to give <b>14d</b> as a light yellow solid (120 mg, yield 16%). MS (ESI) <i>m</i>/<i>z</i>: 366 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Methyl 2,3-Bis(4-((dimethylamino)methyl)phenyl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>14e</b>)</h4><div class="NLM_p last">Compound <b>14e</b> was synthesized by employing the procedure described for compound <b>12</b> using 4-((dimethylamino)methyl)benzaldehyde (539 mg, 3.3 mmol) and <b>7</b> (223 mg, 1.5 mmol) and adjusting the other reagents proportionally. Purification was using column chromatography (silica gel, petroleum ether/ethyl acetate = 100:1 to 10:1) to give <b>14e</b> as a light yellow solid (165 mg, yield 23%). MS (ESI) <i>m</i>/<i>z</i>: 472 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Synthesis of 8,9-(Biaryl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-ones (<b>13</b>, <b>15</b>–<b>19</b>)</h3><div id="sec5_2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 8,9-Diphenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>13</b>)</h4><div class="NLM_p last">A suspension of methyl 4-oxo-2,3-diphenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>12</b>) (100 mg, 0.28 mmol) in 85% hydrazine monohydrate (25 mL) was heated to reflux for 20 h. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated to give a crude product, which was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 20:1 to 8:1) to give compound <b>13</b> (15.6 mg, yield 16%) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 340 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 4.22–4.24 (d, <i>J</i> = 8 Hz, 1H), 4.66–4.68 (d, <i>J</i> = 8 Hz, 1H), 4.89 (s, 1H), 7.02–7.06 (m, 3H), 7.16–7.26 (m, 8H), 7.57–7.61 (t, <i>J</i> = 7.8 Hz, 1H), 7.74–7.76 (d, <i>J</i> = 7.6 Hz, 1H), 9.82 (s, 1H).</div></div><div id="sec5_2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 8,9-Di-(4-pyridyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>15</b>)</h4><div class="NLM_p last">Compound <b>15</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>14a</b> (60 mg, 0.17 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>15</b> as a light yellow solid (15 mg, yield 26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 4.46–4.48 (d, <i>J</i> = 8.4 Hz, 1H), 4.90–4.92 (d, <i>J</i> = 8.4 Hz, 1H), 7.16–7.20 (m, 3H), 7.32–7.34 (d, <i>J</i> = 5.2 Hz, 2H), 7.40–7.42 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (s, 1H), 7.59–7.63 (t, <i>J</i> = 8.0 Hz, 1H), 8.40–8.40 (d, <i>J</i> = 5.2 Hz, 2H), 8.44–8.45 (d, <i>J</i> = 5.2 Hz, 2H), 12.24 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 342 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 8,9-Di-(2-pyridyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>16</b>)</h4><div class="NLM_p last">Compound <b>16</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>14b</b> (68 mg, 0.19 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>16</b> as a light yellow solid (24 mg, yield 37%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 5.42–5.43 (d, <i>J</i> = 5.2 Hz, 1H), 5.56–5.57 (d, <i>J</i> = 5.2 Hz, 1H), 7.30–7.32 (d, <i>J</i> = 8.0 Hz,1H), 7.37–7.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.63–7.66 (t, <i>J</i> = 6.6 Hz, 1H), 7.68–7.70 (m, 2H), 7.78–7.80 (d, <i>J</i> = 7.2 Hz, 1H), 7.87–7.89 (d, <i>J</i> = 8.0 Hz, 2H), 8.11–8.16 (m, 2H), 8.66–8.67 (d, <i>J</i> = 4.8 Hz, 1H), 8.74–8.76 (d, <i>J</i> = 5.6 Hz, 1H), 10.69 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 342 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 8,9-Di-(3-pyridyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>17</b>)</h4><div class="NLM_p last">Compound <b>17</b> was synthesized by employing a modified procedure for compound <b>13</b> using compound <b>14c</b> (480 mg, 1.33 mmol) mixed with 85% hydrazine monohydrate (20 mL) and methanol (5 mL). Refluxed for 2 h, the mixture was cooled to room temperature and filtered, affording <b>17</b> (320 mg, yield 70%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 4.51–4.53 (d, <i>J</i> = 8.4 Hz, 1H), 4.89–4.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.18–7.20 (d, 1H), 7.24–7.27 (m, 1H), 7.31–7.33 (m, 1H), 7.43–7.44 (d, 1H), 7.60 (s, 1H), 7.58–7.63 (m, 2H), 7.79–7.81 (m, 1H), 8.32–8.34 (m, 2H), 8.41–8.43 (m, 1H), 8.45–8.46 (d, <i>J</i> = 1.6 Hz, 1H), 12.18 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 342 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 8,9-Di-(1-methyl-imidazol-2-yl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>18</b>)</h4><div class="NLM_p last">Compound <b>18</b> was synthesized by employing a modified procedure for compound <b>13</b> using compound <b>14d</b> (120 mg, 0.32 mmol) mixed with 85% hydrazine monohydrate (2 mL) and methanol (3 mL). Stirred at room temperature for 3.5 h, the mixture was concentrated, filtered, and washed with methanol, affording <b>18</b> (45 mg, yield 39%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 3.46 (s, 3H), 3.49 (s, 3H), 4.78–4.81 (d, <i>J</i> = 12.0 Hz, 1H), 5.08–5.11 (d, <i>J</i> = 12.0 Hz, 1H), 6.69 (s, 1H), 6.76–6.79 (m, 3H), 6.99–7.02 (d, <i>J</i> = 7.6 Hz, 1H), 7.42–7.49 (m, 2H). LC-MS (ESI) <i>m</i>/<i>z</i>: 348 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 8,9-Bis(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>19</b>)</h4><div class="NLM_p last">Compound <b>19</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>14e</b> (165 mg, 0.35 mmol) mixed with 85% hydrazine monohydrate (12 mL) and methanol (5 mL). Stirred at 40 °C for 6 h, the crude product was purified by prep-HPLC, affording <b>19</b> (34 mg, yield 21%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 2.04 (s, 6H), 2.05 (s, 6H), 3.19–3.20 (m, 2H), 3.24–3.26 (m, 2H), 4.09–4.11 (d, <i>J</i> = 8.8 Hz, 1H), 4.52–4.54 (d, <i>J</i> = 8.8 Hz, 1H), 7.02–7.12 (m, 6H), 7.16–7.22 (m, 4H), 7.36–7.38 (d, 1H), 7.55–7.57 (t, 1H), 12.2 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 454 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Synthesis of 9-(Piperidin-3-yl)-8-(pyridin-3-yl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>20</b>)</h3><div class="NLM_p last">A suspension of compound <b>17</b> (120 mg, 0.35 mmol) and platinum(IV) oxide (60 mg) in methanol (20 mL) was purged with 20 atm hydrogen and stirred at 50 °C for 24 h. The mixture was filtered, and the filtrate was concentrated to give a crude product, which was purified by prep-HPLC to give compound <b>20</b> (4 mg, yield 4%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 1.19–1.32 (m, 2H), 1.60–1.65 (m, 2H), 1.94–1.97 (d, <i>J</i> = 10.0 Hz, 1H), 2.31–2.43 (m, 2H), 2.82–2.85 (d, <i>J</i> = 12.4 Hz, 1H), 3.02–3.05 (d, <i>J</i> = 12 Hz, 1H), 3.29–3.32 (dd, <i>J</i><sub>1</sub> = 2.8 Hz, <i>J</i><sub>2</sub> = 8.4 Hz,1H), 4.25–4.26 (d, <i>J</i> = 2.8 Hz, 1H), 7.02–7.05 (dd, <i>J</i><sub>1</sub> = 0.8 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1H), 7.22–7.25 (m, 1H), 7.40–7.53 (m, 3H), 8.25–8.29 (m, 2H). LC-MS (ESI) <i>m</i>/<i>z</i>: 348 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Synthesis of (<i>E</i>)-4-((Arylmethylene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21a</b>–<b>k</b>)</h3><div id="sec5_2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>E</i>)-4-((4-Fluorobenzylidene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21f</b>)</h4><div class="NLM_p last">To a stirred mixture of 4-fluorobenzaldehyde (3 g, 20.4 mmol) and anhydrous sodium sulfate (29 g, 20.4 mmol) in anhydrous dichloromethane (200 mL) was added 4-aminoisobenzofuran-1(3<i>H</i>)-one. The mixture was heated to reflux for 24 h. After cooling to room temperature, it was filtered and the cake was washed with dichloromethane (50 mL × 3). The filtrate was concentrated to render a crude product, which was washed with petroleum ether to afford the title compound <b>21f</b> (4.25 g, yield 81%) as a slightly yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 5.519 (s, 2H), 7.417 (dd, <i>J</i> = 8.8 Hz, 2H), 7.656 (m, 2H), 7.737 (dd, <i>J</i><sub>1</sub> = 5.6 Hz, <i>J</i><sub>2</sub> = 1.2 Hz, 1H), 8.042–8.079 (dd, <i>J</i><sub>1</sub> = 6 Hz, <i>J</i><sub>2</sub> = 3.2 Hz, 2H), 8.801 (s, 1H); LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 256 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>E</i>)-4-((4-((Dimethylamino)methyl)benzylidene)amino)-6-fluoroisobenzofuran-1(3<i>H</i>)-one (<b>21a</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using 4-((dimethylamino)methyl)benzaldehyde (4 g, 24.5 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (4 g, 22.3 mmol) as the starting reagents. Compound <b>21a</b> was obtained as an off-white solid (3.7 g, yield 55%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 313 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 2.28 (s, 6H), 3.52 (s, 2H), 5.38–5.38 (m, 2H), 7.09–7.12 (m, 1H), 7.42–7.44 (m,1H), 7.46–7.48 (d, <i>J</i> = 8 Hz, 2H), 7.87–7.89 (d, <i>J</i> = 8 Hz, 2H), 8.51 (s, 1H).</div></div><div id="sec5_2_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>E</i>)-4-(Benzylideneamino)-6-fluoroisobenzofuran-1(3<i>H</i>)-one (<b>21b</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure described for <b>21f</b> using benzaldehyde (4.125 g, 29.9 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (5 g, 29.9 mmol) as the starting reagents. Compound <b>21b</b> was obtained as an off-white solid (5 g, yield 66%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 256 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 5.40 (s, 2H); 7.11–7.14 (dd, <i>J</i><sub>1</sub> = 9.6 Hz, <i>J</i><sub>2</sub> = 2 Hz, 1H), 7.44–7.46 (dd, <i>J</i><sub>1</sub> = 6.8 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H), 7.52–7.59 (m, 3H), 7.93–7.95 (m, 2H), 8.54 (s, 1H).</div></div><div id="sec5_2_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>E</i>)-6-Fluoro-4-((4-fluorobenzylidene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21c</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure described for <b>21f</b> using 4-fluorobenzaldehyde (1.67 g, 13.5 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (1.5 g, 8.98 mmol) as the starting reagents. Compound <b>21c</b> was obtained as a yellowish solid (0.85 g, yield 35%). LC-MS (ESI) <i>m</i>/<i>z</i>: 274 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 5.37 (s, 2), 7.09–7.12 (dd, 1H), 7.19–7.23 (t, 2H), 7.43–7.45 (dd, 1H), 7.92–7.95 (m, 2H), 8.49 (s, 1H).</div></div><div id="sec5_2_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>E</i>)-4-(Benzylideneamino)isobenzofuran-1(3<i>H</i>)-one (<b>21d</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using benzaldehyde (0.43 g, 4 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (0.6 g, 4 mmol) as the starting reagents. Compound <b>21d</b> was obtained as a white solid (0.9 g, yield 95%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 238 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 5.41 (s, 2H), 7.36–7.37 (d, <i>J</i> = 7.6 Hz, 1H), 7.49–7.59 (m, 4H), 7.77–7.78 (d, <i>J</i> = 7.6 Hz, 1H), 7.92–7.94 (d, <i>J</i> = 8.0 Hz, 2H), 8.55 (s, 1H).</div></div><div id="sec5_2_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>E</i>)-4-((4-((Dimethylamino)methyl)benzylidene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21e</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure described for <b>21f</b> using 4-((dimethylamino)methyl)benzaldehyde (3.16 g, 19.4 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (2.89 g, 19.4 mmol) as the starting reagents. Compound <b>21e</b> was obtained as a light yellow solid (1.83 g, yield 32%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 295 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>E</i>)-4-((4-Chlorobenzylidene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21g</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using 4-chlorobenzaldehyde (2.3 g, 16.1 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (2.0 g, 13.4 mmol) as the starting reagents. Compound <b>21g</b> was obtained as an off-white solid (2.0 g, yield 55%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 272 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>E</i>)-4-((4-(Trifluoromethyl)benzylidene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21h</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using 4-(trifluoromethyl)benzaldehyde (2.8 g, 16.1 mmol) and 4-amino-6-fluoroisobenzofuran-1(3<i>H</i>)-one (2.0 g, 13.4 mmol) as the starting reagents. Compound <b>21h</b> was obtained as a yellowish solid (2.8 g, yield 68%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 306 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>E</i>)-4-(Benzylideneamino)-6-chloroisobenzofuran-1(3<i>H</i>)-one (<b>21i</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using benzaldehyde (0.72 g, 6.79 mmol) and 4-amino-6-chloroisobenzofuran-1(3<i>H</i>)-one <b>7b</b> (1.0 g, 5.46 mmol) as the starting reagents. Compound <b>21i</b> was obtained as a light yellow solid (0.74 g, yield 50%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 272 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (E)-4-(((1-Methyl-1<i>H</i>-imidazol-2-yl)methylene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21j</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using 1-methyl-1<i>H</i>-imidazole-2-carbaldehyde (2.50 g, 23.0 mmol) and 4-amino-isobenzofuran-1(3<i>H</i>)-one (2.80 g, 19.0 mmol) as the starting reagents. Compound <b>21j</b> was obtained as a white solid (5.0 g, yield 98%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 242 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 4.06 (s, 3H), 5.52 (s, 2H), 7.22 (s, 1H), 7.52 (s, 1H), 7.65–7.67 (m, 1H), 7.72–7.74 (m, 2H), 8.66 (s, 1H).</div></div><div id="sec5_2_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>E</i>)-4-((4-(Diethoxymethyl)benzylidene)amino)isobenzofuran-1(3<i>H</i>)-one (<b>21k</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using 4-(diethoxymethyl)benzaldehyde (3.75 g, 18.0 mmol) and 4-amino-isobenzofuran-1(3<i>H</i>)-one (2.24 g, 15.0 mmol) as the starting reagents. Compound <b>21k</b> was obtained as a light yellow solid (4.3 g, yield 84%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 340 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>E</i>)-4-(3-(Diethoxymethyl)benzylideneamino)isobenzofuran-1(3<i>H</i>)-one (<b>21l</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>21f</b> using 3-(diethoxymethyl)benzaldehyde (3.75 g, 18.0 mmol) and 4-amino-isobenzofuran-1(3<i>H</i>)-one (2.24 g, 15.0 mmol) as the starting reagents. Compound <b>21k</b> was obtained as a white solid (3.1 g, yield 61%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 340 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Synthesis of Methyl or Ethyl 2,3-Disubstituted-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylates (<b>22a</b>–<b>u</b> and <b>23a</b>–<b>h</b>)</h3><div id="sec5_2_6_0" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Ethyl 3-(1-methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22d</b>)</h4><div class="NLM_p last">A mixture of (<i>E</i>)-4-(benzylideneamino)isobenzofuran-1(3<i>H</i>)-one (<b>21d</b>) (500 mg, 2.1 mmol) and 1-methyl-1<i>H</i>-imidazole-2- carbaldehyde (255 mg, 2.3 mmol) in ethyl propionate (20 mL) was cooled to 0 °C. Then, a solution of sodium ethoxide in ethanol [sodium (194 mg, 8.4 mmol) in ethanol (10 mL)] was added dropwise. After the addition, the mixture was stirred at room temperature for 2.5 h. The mixture was quenched with water (20 mL), and solvent was removed in vacuum. The residue was suspended in water and then filtered. The cake was washed with water and ethyl acetate to give a crude product, which was then purified with column chromatography on silica gel (petroleum ether/ethyl acetate 10:1 to 1:10) to give compound <b>22d</b> as a yellow solid (140 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 1.18–1.21 (t, <i>J</i> = 7.2 Hz, 3H), 3.31 (s, 3H), 4.16–4.19 (m, 2H), 4.56–4.59 (d, <i>J</i> = 13.2 Hz, 1H), 5.14–5.17 (d, <i>J</i> = 13.2 Hz, 1H), 6.54–6.56 (d, <i>J</i> = 7.2 Hz, 1H), 6.72 (s, 1H), 6.86 (s, 1H), 6.98–6.99 (d, <i>J</i> = 4.8 Hz, 1H), 7.24–7.29 (m, 3H), 7.34–7.38 (t, <i>J</i> = 8.0 Hz, 1H), 7.42–7.44 (d, <i>J</i> = 7.2 Hz, 2H), 7.49 (s, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 376 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Methyl 3-Isopropyl-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22a</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21d</b> (237 mg, 1.0 mmol) and isobutyraldehyde (216 mg, 3.0 mmol) as the starting reagents. Compound <b>22a</b> was obtained as a white solid (35 mg, yield 11%). LC-MS (ESI) <i>m</i>/<i>z</i>: 324 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Methyl 3-(4-((Dimethylamino)methyl)phenyl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22b</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21d</b> (474 mg, 2.0 mmol) and 4-((dimethylamino)methyl)benzaldehyde (326 mg, 2.0 mmol) as the starting reagents. Compound <b>22b</b> was obtained as a light yellow solid (166 mg, yield 20%). LC-MS (ESI) <i>m</i>/<i>z</i>: 415 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Methyl 3-(3-(Diethoxymethyl)phenyl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22c</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21d</b> (474 mg, 2.0 mmol) and 3-(diethoxymethyl)benzaldehyde (418 mg, 2.0 mmol) as the starting reagents. It was obtained as a light yellow solid (230 mg, yield 25%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 1.05–1.09 (t, <i>J</i> = 6.8 Hz, 6H), 3.27–3.31 (q, 4H), 3.68 (s, 3H), 4.22–4.25 (d, <i>J</i> = 12.0 Hz, 1H), 4.96–4.99 (d, <i>J</i> = 12.0 Hz, 1H), 5.33 (s, 1H), 6.54–6.56 (dd, <i>J</i><sub>1</sub> = 7.2 Hz, <i>J</i><sub>2</sub> = 0.8 Hz, 1H), 6.98–7.00 (dd, <i>J</i><sub>1</sub> = 8.4 Hz, <i>J</i><sub>2</sub> = 0.8 Hz, 1H), 7.12–7.23 (m, 7H), 7.31–7.38 (m, 3H), 7.58 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 460 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Ethyl 3-(1-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22e</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21d</b> (1.78g, 7.5 mmol) and 1-methyl-4<i>H</i>-1,2,4-triazole-5-carbaldehyde (1.01 g, 9.16 mmol) as the starting reagents. Compound <b>22e</b> was obtained as a greenish solid (400 mg, yield 14%). LC-MS (ESI) <i>m</i>/<i>z</i>: 377 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Ethyl 3-(4-Methyl-4<i>H</i>-1,2,4-triazol-3-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22f</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21d</b> (634 mg, 2.7 mmol) and 4-methyl-4<i>H</i>-1,2,4-triazole-3-carbaldehyde (300 mg, 2.7 mmol) as the starting reagents. Compound <b>22f</b> was obtained as a light yellow solid (51 mg, yield 5%). LC-MS (ESI) <i>m</i>/<i>z</i>: 377 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Ethyl 2-(4-(Diethoxymethyl)phenyl)-3-(4-fluorophenyl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22g</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21k</b> (10.8 g, 31.9 mmol) and 4-fluorobenzaldehyde (3.95 g, 31.9 mmol) as the starting reagents. It was obtained as a white solid (4.2 g, yield 26%). LC-MS (ESI) <i>m</i>/<i>z</i>: 492 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Ethyl 2-(4-((Dimethylamino)methyl)phenyl)-3-(4-isopropylphenyl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22h</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21e</b> (588 mg, 2.0 mmol) and 4-isopropylbenzaldehyde (296 mg, 2.0 mmol) as the starting reagents. It was obtained as a light yellow solid (210 mg, yield 22%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 471 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Ethyl 2-(4-((Dimethylamino)methyl)phenyl)-4-oxo-3-<i>p</i>-tolyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22i</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21e</b> (500 mg, 1.70 mmol) and 4-methylbenzaldehyde (204 mg, 1.70 mmol) as the starting reagents. It was obtained as a white solid (110 mg, yield 15%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 443 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Ethyl 2-(4-((dimethylamino)methyl)phenyl)-4-oxo-3-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22j</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21e</b> (541 mg, 1.84 mmol) and 4-(trifluoromethyl)benzaldehyde (320 mg, 1.84 mmol) as the starting reagents. It was obtained as a light yellow solid (150 mg, yield 16%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 497 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Ethyl 2-(3-(Diethoxymethyl)phenyl)-4-oxo-3-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22l</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21l</b> (678 mg, 2 mmol) and benzaldehyde (212 mg, 2.2 mmol) as the starting reagents. It was obtained as a white solid (160 mg, yield 17%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 474 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Methyl 2-(4-(Dimethoxymethyl)phenyl)-4-oxo-3-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22m</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21k</b> (600 mg, 1.0 mmol) and benzaldehyde (616 mg, 3.0 mmol) as the starting reagents. It was obtained as a white solid (120 mg, yield 22%). LC-MS (ESI) <i>m</i>/<i>z</i>: 432 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Ethyl 2-(1-Methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-3-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22n</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21k</b> (241 mg, 1.0 mmol) and benzaldehyde (116 mg, 1.1 mmol) as the starting reagents. It was obtained as a white solid (87 mg, yield 24%). LC-MS (ESI) <i>m</i>/<i>z</i>: 376 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Ethyl 2-(4-Fluorophenyl)-4-oxo-3-(thiazol-2-yl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22o</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21f</b> (1.88 g, 7.37 mmol) and thiazole-2-carbaldehyde (1.0 g, 8.8 mmol) as the starting reagents. It was obtained as a white solid (180 mg, yield 6%). LC-MS (ESI) <i>m</i>/<i>z</i>: 397 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Ethyl 3-(4-Methyl-4<i>H</i>-1,2,4-triazol-3-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22p</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21d</b> (393 mg, 1.7 mmol) and 4-methyl-4<i>H</i>-1,2,4-triazole-3-carbaldehyde (220 mg, 3.0 mmol) as the starting reagents. It was obtained as a yellow solid (32 mg, yield 5%). LC-MS (ESI) <i>m</i>/<i>z</i>: 377 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Ethyl 2-(4-Fluorophenyl)-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22q</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21f</b> (5.0 g, 19.6 mmol) and 1-methyl-4<i>H</i>-1,2,4-triazole-5-carbaldehyde (2.8 g, 25.5 mmol) as the starting reagents. It was obtained as a light yellow solid (2.4 g, yield 31%). LC-MS (ESI) <i>m</i>/<i>z</i>: 395 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Ethyl 2-(4-Fluorophenyl)-3-(1-methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22r</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21f</b> (2.53 g, 10.0 mmol) and 1-methyl-1<i>H</i>- imidazole-2-carbaldehyde (1.21 g, 11.0 mmol) as the starting reagents. It was obtained as a light yellow solid (1.52 g, yield 59%). LC-MS (ESI) <i>m</i>/<i>z</i>: 394 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Ethyl 7-Fluoro-2-(4-fluorophenyl)-3-(1-methyl-1<i>H</i>-pyrazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22s</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21c</b> (2.0 g, 7.27 mmol) and 1-methyl-1<i>H</i>-pyrazole-5-carbaldehyde (2.0 g, 18.2 mmol) as the starting reagents. It was obtained as a light yellow solid (1.0 g, yield 33%). LC-MS (ESI) <i>m</i>/<i>z</i>: 412 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Ethyl 3-(1-Methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-2-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>22t</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21h</b> (1.0 g, 3.28 mmol) and 1-methyl-1<i>H</i>- imidazole-2-carbaldehyde (0.40 g, 3.61 mmol) as the starting reagents. It was obtained as a white solid (150 mg, yield 8%). LC-MS (ESI) <i>m</i>/<i>z</i>: 444 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Ethyl 2-(4-((Dimethylamino)methyl)phenyl)-7-fluoro-4-oxo-3-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>23a</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21a</b> (220 mg, 0.71 mmol) and benzaldehyde (75 mg, 0.71 mmol) as the starting reagents. It was obtained as a yellow solid (80 mg, yield 25%). LC-MS (ESI) <i>m</i>/<i>z</i>: 447 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Ethyl 2-(4-((Dimethylamino)methyl)phenyl)-7-fluoro-3-(4-fluorophenyl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>23b</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21a</b> (500 mg, 1.60 mmol) and 4-fluorobenzaldehyde (218 mg, 1.76 mmol) as the starting reagents. It was obtained as a white solid (100 mg, yield 13%). LC-MS (ESI) <i>m</i>/<i>z</i>: 465 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Ethyl 7-Fluoro-3-(1-methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>23c</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21b</b> (2.0 g, 7.80 mmol) and 1-methyl-1<i>H</i>- imidazole-2-carbaldehyde (0.95 g, 8.63 mmol) as the starting reagents. It was obtained as a white solid (141 mg, yield 5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 1.18–1.22 (t, <i>J</i> = 7.2 Hz, 3H), 3.31 (s, 3H), 4.17–4.21 (q, <i>J</i> = 7.2 Hz, 2H), 4.62–4.65 (d, <i>J</i> = 13.2 Hz, 1H), 5.17–5.20 (d, <i>J</i> = 13.2 Hz, 1H), 6.48–6.51 (d, <i>J</i> = 8.4 Hz, 1H), 6.70–6.73 (m, 2H), 6.86 (s, 1H), 7.24–7.30 (m, 3 H), 7.42–7.44 (t, 2H), 7.76 (s, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 394 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Ethyl 7-Fluoro-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>23d</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21b</b> (1.25 g, 4.90 mmol) and 1-methyl-4<i>H</i>-1,2,4-triazole-5-carbaldehyde (0.90 g, 8.10 mmol) as the starting reagents. It was obtained as a greenish solid (190 mg, yield 10%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 395 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Methyl 7-Fluoro-2-(4-fluorophenyl)-3-(1-methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-1,2,3,4-tetrahydroquinolie-5-carboxylate (<b>23e</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21c</b> (0.85 g, 3.13 mmol) and 1-methyl-1<i>H</i>- imidazole-2-carbaldehyde (0.34 g, 3.13 mmol) as the starting reagents. It was obtained as a white solid (20 mg, yield 2%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 412 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Ethyl 7-Fluoro-2-(4-fluorophenyl)-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>23f</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21c</b> (4.0 g, 14.6 mmol) and 1-methyl-4<i>H</i>-1,2,4-triazole-5-carbaldehyde (4.10 g, 36.9 mmol) as the starting reagents. It was obtained as a greenish solid (1.02 g, yield 14%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 413 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Ethyl 7-Chloro-3-(1-methyl-1<i>H</i>-imidazol-2-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>23g</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>22d</b> using <b>21i</b> (0.72 g, 2.66 mmol) and 1-methyl-1<i>H</i>- imidazole-2-carbaldehyde (0.33 g, 3.0 mmol) as the starting reagents. It was obtained as a greenish solid (170 mg, yield 14%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 410 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Synthesis of 8,9-Diaryl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-ones (<b>24</b>, <b>28</b>–<b>51</b>)</h3><div id="sec5_2_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 9-(4-((Dimethylamino)methyl)phenyl)-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>24</b>)</h4><div class="NLM_p last">Compound <b>24</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22b</b> (80 mg, 0.19 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>24</b> as a light yellow solid (12 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.31(s, 6H), 3.57 (s, 2H), 4.33 (d, 1H), 4.73 (d, 1H), 7.10–7.12 (m, 2H), 7.19–7.21 (m, 6H), 7.26–7.27 (m, 2H), 7.58 (d, 1H), 7.64 (t, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 397(M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 8-(4-((Dimethylamino)methyl)phenyl)-9-(4-isopropylphenyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22h</b> (210 mg, 0.45 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>28</b> as a white solid (72 mg, yield 37%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 1.18 (d, 3H), 1.19 (d, 3H), 2.26 (s, 6H), 2.79–2.83 (m, 1H), 3.51 (d, 2H), 4.27 (d, <i>J</i> = 8.0 Hz, 1H), 4.73 (d, <i>J</i> = 8.0 Hz, 1H), 6.98–7.00 (m, 2H), 7.05–7.07 (m, 2H), 7.18–7.22 (m, 3 H), 7.25–7.27 (m, 2H), 7.54–7.56 (m, 1H), 7.56–7.59 (m, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 439 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 8-(4-((Dimethylamino)methyl)phenyl)-9-p-tolyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>29</b>)</h4><div class="NLM_p last">Compound <b>29</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22i</b> (120 mg, 0.27 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>29</b> as a white solid (14 mg, yield 13%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.18 (s, 3H), 2.31 (s, 6H), 3.57 (s, 2H), 4.25–4.27 (d, <i>J</i> = 8.4 Hz, 1H), 4.72–4.74 (d, <i>J</i> = 8.4 Hz, 1H), 6.95–7.02 (m, 4H), 7.19–7.29 (m, 5H), 7.55–7.57 (m, 1H), 7.62–7.64 (t, <i>J</i> = 8 Hz, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 411 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 8-(4-((Dimethylamino)methyl)phenyl)-9-(4-(trifluoromethyl)phenyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22j</b> (150 mg, 0.30 mmol) as the starting material. Purification was performed using flash column chromatography on silia gel to give <b>30</b> as a white solid (60 mg, yield 35%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 2.64 (s, 3H), 2.65 (s, 3H), 4.19–4.20 (d, <i>J</i> = 4.0 Hz, 2H), 4.53–4.55 (d, <i>J</i> = 9.2 Hz, 1H), 4.88–4.90 (d, <i>J</i> = 9.2 Hz, 1H), 7.20–7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.35–7.46 (m, 7H), 7.50 (s, 1H), 7.56–7.63 (m, 3H), 9.69–9.71 (br s, 1 H), 12.20 (s, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 465 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 8-(4-((Dimethylamino)methyl)phenyl)-5-fluoro-9-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23a</b> (80 mg, 0.18 mmol) as the starting material. Purification was performed using flash column chromatography on silia gel to give <b>31</b> as a light yellow solid (22 mg, yield 30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 2.14 (s, 6H), 3.36 (s, 2H), 4.18–4.21 (d, <i>J</i> = 8.8 Hz, 1H), 4.67–4.69 (d, <i>J</i> = 9.2 Hz, 1H), 6.81–6.84 (m, 1H), 6.99–7. 01 (m, 2H), 7.08–7.19 (m, 8H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 415 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 8-(4-((Dimethylamino)methyl)phenyl)-5-fluoro-9-(4-fluorophenyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>32</b>)</h4><div class="NLM_p last">Compound <b>32</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23b</b> (100 mg, 0.21 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>32</b> as a light yellow solid (35 mg, yield 37%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.12 (s, 6H), 3.35 (s, 2H), 4.20–4.22 (d, <i>J</i> = 8.0 Hz, 1H), 4.63–4.65 (d, <i>J</i> = 8.0 Hz, 1H), 6.83–6.86 (m, 3H), 6.99–7.01 (m, 2H), 7.13–7.17 (m, 5H); <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) −105.66 (s), −118.17 (s). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 433 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 9-Isopropyl-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22a</b> (35 mg, 0.1 mmol) as the starting material. Purification was performed using flash column chromatography on silica gel to give <b>33</b> as a light yellow solid (5 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 0.82–0.83 (d, <i>J</i> = 5.2 Hz, 3H), 1.15–1.17 (d, <i>J</i> = 5.2 Hz, 3H), 1.89–1.93 (m, 1H), 2.71–2.73 (d, <i>J</i> = 6.0 Hz, 1H), 4.83 (s, 1H), 7.11–7.26 (m, 7H), 7.51–7.54 (m, 2H), 12.11 (s, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 306 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 8-(1-Methyl-1<i>H</i>-imidazol-2-yl)-9-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>34</b>)</h4><div class="NLM_p last">Compound <b>34</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22n</b> (87 mg, 0.23 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>34</b> as a light yellow solid (34 mg, yield 42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.41 (s, 3H), 4.49 (d, 1H), 5.35 (d, 1H), 7.18–7.20 (m, 2H), 7.26–7.29 (m, 1H), 7.33–7.35 (m, 3H), 7.40 (d, 1H), 7.61 (d, 1H), 7.71–7.75 (m, 2H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 344 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 9-(1-Methyl-1<i>H</i>-imidazol-2-yl)-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>35</b>)</h4><div class="NLM_p last">Compound <b>35</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22d</b> (140 mg, 0.37 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>35</b> as a light yellow solid (95 mg, yield 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.40 (s, 3H), 4.64–4.67 (d, <i>J</i> = 10.8 Hz, 1H), 4.92–4.94 (d, <i>J</i> = 10.4 Hz, 1H), 6.72 (s, 1H), 6.87 (s, 1H), 7.15–7.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.26–7.30 (m, 3H), 7.38 (s, 3H), 7.55–7.59 (t, <i>J</i> = 7.6 Hz, 1H), 12.15 (s, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 344 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 8-(4-Fluorophenyl)-9-(1-methyl-1<i>H</i>-imidazol-2-yl)- 8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>36</b>)</h4><div class="NLM_p last">Compound <b>36</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22r</b> (210 mg, 0.53 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>36</b> as a light yellow solid (36 mg, yield 19%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.42 (s, 3H), 4.66 (d, <i>J</i> = 8.0 Hz, 1H), 4.95 (d, <i>J</i> = 8.0 Hz, 1H), 6.72 (s, 1H), 6.89 (s, 1H), 7.11–7.17 (m, 3H), 7.30 (s, 1H), 7.40 (d, 1H), 7.43–7.44 (m, 2H), 7.58 (d, 1H), 12.17 (s, 1H). <sup>19</sup>F NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) −114.58. LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 362 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 5-Fluoro-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>37</b>)</h4><div class="NLM_p last">Compound <b>37</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23c</b> (141 mg, 0.35 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>37</b> as a light yellow solid (11 mg, yield 9%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 3.34 (s, 3H), 4.65 (d, <i>J</i> = 8.0 Hz, 1H), 4.94 (d, <i>J</i> = 8.0 Hz, 1H), 6.81 (s, 1H), 6.88–7.02 (m, 2H), 7.18 (dd, 1H), 7.28–7.29 (m, 3H), 7.34–7.36 (m, 2H). <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) −105.70 (s). LC-MS (ESI) <i>m</i>/<i>z</i>: 362 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 8-(4-Fluorophenyl)-9-(thiazol-2-yl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>38</b>)</h4><div class="NLM_p last">Compound <b>38</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22o</b> (180 mg, 0.45 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>38</b> as a light yellow solid (3 mg, yield 2%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 4.88 (d, <i>J</i> = 8.0 Hz, 1H), 5.09 (d, <i>J</i> = 8.0 Hz, 1H), 7.01 (t, 2H), 7.21 (d, 1H), 7.36–7.40 (m, 2H), 7.47 (d, 1H), 7.59 (d, 1H), 7.65 (t, 1H), 7.74 (d, 1H). <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) −116.36 (s). LC-MS (ESI) <i>m</i>/<i>z</i>: 365 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-pyrazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>39</b>)</h4><div class="NLM_p last">Compound <b>39</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22s</b> (400 mg, 0.97 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>39</b> as a white solid (200 mg, yield 54%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.64 (s, 3 H), 4.72–4.75 (d, <i>J</i> = 12 Hz, 1H), 4.89–4.92 (d, <i>J</i> = 12 Hz, 1H), 6.10–6.11 (d, <i>J</i> = 4 Hz, 1H), 6.89–6.92 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 2.0 Hz, 1H), 7.03–7.06 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H), 7.12–7.17 (t, <i>J</i> = 8.8 Hz, 2H), 7.22–7.23 (d, <i>J</i> = 2.4 Hz, 1H), 7.46–7.49 (m, 2H), 7.73 (s, 1H), 12.34 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 380 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 9-(1-Methyl-1<i>H</i>-imidazol-2-yl)-8-(4-(trifluoromethyl)phenyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>40</b>)</h4><div class="NLM_p last">Compound <b>40</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22t</b> (150 mg, 0.34 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>40</b> as a white solid (25 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.46 (s, 3H), 4.81 (d, <i>J</i> = 10.8 Hz, 1H), 5.07 (d, <i>J</i> = 10.8 Hz, 1H), 6.82 (s, 1H), 6.97 (d, 1H), 7.16 (d, <i>J</i> = 8 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz 2H), 7.58–7.69 (m, 5H), 12.22 (d, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 412 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 5-Chloro-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>41</b>)</h4><div class="NLM_p last">Compound <b>41</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23g</b> (429 mg, 1.05 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>41</b> as a white solid (56 mg, yield 14%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.42 (s, 3H), 4.69 (d, <i>J</i> = 10.0 Hz, 1H), 4.98 (d, <i>J</i> = 10.4 Hz, 1H), 5.76 (s, 1H), 6.73 (s, 1H), 6.89 (s, 1H), 7.14 (s, 1H), 7.26–7.30 (m, 3H), 7.38–7.40 (d, <i>J</i> = 8 Hz, 2H), 7.62 (s, 1H), 12.36 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 378 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>42</b>)</h4><div class="NLM_p last">Compound <b>42</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23e</b> (20 mg, 0.05 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>42</b> as a white solid (5.6 mg, yield 31%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 3.35 (s, 3H), 4.64–4.66 (d, <i>J</i> = 8 Hz, 1H), 4.95–4.97 (d, <i>J</i> = 8 Hz, 1H), 6.84 (s, 1H), 6.87–6.91 (m, 2H), 7.02 (t, 2H), 7.17–7.20 (dd, 1H), 7.37–7.40 (m, 2H). LC-MS (ESI) <i>m</i>/<i>z</i>: 380 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 9-(1-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>43</b>)</h4><div class="NLM_p last">Compound <b>43</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22e</b> (400 mg, 1.06 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>43</b> as a white solid (110 mg, yield 30%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.77 (s, 3H), 4.48–4.49 (d, <i>J</i> = 6.4 Hz, 1H), 5.16–5.19 (d, <i>J</i> = 6.4 Hz, 1H), 7.08–7.10 (d, <i>J</i> = 8 Hz, 1H), 7.17–7.27 (m, 5H), 7.40–7.42 (d, <i>J</i> = 8 Hz, 2H), 7.54–7.58 (t, <i>J</i> = 8 Hz, 1H), 7.74 (s, 1H), 12.23 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 345 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 5-Fluoro-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-8-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>44</b>)</h4><div class="NLM_p last">Compound <b>44</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23d</b> (186 mg, 0.47 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>44</b> as a white solid (40 mg, yield 24%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.63 (s, 3H), 4.94–5.03 (m, 2H), 6.91–6.94 (dd, <i>J</i><sub>1</sub>= 11.6 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H), 7.05–7.08 (dd, <i>J</i><sub>1</sub> = 9.6 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H), 7.29–7.35 (m, 3H), 7.42–7.48 (m, 2H), 7.74 (s, 1H), 7.79 (s, 1H), 12.34 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 363 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 9-(4-Methyl-4<i>H</i>-1,2,4-triazol-3-yl)-8-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>45</b>)</h4><div class="NLM_p last">Compound <b>45</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22p</b> (32 mg, 0.08 mmol) as the starting material. Purification was performed using prep-HPLC to give <b>45</b> as a white solid (4.5 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 3.46 (s, 3H), 4.81–5.00 (m, 2H), 7.20 (d, 1H), 7.29–7.32 (m, 3H), 7.42–7.45 (m, 2H), 7.57–7.65 (m, 2H), 8.31(s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 345 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 8-(4-Fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>46</b>)</h4><div class="NLM_p last">Compound <b>46</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22q</b> (1.72 g, 4.4 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>46</b> as a white solid (1.4 g, yield 90%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.65 (s, 3H), 4.91–5.00 (m, 2H), 7.12–7.19 (m, 3H), 7.39–7.43 (m, 2H), 7.47–7.50 (m, 2H), 7.58–7.60 (m, 1H), 7.79 (s, 1H), 12.22 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 363 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>47</b>)</h4><div class="NLM_p last">Compound <b>47</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>23f</b> (840 mg, 2.04 mmol) as the starting material. It was obtained as a white solid (650 mg, yield 84%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.66 (s, 3H), 4.97–5.04 (m, 2H), 6.91–6.94 (dd, <i>J</i><sub>1</sub> = 11.2 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H), 7.06–7.09 (dd, <i>J</i><sub>1</sub>= 8.8 Hz, <i>J</i><sub>2</sub> = 2.4 Hz, 1H), 7.14–7.18 (m, 2H), 7.47–7.51 (m, 2H), 7.72 (s, 1H), 7.80 (s, 1H), 12.35 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 381 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>6</sub>O·H<sub>2</sub>O: C, 57.29; H, 4.05; N, 21.10. Found: C, 57.37; H, 4.09; N, 21.21.</div></div><div id="sec5_2_7_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 8-(4-(Dimethoxymethyl)phenyl)-9-phenyl-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>48</b>)</h4><div class="NLM_p last">Compound <b>48</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22m</b> (120 mg, 0.28 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>48</b> as a white solid (89 mg, yield 78%). LC-MS (ESI) <i>m</i>/<i>z</i>: 414 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 9-(3-(Diethoxymethyl)phenyl)-8-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>49</b>)</h4><div class="NLM_p last">Compound <b>49</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22c</b> (300 mg, 0.65 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>49</b> as a white solid (95 mg, yield 33%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 1.04–1.08 (t, <i>J</i> = 7.0 Hz, 6H), 3.27–3.31 (q, 4H), 4.34–4.36 (d, <i>J</i> = 8.8 Hz, 1H), 4.74–4.76 (d, <i>J</i> = 8.8 Hz, 1H), 5.34 (s, 1H), 7.08 (s, 1H), 7.14–7.24 (m, 7H), 7.27–7.29 (m, 2H), 7.37–7.39 (d, <i>J</i> = 7.2 Hz, 1H), 7.43 (s, 1H), 7.56–7.60 (t, <i>J</i> = 8.0 Hz, 1H), 12.15 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 442 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 8-(3-(Diethoxymethyl)phenyl)-9-phenyl- 8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>50</b>)</h4><div class="NLM_p last">Compound <b>50</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22l</b> (160 mg, 0.36 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>50</b> as a white solid (90 mg, yield 58%). LC-MS (ESI) <i>m</i>/<i>z</i>: 442 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_7_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 8-(4-(Diethoxymethyl)phenyl)-9-(4-fluorophenyl)-8,9-dihydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-3(7<i>H</i>)-one (<b>51</b>)</h4><div class="NLM_p last">Compound <b>51</b> was synthesized by employing the procedure for compound <b>13</b> using compound <b>22g</b> (4.2 g, 8.54 mmol) as the starting material. Purification was performed using column chromatography on silica gel to give <b>51</b> as a white solid (3.0 g, yield 76%). LC-MS (ESI) <i>m</i>/<i>z</i>: 460 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Synthesis of (3-Oxo-8 (9)-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-9-yl)benzaldehyde derivatives (<b>48a</b>–<b>51a</b>)</h3><div id="sec5_2_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 4-(3-Oxo-9-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-8-yl)benzaldehyde (<b>48a</b>)</h4><div class="NLM_p last">A mixture of compound <b>48</b> (89 mg, 0.22 mmol) and 3 N hydrochloric acid (20 mL) was stirred at room temperature for 2 h. The resulting mixture was neutralized with potassium carbonate and then filtered to give compound <b>48a</b> as a white solid (59 mg, yield 73%). LC-MS (ESI) <i>m</i>/<i>z</i>: 368 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 3-(3-Oxo-8-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-9-yl)benzaldehyde (<b>49a</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>48a</b> using <b>49</b> (90 mg, 0.20 mmol) as the starting material. It was obtained as a white solid (66 mg, yield 88%). LC-MS (ESI) <i>m</i>/<i>z</i>: 368 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 3-(3-oxo-9-Phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-8-yl)benzaldehyde (<b>50a</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>48a</b> using <b>50</b> (90 mg, 0.21 mmol) as the starting material. It was obtained as a light yellow solid (40 mg, yield 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 4.24 (d, <i>J</i> = 7.6 Hz, 1H), 4.77 (d, <i>J</i> = 7.6 Hz, 1H), 4.85 (brs, 1H), 7.01–7.03 (m, 2H), 7.08–7.10 (m, 1H), 7.21–7.24 (m, 3H), 7.37–7.39 (m, 2H), 7.61–7.65 (m, 1H), 7.74–7.75 (m, 2H), 7.79–7.81 (m, 1H), 9.59 (brs, 1 H), 9.92 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 368 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 4-(9-(4-Fluorophenyl)-3-oxo-3,7,8,9-tetrahydro-2<i>H</i>-pyrido[4,3,2-de]phthalazin-8-yl)benzaldehyde (<b>51a</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>48a</b> using <b>51</b> (3.0 g, 6.53 mmol) as the starting material. It was obtained as a light yellow solid (2.5 g, yield 98%). LC-MS (ESI) <i>m</i>/<i>z</i>: 386 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Synthesis of 8(9)-((Alkylamino)methyl)phenyl)-9(8)-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one derivatives (<b>25</b>–<b>27</b>, <b>52</b>–<b>57</b>)</h3><div id="sec5_2_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 9-(3-((Dimethylamino)methyl)phenyl)-8-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>26</b>)</h4><div class="NLM_p last">A mixture of <b>4a</b> (45 mg, 0.12 mmol) and 33% dimethylamine solution (50.2 mg, 0.366 mmol) in methanol (5 mL) was stirred at room temperature for 1 h. After cooling to 0 °C, sodium borohydride (6.95 mg, 0.184 mmol) was added to the mixture. It was stirred at this temperature for 2 h. Methanol was removed under reduced pressure. The residue was purified by prep-HPLC to give <b>26</b> (21 mg, yield 44%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.59 (s, 3H), 2.75 (s, 3H), 4.11–4.27 (q, 2H), 4.31–4.34 (d, <i>J</i> = 10.4 Hz, 1H), 4.68–4.71 (d, <i>J</i> = 10.4 Hz, 1H), 7.17–7.30 (m, 9H), 7.33–7.37 (t, <i>J</i> = 7.6 Hz, 1H), 7.56–7.58 (d, <i>J</i> = 7.6 Hz, 1H), 7.60–7.64 (t, <i>J</i> = 8.0 Hz, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 397 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 8-(4-((Dimethylamino)methyl)phenyl)-9-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>25</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>48a</b> (59 mg, 0.16 mmol) as the starting material. Compound <b>25</b> was obtained as a light yellow solid (20 mg, yield 32%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.79 (s, 6H), 4.23 (s, 2H), 4.31–4.33 (d, <i>J</i> = 8 Hz, 1H), 4.81–4.83 (d, <i>J</i> = 8 Hz, 1H), 7.08–7.1 (m, 2H), 7.10–7.22 (m, 4H), 7.34–7.36 (d, <i>J</i> = 8 Hz, 2H), 7.41–7.43 (d, <i>J</i> = 8 Hz, 2H), 7.55–7.56 (d, <i>J</i> = 8 Hz, 1H), 7.57–7.65 (t, <i>J</i> = 8 Hz, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 397 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 8-(3-((Dimethylamino)methyl)phenyl)-9-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>27</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>50a</b> (50 mg, 0.14 mmol) as the starting material. Compound <b>27</b> was obtained as a light yellow solid (34 mg, yield 64%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.17 (s, 6H), 3.17–3.41 (q, 2H), 4.31 (d, <i>J</i> = 8.0 Hz, 1H), 4.74 (d, <i>J</i> = 8.0 Hz, 1H), 7.08–7.10 (m, 2H), 7.13–7.25 (m, 8H), 7.55–7.57 (d, <i>J</i> = 8.0 Hz, 1H), 7.61–7.65 (m, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 397 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 8-(4-((Dimethylamino)methyl)phenyl)-9-(4-fluorophenyl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>52</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>51a</b> (80 mg, 0.21 mmol) as the starting material. Compound <b>52</b> was obtained as a light yellow solid (21 mg, yield 24%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.82 (s, 6H), 4.26 (s, 2H), 4.32 (d, <i>J</i> = 8.0 Hz, 1H), 4.77 (d, <i>J</i> = 8.0 Hz, 1H), 6.93–6.95 (m, 2H), 7.10–7.11 (m, 2 H), 7.23 (m, 1H), 7.40–7.41 (m, 4H), 7.59 (d, <i>J</i> = 8.0 Hz, 1H), 7.65 (t, <i>J</i> = 8.0 Hz, 1H). <sup>19</sup>F NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) −77.09, −118.00. LC-MS (ESI) <i>m</i>/<i>z</i>: 415 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 8-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-9-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>53</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>48a</b> (150 mg, 0.40 mmol) and <i>N</i>-methyl-piperazine (123 mg, 1.2 mmol) as the starting materials. Compound <b>52</b> was obtained as a light yellow solid (36 mg, yield 19%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.29 (s, 3H), 2.12–2.73 (br s, 8H), 3.47 (s, 2H), 4.30 (d, <i>J</i> = 8.0 Hz, 1H), 4.74 (d, <i>J</i> = 8.0 Hz, 1H), 7.08–7.10 (m, 2H), 7.18–7.21 (m, 6 H), 7.23–7.25 (m, 2H), 7.55–7.57 (d, <i>J</i> = 8.0 Hz, 1H), 7.62–7.64 (m, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 452 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> 9-Phenyl-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>54</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>48a</b> (367 mg, 1.00 mmol) and pyrrolidine (213 mg, 3.00 mmol) as the starting materials. Compound <b>54</b> was obtained as a white solid (62 mg, yield 14%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 1.82–1.85 (m, 2H), 1.97 (s, 2H), 3.01–3.05 (m, 2H), 3.26 (d, 2H), 4.27 (d, 2H), 4.36 (d, 1H), 4.84 (d, 1H), 7.13–7.23 (m, 6H), 7.36–7.40 (m, 5H), 7.48 (s, 1H), 7.57–7.61 (t, 1H), 12.18 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 423 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 8-(4-(Azetidin-1-ylmethyl)phenyl)-9-phenyl-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>55</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>48a</b> (150 mg, 0.41 mmol) and azetidine (70 mg, 1.23 mmol) as the starting materials and sodium triacetoxyborohydride (131 mg, 0.62 mmol) as the reducing agent. Compound <b>55</b> was obtained as a yellow solid (84 mg, yield 51%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.38–2.43 (m, 2H), 3.98 (t, <i>J</i> = 8 Hz, 4H), 4.20 (s, 2H), 4.27 (d, <i>J</i> = 8 Hz, 1H), 4.77 (d, <i>J</i> = 8 Hz, 1H), 7.03–7.05 (m, 2H), 7.10–7.17 (m, 4H), 7.27–7.35 (m, 4H), 7.50–7.52 (m, 1H), 7.57–7.62 (m, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 409 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 9-(4-Fluorophenyl)-8-(4-(pyrrolidin-1-ylmethyl)phenyl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>56</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>51a</b> (100 mg, 0.26 mmol) and pyrrolidine (37 mg, 0.52 mmol) as the starting materials and sodium triacetoxyborohydride (131 mg, 0.62 mmol) as the reducing agent. Compound <b>56</b> was obtained as a yellow solid (30 mg, yield 26%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 2.00 (s, 2H), 2.16 (s, 2H), 3.14 (s,2H), 3.41 (s, 2H), 4.32 (s,2H), 4.35–4.38 (d, 1H), 4.78–4.80 (d, 1H), 6.91–6.95 (t, 2H), 7.10–7.13 (t,2H), 7.22–7.24 (d, 1H), 7.42 (m, 4H), 7.56–7.58 (d, 2H), 7.64–7.70 (1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 441 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 8-(4-(Azetidin-1-ylmethyl)phenyl)-9-(4-fluorophenyl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>57</b>)</h4><div class="NLM_p last">This compound was synthesized by employing the procedure for <b>26</b> using <b>51a</b> (930 mg, 2.42 mmol) and azetidine (670 mg, 11.8 mmol) as the starting materials and sodium triacetoxyborohydride (764 mg, 3.62 mmol) as the reducing agent. Compound <b>57</b> was obtained as a white solid (500 mg, yield 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 1.92–1.95 (m, 2H), 3.02–3.06 (m, 4H), 3.41 (s, 2H), 4.33–4.35 (d, <i>J</i> = 8 Hz, 1H), 4.72–4.74 (d, <i>J</i> = 8 Hz, 1H), 7.03 (t, 2H), 7.11–7.18 (m, 5H), 7.21–7.23 (d, <i>J</i> = 8 Hz, 2H), 7.36–7.39 (m, 2H), 7.55–7.59 (t, 1H), 12.15 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 427 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Synthesis of (<i>Z</i>)-6-Fluoro-3-((1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)methylene)-4-nitroisobenzofuran-1(3<i>H</i>)-one (<b>58</b>)</h3><div class="NLM_p last">To a solution of <b>7c</b> (20 g, 100 mmol), 2-methyl-2<i>H</i>-1,2,4-triazole-3-carbaldehyde (22 g, 203 mmol), and Et<sub>3</sub>N (40 mL, 304 mmol) in anhydrous 2-methyl-tetrahydrofuran (300 mL) was added acetic anhydride (70 mL) dropwise with stirring at room temperature over 6 min. The mixture was stirred under reflux for 1 h; at this point, a green solid started to precipitate out from the solution. The mixture was concentrated to a volume of 30 mL and cooled to 0 °C. The solid was collected by filtration, washed with ethyl acetate (30 mL), and dried in vacuum, furnishing compound <b>58</b> as a greenish solid (23 g, yield 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.94 (s, 3H), 7.15 (s, 1H), 8.10 (s, 1H), 8.40–8.42 (dd, <i>J</i><sub>1</sub> = 2.4, <i>J</i><sub>2</sub> = 6.4 Hz, 1H), 8.58–8.61 (dd, <i>J</i><sub>1</sub> = 2.4, <i>J</i><sub>2</sub> = 8.8 Hz, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 291 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>12</sub>H<sub>7</sub>FN<sub>4</sub>O<sub>4</sub>: C, 49.66; H, 2.43; N, 19.31. Found: C, 49.91; H, 2.43; N, 19.28.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> Synthesis of Methyl 5-Fluoro-2-(2-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)acetyl)-3-nitrobenzoate (<b>59</b>)</h3><div class="NLM_p last">To a suspension of compound <b>58</b> (18 g, 62 mmol) in MeOH (500 mL) was added AcOH (1 mL, 16.7 mmol). The reaction mixture was stirred at 50 °C for 4 h when TLC (PE/EA= 2:1) and LC-MS (acid) showed that the starting material was consumed completely and the solution turned clear. After the removal of the solvents, the product was dried in vacuum. Compound <b>59</b> was obtained as a yellow solid (20 g, yield 99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.89 (s, 3H), 3.92 (s, 3H), 4.60 (s, 2H), 7.85 (s, 1H), 8.25–8.28 (dd, <i>J</i><sub>1</sub> = 2.8, <i>J</i><sub>2</sub> = 8.4 Hz, 1H), 8.52–8.54 (dd, <i>J</i><sub>1</sub> = 2.8, <i>J</i><sub>2</sub> = 8.4 Hz, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 323 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>13</sub>H<sub>11</sub>FN<sub>4</sub>O<sub>5</sub>: C, 48.45; H, 3.44; N, 17.39. Found: C, 48.64; H, 3.53; N, 17.31.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> Synthesis of Methyl 7-Fluoro-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-2-aryl-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>60a</b>–<b>e</b>)</h3><div id="sec5_2_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Methyl 7-Fluoro-2-(4-fluorophenyl)-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>60a</b>)</h4><div class="NLM_p last">To a suspension of <b>59</b> (5 g, 15.5 mmol) and 4-fluorobenzaldehyde (3.6 g, 29 mmol) in THF (30 mL) and MeOH (5 mL) was added titanium(III) chloride (20% w/w solution in 2 N hydrochloric acid) (80 mL, 6 equiv) dropwise with stirring at room temperature. The reaction mixture was allowed to stir at 30–50 °C for 2 h before it was diluted with water (160 mL). The resulting solution was extracted with EtOAc (100 mL × 4). The combined organic layers were washed with saturated NaHCO<sub>3</sub> (50 mL × 3) and aqueous NaHSO<sub>3</sub> (100 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness. The crude product was washed with petroleum ether (120 mL), affording compound <b>60a</b> as a yellow solid (5.9 g, yield 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm) 3.58 (s, 3H), 3.87 (s, 3H), 4.16–4.19 (d, <i>J</i><sub>2</sub> = 13.2 Hz, 1H), 4.88 (s, 1H), 5.37–5.40 (d, <i>J</i><sub>2</sub> = 13.2 Hz, 1H), 6.47–6.53 (m, 2H), 6.97–7.01 (m, 2H), 7.37–7.41 (m, 2H), 7.80 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 399 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>20</sub>H<sub>16</sub>F<sub>2</sub>N<sub>4</sub>O: C, 60.30; H, 4.05; N, 14.06. Found: C, 60.15; H, 3.98; N, 14.00.</div></div><div id="sec5_2_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Methyl 2-(4-Acetamidophenyl)-7-fluoro-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>60b</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>60a</b> using <b>59</b> (1.0 g, 3.1 mmol) and <i>N</i>-(4-formylphenyl)acetamide (0.95 g, 5.8 mmol) as the starting reagents. Compound <b>60b</b> was obtained as a white solid (1.0 g, yield 73%). LC-MS (ESI) <i>m</i>/<i>z</i>: 438 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Methyl 7-Fluoro-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>60c</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>60a</b> using <b>59</b> (0.644 g, 2.0 mmol) and pyrimidine-5-carbaldehyde (0.259 g, 2.40 mmol) as the starting reagents. Compound <b>60c</b> was obtained as a white solid (0.164 g, yield 22%). LC-MS (ESI) <i>m</i>/<i>z</i>: 382 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> Methyl 7-Fluoro-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2-(1-methyl-1<i>H</i>-pyrazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>60d</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>60a</b> using <b>59</b> (1.46 g, 4.5 mmol) and 1-methyl-1<i>H</i>-pyrazole-5-carbaldehyde (1.0 g, 9.0 mmol) as the starting reagents. Compound <b>60d</b> was obtained as a white solid (1.66 g, yield 96%). LC-MS (ESI) <i>m</i>/<i>z</i>: 385 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Methyl 2-(4-Cyanophenyl)-7-fluoro-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (<b>60e</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>60a</b> using <b>59</b> (0.644 g, 2.0 mmol) and 4-formylbenzonitrile (0.524 g, 4.0 mmol) as the starting reagents. Compound <b>60e</b> was obtained as a white solid (0.794 g, yield 98%). LC-MS (ESI) <i>m</i>/<i>z</i>: 406 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> Synthesis of 5-Fluoro-8-aryl-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>47</b>, <b>61</b>–<b>64</b>)</h3><div id="sec5_2_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> 5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>47</b>)</h4><div class="NLM_p last">To a solution of compound <b>60a</b> (7.3 g, 18.3 mmol) in methanol (20 mL) was added hydrazine monohydrate (5 mL), and the mixture was stirred at 25 °C for 10 h. Then, the mixture was filtered to obtain compound <b>47</b> as a white solid (6.9 g, yield 80%). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 381 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.66 (s, 3H), 4.97–5.04 (m, 2H), 6.91–6.94 (dd, <i>J</i><sub>1</sub> = 2.4, <i>J</i><sub>2</sub> = 11.2 Hz, 1H), 7.06–7.09 (dd, <i>J</i><sub>1</sub> = 2.4, <i>J</i><sub>2</sub> = 8.8 Hz, 1H), 7.14–7.18 (m, 2H), 7.47–7.51 (m, 2H), 7.72 (s, 1H), 7.80 (s, 1H), 12.35 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 381 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>6</sub>O·H<sub>2</sub>O: C, 57.29; H, 4.05; N, 21.10. Found: C, 57.60; H, 4.14; N, 21.20.</div></div><div id="sec5_2_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> <i>N</i>-(4-(5-Fluoro-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-3-oxo-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-8-yl)phenyl)acetamide (<b>61</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>47</b> using <b>60b</b> (0.20 g, 0.46 mmol) as the starting reagent. Compound <b>61</b> was obtained as a white solid (50 mg, yield 26%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 2.01 (s, 3H), 3.63 (s, 3H), 4.87–4.97 (dd, <i>J</i><sub>1</sub> = 12 Hz, <i>J</i><sub>2</sub> = 12 Hz, 2H), 6.89–6.93 (m, 1H), 7.01–7.07 (m, 2H), 7.32–7.34 (d, <i>J</i> = 8.0 Hz, 2H), 7.48–7.51 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (s, 1H), 7.79 (s, 1H), 9.95 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 420 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> 5-Fluoro-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-8-(pyrimidin-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>62</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>47</b> using <b>60c</b> (0.164 g, 0.43 mmol) as the starting reagent. Compound <b>62</b> was obtained as a white solid (60 mg, yield 38%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ (ppm) 3.76 (s, 3H), 5.17 (q, 2H), 6.92 (dd,1H), 7.13 (dd, 1H),7.85 (d, 2H), 8.93 (s, 2H), 9.12 (s, 1H), 12.43 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 365 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> 5-Fluoro-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-8-(1-methyl-1<i>H</i>-pyrazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (<b>63</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>47</b> using <b>60d</b> (0.26 g, 0.67 mmol) as the starting reagent. Compound <b>63</b> was obtained as a white solid (120 mg, yield 49%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.82 (s, 3 H), 3.86 (s, 3 H), 5.07–5.09 (d, <i>J</i> = 8 Hz, 1H), 5.29–5.32 (d, <i>J</i> = 12 Hz, 1H), 6.35–6.36 (d, <i>J</i> = 4.0 Hz, 1H), 6.86–6.90 (dd, <i>J</i><sub>1</sub>= 2.4 Hz, <i>J</i><sub>2</sub> = 11.2 Hz, 1H), 7.06–7.09 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 9.2 Hz, 1H), 7.31–7.32 (d, <i>J</i> = 1.6 Hz, 1H), 7.76–7.80 (d, <i>J</i> = 16.4 Hz, 2H), 12.38 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 367 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> 4-(5-Fluoro-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-3-oxo-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-8-yl)benzonitrile (<b>64</b>)</h4><div class="NLM_p last">This compound was synthesized in the same manner as that for <b>47</b> using <b>60e</b> (0.794 g, 1.94 mmol) as the starting reagent. Compound <b>64</b> was obtained as a light yellow solid (0.62 g, yield 81%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 3.69 (s, 3H), 5.06–5.14 (dd, 2H), 6.91–6.94 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 10.8 Hz, 1H), 7.08–7.11 (dd, <i>J</i><sub>1</sub> = 2.4 Hz, <i>J</i><sub>2</sub> = 8.8 Hz, 1H), 7.65–7.67 (d, <i>J</i> = 8.0 Hz, 2H), 7.80 (s, 1H), 7.81 (s, 1H), 7.83 (d, <i>J</i> = 8.8 Hz, 2H), 12.38 (s, 1H). LC-MS (ESI) <i>m</i>/<i>z</i>: 388 (M + H)<sup>+</sup>.</div></div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Chiral Resolution of the Racemates <b>36</b>, <b>42</b>, <b>46</b>, <b>47</b>, <b>57</b>, and <b>60a</b></h3><div id="sec5_2_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> (8<i>S</i>,9<i>R</i>)-8-(4-Fluorophenyl)-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>S</i>,9<i>R</i>)-<b>37</b>) and (8<i>R</i>,9<i>S</i>)-8-(4-Fluorophenyl)-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>R</i>,9<i>S</i>-<b>37</b>)</h4><div class="NLM_p last">Compound <b>36</b> was dissolved in DMF, and chiral resolution was performed using supercritical-fluid chromatography (SFC) with a CHIRALPAK IA chiral column and methanol (30% with 0.1% DEA) and CO<sub>2</sub> (70%) as the eluents. Yield 63%. For (8<i>R</i>,9<i>S</i>)<b>-36</b>: retention time 3.27 min and ee 98.7%. For (8<i>S</i>,9<i>R</i>)<b>-36</b>: retention time 3.74 min and ee 99.2%.</div></div><div id="sec5_2_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> (8<i>S</i>,9<i>R</i>)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>S</i>,9<i>R</i>)-<b>42</b>) and (8<i>R</i>,9<i>S</i>)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-imidazol-2-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>R</i>,9<i>S</i>-<b>42</b>)</h4><div class="NLM_p last">Compound <b>42</b> was dissolved in DMF, and chiral resolution was performed using supercritical-fluid chromatography (SFC) with a CHIRALPAK IA chiral column and methanol (30% with 0.1% DEA) and CO<sub>2</sub> (70%) as the eluents. Yield 79%. For (8<i>R</i>,9<i>S</i>)<b>-42</b>: retention time 2.2 min and ee 100%. For (8<i>S</i>,9<i>R</i>)<b>-42</b>: retention time 2.74 min and ee 99.1%.</div></div><div id="sec5_2_14_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> (8<i>S</i>,9<i>R</i>)-8-(4-Fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>S</i>,9<i>R</i>)<b>-46</b>) and (8<i>R</i>,9<i>S</i>)-8-(4-Fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>R</i>,9<i>S</i>)<b>-46</b></h4><div class="NLM_p last">Compound <b>46</b> was dissolved in DMF, and chiral resolution was performed using supercritical-fluid chromatography (SFC) with a CHIRALPAK IA chiral column and methanol (30% with 0.1% DEA) and CO<sub>2</sub> (70%) as the eluents. Yield 90%. For (8<i>S</i>,9<i>R</i>)-<b>46</b>: retention time 3.23 min and ee 100%. For (8<i>R</i>,9<i>S</i>)-<b>46</b>: retention time 4.36 min and ee 98.6%.</div></div><div id="sec5_2_14_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> (8<i>S</i>,9<i>R</i>)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>S</i>,9<i>R</i>)-<b>47</b> or BMN 673 and (8<i>R</i>,9<i>S</i>)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>R</i>,9<i>S</i>)-<b>47</b></h4><div class="NLM_p">Compound <b>47</b> was dissolved in DMF, and chiral resolution was performed using supercritical-fluid chromatography (SFC) with a CHIRALPAK IA chiral column and methanol (20% with 0.1% DEA) and CO<sub>2</sub> (80%) as the eluents. Yield 90%. For (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673): retention time 8.8 min and ee 99.3%. For (8<i>R</i>,9<i>S</i>)-<b>47</b>: retention time 10.2 min and ee 99.2%.</div><div class="NLM_p">Alternatively, compound (8<i>S</i>,9<i>R</i>)-<b>47</b> could also be made using (2<i>S</i>,3<i>R</i>)-<b>60a</b> as a starting material and employing the same procedure described for the conversion of <b>60a</b> to <b>47</b>.</div><div class="NLM_p last">The optical rotation for both (8<i>S</i>,9<i>R</i>)-<b>47</b> and (8<i>R</i>,9<i>S</i>)-<b>47</b> was measured using a RUDOLPH (AUTOPOL V) automatic polarimeter at a concentration of 6.67 mg/mL in MeOH/MeCN/DMF = 0.5:0.5:1 at 20 °C. The specific rotation for (8<i>S</i>,9<i>R</i>)-<b>47</b> was +92.2°, whereas it was −93.4° for (8<i>R</i>,9<i>S</i>)-<b>47</b>.</div></div><div id="sec5_2_14_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> (8<i>S</i>,9<i>R</i>)-8-(4-(Azetidin-1-ylmethyl)phenyl)-9-(4-fluorophenyl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>S</i>,9<i>R</i>)-<b>57</b> and (8<i>R</i>,9<i>S</i>)-8-(4-(Azetidin-1-ylmethyl)phenyl)-9-(4-fluorophenyl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one (8<i>R</i>,9<i>S</i>)-<b>57</b></h4><div class="NLM_p last">Compound <b>57</b> was dissolved in methanol, and chiral resolution was performed using supercritical-fluid chromatography (SFC) with a CHIRALPAK OJ-H chiral column and methanol (40%) and CO<sub>2</sub> (60%) as the eluents. Yield 95%. For (8<i>S</i>,9<i>R</i>)-<b>57</b>: retention time 2.67 min and ee 100%. For (8<i>R</i>,9<i>S</i>)-<b>57</b>: retention time 4.64 min and ee 99.5%.</div></div><div id="sec5_2_14_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> Methyl (2<i>S</i>,3<i>R</i>)-7-Fluoro-2-(4-fluorophenyl)-4-imino-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (2<i>S</i>,3<i>R</i>)-<b>60a</b> and Methyl (2<i>R</i>,3<i>S</i>)-7-Fluoro-2-(4-fluorophenyl)-4-imino-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,2,3,4-tetrahydroquinoline-5-carboxylate (2<i>R</i>,3<i>S</i>)-<b>60a</b></h4><div class="NLM_p last">Compound <b>60a</b> was dissolved in methanol (45 mg/mL), and chiral resolution was performed using supercritical-fluid chromatography (SFC) with a CHIRALPAK IC chiral column (250 × 30 mm i.d.) and methanol (20%) and CO<sub>2</sub> (80%) as the eluents. The flow rate was 65 g/min, and the column temperature was maintained at 35 °C. Yield 92%. For (2<i>S</i>,3<i>R</i>)-<b>60a</b>: retention time 2.3 min and ee > 98%. For (2<i>R</i>,3<i>S</i>)-<b>60a</b>: retention time 4.3 min and ee > 98%.</div></div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> Preparation of (8<i>S</i>,9<i>R</i>)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3<i>H</i>-pyrido[4,3,2-de]phthalazin-3-one Tosylate Salt ((8<i>S</i>,9<i>R</i>)-<b>47</b> Tosylate Salt)</h3><div class="NLM_p last">A suspension of (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673) (400 mg, 1.05 mmol) in a mixture of acetone (27 mL) and THF (13 mL) was heated to reflux until the suspension became clear. TsOH (220 mg, 1.16 mmol) was then added to the solution. White solids started to precipitate out from the solution shortly after the addition of TsOH. After stirring at 25 °C for 30 min, the mixture was filtered to collect the white crystal solids, which were washed with a mixture of acetone (10 mL) and 1,4-dioxane (4 mL) and then dried under vacuum at 45 °C for 3 days. This afforded the product as a white crystalline solid (540 mg, yield 93%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 2.29 (s, 3H), 3.67 (s, 3H), 4.97–5.06 (m, 2H), 6.91–6.94 (dd, <i>J</i><sub>1</sub> = 2.0 Hz, <i>J</i><sub>2</sub> = 10.8 Hz, 1H), 7.06–7.19 (m, 5H), 7.19–7.51 (m, 4H), 7.74 (s, 1H), 7.87 (s, 1H), 10.32 (brs, 1H), 12.36 (s, 1H). LC<b>-</b>MS (ESI) <i>m</i>/<i>z</i>: 381 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>19</sub>H<sub>14</sub>F<sub>2</sub>N<sub>6</sub>O·toluene sulfonic acid: C, 56.52; H, 4.01; N, 15.21. Found: C, 56.49; H, 3.94; N, 15.39.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> Absolute Configuration Determination for BMN 673 Tosylate Salt</h3><div class="NLM_p last">Crystals of BMN 673 tosylate were prepared at SSCI, a division of Aptuit, West Lafayette, IN, and submitted for single-crystal structure analysis. The structure was determined by single-crystal X-ray diffraction at the Crystallography Laboratory at Purdue University. Preliminary examination and data collection were performed with Cu Kα radiation (λ = 1.54184 Å) on a Rigaku Rapid II diffractometer equipped with confocal optics. Refinements were performed on a LINUX PC using SHELX97.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The measured Flack factor for the structure of BMN 673 shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> is 0.04 with a standard uncertainty of 0.02, and the Flack equivalent (Hooft) factor<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> was determined to be 0.056, corresponding to a probability of 1.000 that the structure in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> is correct (more details are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01498/suppl_file/jm5b01498_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> Pharmacokinetic Analysis</h3><div class="NLM_p last">Rat plasma samples were aliquoted into 96-well plates, and proteins were precipitated using acetonitrile with the internal standard spiked-in. Supernatants were stored at −20 °C and vortexed before being loaded onto a LC-MS/MS instrument for analysis. Sample analysis was performed by LC-MS/MS using an Agilent 1100 chromatography system with an Ultimate XB-C18 5 cm column. The mobile phase consisted of mixtures of methanol and 0.1% formic acid in water, which was run in gradient mode at a flow rate of 0.5 mL/min. Mass spectra were detected with an Agilent 6410 triple quadruple equipped with an ESI source. Internal standards were used to track the response of analytes in plasma samples. The limit of detection was 1 ng/mL.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> PARP Enzyme Assays</h3><div class="NLM_p last">The ability of a test compound to inhibit PARP1 enzyme activity was assessed using Trevigen’s PARP1 assay kit (Trevigen, cat. no. 4676-096-K) following the manufacturer’s instruction. IC<sub>50</sub> values were calculated using GraphPad Prism5 software (San Diego, CA, USA). For PARP inhibitor <i>K</i><sub>i</sub> determination, enzyme assays were conducted in 96-well FlashPlate (PerkinElmer) with 0.5 U of PARP1 enzyme (Trevigen; cat. no. 4667-250-EB), 0.25× activated DNA (Trevigen), 0.2 μCi [<sup>3</sup>H]NAD (PerkinElmer; cat. no. NET443H250UC), and 5 μM cold NAD (Sigma) in a final volume of 50 μL in reaction buffer containing 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl<sub>2</sub>, 50 mM KCl, 1 mM dithiothreitol (DTT), and 0.01% NP-40 (v/v), pH 7.6. Reactions were initiated by adding NAD to the PARP reaction mixture with or without inhibitors and incubated for 1 min at room temperature. Fifty microliters of ice-cold 20% trichloroacetic acid (TCA) was then added to each well to quench the reaction. The plate was sealed and shaken for a further 120 min at room temperature, followed by centrifugation. Radioactive signal bound to the FlashPlate was determined using TopCount. PARP1 <i>K</i><sub>m</sub> was determined using the Michaelis–Menten equation from various substrate concentrations (1–100 μM NAD). Compound <i>K</i><sub>i</sub> was calculated from the enzyme inhibition curve according to the following formula: <i>K</i><sub>i</sub> = IC<sub>50</sub>/[1 + (substrate)/<i>K</i><sub>m</sub>]. <i>K</i><sub>m</sub> for PARP2 enzyme and compound <i>K</i><sub>i</sub> were determined with the same assay protocol except that 30 ng of PARP2 (BPS Bioscience; cat. no. 80502), 0.25× activated DNA, 0.2 μCi [<sup>3</sup>H]NAD, and 20 μM cold NAD were used in the reaction for 30 min at room temperature.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> Intracellular PARylation Assay</h3><div class="NLM_p last">The cellular PARylation assay evaluates the ability of a test compound to inhibit polymerization of poly(ADP)-ribose (PAR). LoVo human colorectal tumor cells grown in 96-well microtiter plates overnight were pretreated with increasing concentrations of PARP inhibitors for 30 min before H<sub>2</sub>O<sub>2</sub> was added at a final concentration of 50 mM. After a 5 min treatment at room temperature, cells were fixed for 10 min with prechilled methanol/acetone (7:3) at −20 °C. Fixed cells were incubated with anti-PAR monoclonal antibody (Trevigen) for 60 min, followed by incubation with fluorescein isothiocyanate (FITC)-coupled goat anti-mouse immunoglobulin G (IgG; diluted at 1:100) and 1 μg/mL 4′,6-diamidino-2-phenylindole (DAPI) for 60 min. The FITC signal was normalized with the DAPI signal, and EC<sub>50</sub> values were calculated using GraphPad Prism5.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> Temozolomide (TMZ) Sensitization Assays</h3><div class="NLM_p last">During the compound-screening phase, TMZ sensitization was assessed by the concentration of TMZ that kills 50% of the treated cells (GI<sub>50</sub>) in the presence of 0.4 μM PARP inhibitors. LoVo cells were seeded in 96-well microtiter plates in F12K medium containing 10% (v/v) FBS with increasing concentrations of TMZ in the absence or presence of 0.4 μM PARP inhibitors. The final concentration of DMSO was 1%. Cells were grown for 5 days, and cell survival was determined by CellTiter Glo staining (Promega). GI<sub>50</sub> of TMZ with and without PARP inhibitors was calculated using GraphPad Prism5. During the lead compound characterization phase, TMZ sensitization was evaluated by the concentration of a PARP inhibitor that kills 50% of the treated cells in the presence of 200 μM TMZ. PARP inhibitors at various concentrations were combined with 200 μM temozolomide to treat LoVo cells. After treatment for 5 days, cell survival was determined by CellTiter Glo assay and GI<sub>50</sub> values were calculated using GraphPad Prism5.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> Single-Agent Cytotoxicity Assay</h3><div class="NLM_p last">In single-agent assays, Capan-1 cells (<i>BRCA2</i>-deficient), MX-1 (<i>BRCA1</i>-deficient) cells, or other cultured cells were seeded at densities that allow linear growth for 10–12 days in 96-well plates (typically 500–3000 cells/well). Cells were treated in their recommended growth media containing varying concentrations of PARP inhibitors for 10–12 consecutive days (media were changed with fresh compounds every 5 days). IC<sub>50</sub> values were calculated using GraphPad Prism5.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> Xenograft Experiments<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></h3><div class="NLM_p last">Female athymic nu/nu mice (8–10 week old) were used for all in vivo xenograft studies. Mice were quarantined for at least 1 week before experimental manipulation. Exponentially growing cells (LNcap and MDA-MB-468) or in vivo passaged tumor fragments (MX-1) were implanted subcutaneously in the right flank of nude mice. When tumors reached an average volume of approximately 150 mm<sup>3</sup>, mice were randomized into various treatment groups (6–8 mice/group) in each study. Mice were visually observed daily, and tumors were measured twice weekly by calliper to determine tumor volume using the formula [length/2] × [width<sup>2</sup>]. Group median tumor volume (mm<sup>3</sup>) was graphed over time to monitor tumor growth. In single-agent studies, olaparib (100 mg/kg), (8<i>S</i>,9<i>R</i>)-<b>47</b> (various doses as indicated), or vehicle (10% DMAc, 6% Solutol, and 84% PBS) was administered by oral gavage (per os [po]) once daily or (8<i>S</i>,9<i>R</i>)-<b>47</b> (0.165 mg/kg) was administered twice daily for 28 consecutive days. Mice were continuously monitored for 10 more days after last day of dosing. In the cisplatin combination study, (8<i>S</i>,9<i>R</i>)-<b>47</b>, olaparib, or vehicle was administered po once daily for 8 days starting on day 1. Cisplatin at a dosage of 6 mg/kg or its vehicle (saline) was administered intraperitoneally as a single injection on day 3, 30 min after PARP inhibitor was administered. Combination with carboplatin was conducted in a similar way in the MX-1 model in which (8<i>S</i>,9<i>R</i>)-<b>47</b> was administered po once daily for either 8 or 5 days and carboplatin was injected intraperitoneally at a single dose of 35 mg/kg, 30 min after (8<i>S</i>,9<i>R</i>)-<b>47</b> on day 3.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153"> PAR Assay in Vivo<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></h3><div class="NLM_p last">MX-1 tumor xenografts were prepared as described above. When tumors reached an average volume of approximately 150 mm<sup>3</sup>, olaparib (100 mg/kg), (8<i>S</i>,9<i>R</i>)-<b>47</b> (1 mg/kg), or vehicle was administered in a single po dose. Tumors were harvested at 2, 8, and 24 h after drug dosing and snap-frozen in liquid nitrogen. Tumor tissue was then homogenized in PBS on ice and extracted with lysis buffer (25 mmol/L Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 2 mM EGTA, 25 mM NaF, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM Pefabloc, 1% Triton X-100, and protease inhibitor cocktail) containing 1% SDS. Levels of PAR in the tumor lysates were determined by ELISA using PARP in vivo PD assay II kit (Trevigen).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154"> Molecular Modeling</h3><div class="NLM_p last">Inhibitor docking studies were performed using MOE 2014.09 (Molecular Operating Environment; Chemical Computing Group Inc.) with the Amber10:EHT force field.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The crystal structure of the PARP1 catalytic domain (<i>cat</i>PARP1) bound to talazoparib or BMN 673 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT">4PJT</a>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> was optimized using the software’s Structure Preparation application. The 3D structures of compounds (8<i>S</i>,9<i>R</i>)-<b>47</b>, (8<i>S</i>,9<i>R</i>)-<b>47</b>, and (8<i>S</i>,9<i>R</i>)-<b>39</b> were constructed and energy-minimized using the Builder module. These compounds, including co-crystallized and energy-minimized talazoparib molecules as controls, were docked into the ligand site using the default Rigid Receptor and Induced Fit Docking protocols. The resulting dock poses, scored according to the free energy of binding estimated by London Δ<i>G</i> function, were energy-minimized in the pocket consisting of PARP1 residues and waters and then visually inspected. MOE and PyMOL (Schrödinger; <a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>) were used for analyzing docking results and generating figures.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i155"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01498">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01498" class="ext-link">10.1021/acs.jmedchem.5b01498</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR spectra including <sup>1</sup>H NMR, <sup>13</sup>C NMR, HMBC, and HSQC for (8<i>S</i>,9<i>R</i>)-<b>47</b>; optical rotation measurement for (8<i>S</i>,9<i>R</i>)-<b>47</b> and (8<i>R</i>,9<i>S</i>)-<b>47</b>; single-crystal structure information for (8<i>S</i>,9<i>R</i>)-<b>47</b> and (2<i>S</i>,3<i>R</i>)-<b>60a</b>; SMILES strings for the compounds shown in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>; enantiomeric purity analysis for the compounds shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>; and mouse body weight in xenograft model studies (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01498/suppl_file/jm5b01498_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01498/suppl_file/jm5b01498_si_001.pdf">jm5b01498_si_001.pdf (1.18 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01498" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bing Wang</span> - <span class="hlFld-Affiliation affiliation">BioMarin Pharmaceutical
Inc., 105 Digital Drive, Novato, California 94949, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#89ebfee8e7eec9ebe4fbe7a7eae6e4"><span class="__cf_email__" data-cfemail="57352036393017353a25397934383a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Chu</span> - <span class="hlFld-Affiliation affiliation">BioMarin Pharmaceutical
Inc., 105 Digital Drive, Novato, California 94949, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Feng</span> - <span class="hlFld-Affiliation affiliation">BioMarin Pharmaceutical
Inc., 105 Digital Drive, Novato, California 94949, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuqiao Shen</span> - <span class="hlFld-Affiliation affiliation">BioMarin Pharmaceutical
Inc., 105 Digital Drive, Novato, California 94949, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mika Aoyagi-Scharber</span> - <span class="hlFld-Affiliation affiliation">BioMarin Pharmaceutical
Inc., 105 Digital Drive, Novato, California 94949, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leonard E. Post</span> - <span class="hlFld-Affiliation affiliation">BioMarin Pharmaceutical
Inc., 105 Digital Drive, Novato, California 94949, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): B. Wang, Y. Feng, Y. Shen, M. Aoyagi-Scharber, and L.E. Post own shares of stock in BioMarin Pharmaceutical, Inc.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2527e10736-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i156">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Peter Myers for his excellent scientific input and continuous support throughout this work; Xuhui Yan, Yongbo Liu, and the rest of the chemistry team at Shanghai ChemPartner for the chemical syntheses; the DMPK group at Shanghai ChemPartner for performing in vitro ADME and in vivo PK studies; Shanghai HD Biosciences, Inc. for developing and conducting in vitro and in vivo assays; Southern Research (US) for carrying out in vivo antitumor studies; and Dr. Mark Henderson of Drug Substance Contract Manufacturing at BioMarin, who coordinated with SSCI of Aptuit, for generating the single-crystal structures.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i157" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i157"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i158" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i158"> Abbreviations Used</h2><tr><td class="NLM_term">BER</td><td class="NLM_def"><p class="first last">base excision repair</p></td></tr><tr><td class="NLM_term">BRCA</td><td class="NLM_def"><p class="first last">breast cancer susceptibility gene</p></td></tr><tr><td class="NLM_term">DSB</td><td class="NLM_def"><p class="first last">double-strand break</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">homologous recombination</p></td></tr><tr><td class="NLM_term">NAD<sup>+</sup></td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide</p></td></tr><tr><td class="NLM_term">PAR</td><td class="NLM_def"><p class="first last">poly(ADP)ribose</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)polymerase</p></td></tr><tr><td class="NLM_term">rLM</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SSB</td><td class="NLM_def"><p class="first last">single-strand break</p></td></tr><tr><td class="NLM_term">TMZ</td><td class="NLM_def"><p class="first last">temozolomide</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i159">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases</span> <span class="citation_source-journal">Front. Biosci., Landmark Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3046</span><span class="NLM_x">–</span> <span class="NLM_lpage">3082</span><span class="refDoi"> DOI: 10.2741/2909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.2741%2F2909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=17981777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=3046-3082&author=P.+O.+Hassaauthor=M.+O.+Hottiger&title=The+diverse+biological+roles+of+mammalian+PARPS%2C+a+small+but+powerful+family+of+poly-ADP-ribose+polymerases&doi=10.2741%2F2909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span></div><div class="casAuthors">Hassa, Paul O.; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3046-3082</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Poly-ADP-ribose metab. plays a mayor role in a wide range of biol. processes, such as maintenance of genomic stability, transcriptional regulation, energy metab., and cell death.  Poly-ADP-ribose polymerases (PARPs) are an ancient family of enzymes, as evidenced by the poly-ADP-ribosylating activities reported in dinoflagellates and archaebacteria and by the identification of Parp-like genes in eubacterial and archaeabacterial genomes.  Six genes encoding "bona fide" PARP enzymes have been identified in mammalians: PARP1, PARP2, PARP3, PARP4/vPARP, PARP5/Tankyrases-1, and PARP6/Tankyrases-2.  The best studied of these enzymes, PARP1, plays a primary role in the process of poly-ADP-ribosylation.  PARP1-mediated poly-ADP-ribosylation has been implicated in the pathogenesis of cancer, inflammatory, and neurodegenerative disorders.  Here, the authors summarize novel findings and concepts for PARP enzymes and their poly-ADP-ribosylation activity in the regulation of physiol. and pathophysiol. processes.  A special focus is placed on the proposed mol. mechanisms involved in these processes, such as signaling, regulation of telomere dynamics, remodeling of chromatin structure, and transcriptional regulation.  A potential functional cross-talk between PARP family members and other NAD-consuming enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoNyzgIk1gtrVg90H21EOLACvtfcHk0lj44HqXLlSD6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D&md5=1e62c4597ec219b0797a29c1458b98b4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2741%2F2909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F2909%26sid%3Dliteratum%253Aachs%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DThe%2520diverse%2520biological%2520roles%2520of%2520mammalian%2520PARPS%252C%2520a%2520small%2520but%2520powerful%2520family%2520of%2520poly-ADP-ribose%2520polymerases%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2008%26volume%3D13%26spage%3D3046%26epage%3D3082%26doi%3D10.2741%2F2909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Rouleau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendzel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">PARP inhibition: PARP1 and beyond</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1038/nrc2812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnrc2812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=20200537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=293-301&author=M.+Rouleauauthor=A.+Patelauthor=M.+J.+Hendzelauthor=S.+H.+Kaufmannauthor=G.+G.+Poirier&title=PARP+inhibition%3A+PARP1+and+beyond&doi=10.1038%2Fnrc2812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibition: PARP1 and beyond</span></div><div class="casAuthors">Rouleau, Michele; Patel, Anand; Hendzel, Michael J.; Kaufmann, Scott H.; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-301</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets.  To provide a framework for understanding these recent observations, the authors have reviewed what is known about the structures and functions of the family of PARP enzymes, and then outlined a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOiY_n1IClmbVg90H21EOLACvtfcHk0liKOwZqSgrYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yms7w%253D&md5=fa3e3964e84229317dadbd505f11ad86</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2812%26sid%3Dliteratum%253Aachs%26aulast%3DRouleau%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DHendzel%26aufirst%3DM.%2BJ.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DPARP%2520inhibition%253A%2520PARP1%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D293%26epage%3D301%26doi%3D10.1038%2Fnrc2812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Therapeutic applications of PARP inhibitors: anticancer therapy and beyond</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span><span class="refDoi"> DOI: 10.1016/j.mam.2013.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.mam.2013.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23370117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1217-1256&author=N.+J.+Curtinauthor=C.+Szabo&title=Therapeutic+applications+of+PARP+inhibitors%3A+anticancer+therapy+and+beyond&doi=10.1016%2Fj.mam.2013.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span></div><div class="casAuthors">Curtin, Nicola J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1256</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this article is to describe the current and potential clin. translation of pharmacol. inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases.  The first section of the present review summarizes the available preclin. and clin. data with PARP inhibitors in various forms of cancer.  In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-assocd. lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer.  HRR defects are classically assocd. with BRCA1 and 2 mutations assocd. with familial breast and ovarian cancer, but there may be many other causes of HRR defects.  Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects.  Multiple lines of preclin. data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation.  Both single agent and combination clin. trials are underway.  The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clin. development.  The second section of the present review summarizes the role of PARP in selected non-oncol. indications.  In a no. of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clin. translatability of PARP inhibition is supported by multiple lines of preclin. data, as well as observational data demonstrating PARP activation in human tissue samples.  In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathol.  Accordingly, multiple lines of preclin. data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses.  As the clin. trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clin. investigations, aimed at testing of PARP inhibitors for various non-oncol. indications, will be initiated, as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4INVXcZ0zbVg90H21EOLACvtfcHk0liKOwZqSgrYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D&md5=6a514e160666b5dde38e1365211cd41e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DTherapeutic%2520applications%2520of%2520PARP%2520inhibitors%253A%2520anticancer%2520therapy%2520and%2520beyond%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1217%26epage%3D1256%26doi%3D10.1016%2Fj.mam.2013.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Krishnakumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.molcel.2010.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=20603072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8-24&author=R.+Krishnakumarauthor=W.+L.+Kraus&title=The+PARP+side+of+the+nucleus%3A+molecular+actions%2C+physiological+outcomes%2C+and+clinical+targets&doi=10.1016%2Fj.molcel.2010.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span></div><div class="casAuthors">Krishnakumar, Raga; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-24</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The abundant nuclear enzyme PARP-1, a multifunctional regulator of chromatin structure, transcription, and genomic integrity, plays key roles in a wide variety of processes in the nucleus.  Recent studies have begun to connect the mol. functions of PARP-1 to specific physiol. and pathol. outcomes, many of which can be altered by an expanding array of chem. inhibitors of PARP enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy5Mj-wajemLVg90H21EOLACvtfcHk0liKOwZqSgrYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D&md5=afb9423e09ed68d2bfa589ed0d7b9f13</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnakumar%26aufirst%3DR.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DThe%2520PARP%2520side%2520of%2520the%2520nucleus%253A%2520molecular%2520actions%252C%2520physiological%2520outcomes%252C%2520and%2520clinical%2520targets%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D39%26spage%3D8%26epage%3D24%26doi%3D10.1016%2Fj.molcel.2010.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Langelier, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, J. M.</span><span> </span><span class="NLM_article-title">PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1016/j.sbi.2013.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.sbi.2013.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23333033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=134-143&author=M.+F.+Langelierauthor=J.+M.+Pascal&title=PARP-1+mechanism+for+coupling+DNA+damage+detection+to+poly%28ADP-ribose%29+synthesis&doi=10.1016%2Fj.sbi.2013.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis</span></div><div class="casAuthors">Langelier, Marie-France; Pascal, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase 1 (PARP-1) regulates gene transcription, cell death signaling, and DNA repair through prodn. of the posttranslational modification poly(ADP-ribose).  During the cellular response to genotoxic stress PARP-1 rapidly assocs. with DNA damage, which robustly stimulates poly(ADP-ribose) prodn. over a low basal level of PARP-1 activity.  DNA damage-dependent PARP-1 activity is central to understanding PARP-1 biol. function, but structural insights into the mechanisms underlying this mode of regulation have remained elusive, in part due to the highly modular six-domain architecture of PARP-1.  Recent structural studies have illustrated how PARP-1 uses specialized zinc fingers to detect DNA breaks through sequence-independent interaction with exposed nucleotide bases, a common feature of damaged and abnormal DNA structures.  The mechanism of coupling DNA damage detection to elevated poly(ADP-ribose) prodn. has been elucidated based on a crystal structure of the essential domains of PARP-1 in complex with a DNA strand break.  The multiple domains of PARP-1 collapse onto damaged DNA, forming a network of interdomain contacts that introduce destabilizing alterations in the catalytic domain leading to an enhanced rate of poly(ADP-ribose) prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraHOp_vs_b0rVg90H21EOLACvtfcHk0li1vGl9QPkn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qu7w%253D&md5=b0c94b832353bcda25e0ad4dc982cbce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2013.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2013.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DLangelier%26aufirst%3DM.%2BF.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26atitle%3DPARP-1%2520mechanism%2520for%2520coupling%2520DNA%2520damage%2520detection%2520to%2520poly%2528ADP-ribose%2529%2520synthesis%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2013%26volume%3D23%26spage%3D134%26epage%3D143%26doi%3D10.1016%2Fj.sbi.2013.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">DNA repair dysregulation from cancer driver to therapeutic target</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1038/nrc3399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnrc3399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23175119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslagsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=801-817&author=N.+J.+Curtin&title=DNA+repair+dysregulation+from+cancer+driver+to+therapeutic+target&doi=10.1038%2Fnrc3399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair dysregulation from cancer driver to therapeutic target</span></div><div class="casAuthors">Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">801-817</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulation of DNA damage repair and signalling to cell cycle checkpoints, known as the DNA damage response (DDR), is assocd. with a predisposition to cancer and affects responses to DNA-damaging anticancer therapy.  Dysfunction of one DNA repair pathway may be compensated for by the function of another compensatory DDR pathway, which may be increased and contribute to resistance to DNA-damaging chemotherapy and radiotherapy.  Therefore, DDR pathways make an ideal target for therapeutic intervention; first, to prevent or reverse therapy resistance; and second, using a synthetic lethal approach to specifically kill cancer cells that are dependent on a compensatory DNA repair pathway for survival in the context of cancer-assocd. oxidative and replicative stress.  These hypotheses are currently being tested in the lab. and are being translated into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNDBV6krLGBbVg90H21EOLACvtfcHk0li1vGl9QPkn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslagsb3N&md5=1bcb90d4742e46696c8a30a4fce2400c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3399%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DDNA%2520repair%2520dysregulation%2520from%2520cancer%2520driver%2520to%2520therapeutic%2520target%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D801%26epage%3D817%26doi%3D10.1038%2Fnrc3399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Amé, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedergang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apiou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Höger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménissier-de Murcia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">17860</span><span class="NLM_x">–</span> <span class="NLM_lpage">17868</span><span class="refDoi"> DOI: 10.1074/jbc.274.25.17860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1074%2Fjbc.274.25.17860" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=17860-17868&author=J.+C.+Am%C3%A9author=V.+Rolliauthor=V.+Schreiberauthor=C.+Niedergangauthor=F.+Apiouauthor=P.+Deckerauthor=S.+Mullerauthor=T.+H%C3%B6gerauthor=J.+M%C3%A9nissier-de+Murciaauthor=G.+de+Murcia&title=PARP-2%2C+A+novel+mammalian+DNA+damage-dependent+poly%28ADP-ribose%29+polymerase&doi=10.1074%2Fjbc.274.25.17860"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.25.17860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.25.17860%26sid%3Dliteratum%253Aachs%26aulast%3DAm%25C3%25A9%26aufirst%3DJ.%2BC.%26aulast%3DRolli%26aufirst%3DV.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DNiedergang%26aufirst%3DC.%26aulast%3DApiou%26aufirst%3DF.%26aulast%3DDecker%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DH%25C3%25B6ger%26aufirst%3DT.%26aulast%3DM%25C3%25A9nissier-de%2BMurcia%26aufirst%3DJ.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPARP-2%252C%2520A%2520novel%2520mammalian%2520DNA%2520damage-dependent%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D17860%26epage%3D17868%26doi%3D10.1074%2Fjbc.274.25.17860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ame, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose): novel functions for an old molecule</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/nrm1963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnrm1963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=16829982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=517-528&author=V.+Schreiberauthor=F.+Dantzerauthor=J.+C.+Ameauthor=G.+de+Murcia&title=Poly%28ADP-ribose%29%3A+novel+functions+for+an+old+molecule&doi=10.1038%2Fnrm1963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose): novel functions for an old molecule</span></div><div class="casAuthors">Schreiber, Valerie; Dantzer, Francoise; Ame, Jean-Christophe; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The addn. to proteins of the neg. charged polymer of ADP-ribose, which is synthesized by poly(ADP-ribose) polymerase (PARPs) from NAD, is a unique post-translational modification.  It regulates not only cell survival and cell-death programs, but also an increasing no. of other biol. functions with which novel members of the PARP family have been assocd.  These functions include transcriptional regulation, telomere cohesion and mitotic spindle formation during cell division, intracellular trafficking, and energy metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLsI4_BKfjdrVg90H21EOLACvtfcHk0li1vGl9QPkn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D&md5=676e83755491500f3bf2137f348dfa1b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrm1963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1963%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3DAme%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPoly%2528ADP-ribose%2529%253A%2520novel%2520functions%2520for%2520an%2520old%2520molecule%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D517%26epage%3D528%26doi%3D10.1038%2Fnrm1963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">The DNA damage response and cancer therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">481</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1038/nature10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnature10760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=22258607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=287-294&author=C.+J.+Lordauthor=A.+Ashworth&title=The+DNA+damage+response+and+cancer+therapy&doi=10.1038%2Fnature10760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response and cancer therapy</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7381</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genomic instability is one of the most pervasive characteristics of tumor cells and is probably the combined effect of DNA damage, tumor-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells.  Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities.  A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS1sAbqFhmrVg90H21EOLACvtfcHk0ljjrSSfQ2hTKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D&md5=75d12cdb52e8c9a39bced1611bf90298</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10760%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DThe%2520DNA%2520damage%2520response%2520and%2520cancer%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D481%26spage%3D287%26epage%3D294%26doi%3D10.1038%2Fnature10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors: polypharmacology versus selective inhibition</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3575</span><span class="refDoi"> DOI: 10.1111/febs.12298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1111%2Ffebs.12298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23601167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFWksbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=3563-3575&author=T.+Ekbladauthor=E.+Camaioniauthor=H.+Sch%C3%BClerauthor=A.+Macchiarulo&title=PARP+inhibitors%3A+polypharmacology+versus+selective+inhibition&doi=10.1111%2Ffebs.12298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors: polypharmacology versus selective inhibition</span></div><div class="casAuthors">Ekblad, Torun; Camaioni, Emidio; Schueler, Herwig; Macchiarulo, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3563-3575</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Inhibition of ADP-ribosyltransferases with diphtheria toxin homol. (ARTD), widely known as the poly(ADP-ribose) polymerase (PARP) family, is a strategy under development for treatment of various conditions, including cancers and ischemia.  Here, we give a brief summary of ARTD enzyme functions and the implications for their potential as therapeutic targets.  We present an overview of the PARP inhibitors that have been used in clin. trials.  Finally, we summarize recent insights from structural biol., and discuss the mol. aspects of PARP inhibitors in terms of broad-range vs. selective inhibition of ARTD family enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_9XKFIi3olbVg90H21EOLACvtfcHk0ljjrSSfQ2hTKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFWksbjP&md5=ec08e437f8b0150a44df2f9dda7cd5f7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12298%26sid%3Dliteratum%253Aachs%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%253A%2520polypharmacology%2520versus%2520selective%2520inhibition%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D3563%26epage%3D3575%26doi%3D10.1111%2Ffebs.12298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lupo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1846</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2014.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.bbcan.2014.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25026313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1846&publication_year=2014&pages=201-215&author=B.+Lupoauthor=L.+Trusolino&title=Inhibition+of+poly%28ADP-ribosyl%29ation+in+cancer%3A+old+and+new+paradigms+revisited&doi=10.1016%2Fj.bbcan.2014.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited</span></div><div class="casAuthors">Lupo, Barbara; Trusolino, Livio</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1846</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-215</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inhibitors of poly(ADP-ribose) polymerases actualized the biol. concept of synthetic lethality in the clin. practice, yielding a paradigmatic example of translational medicine.  The profound sensitivity of tumors with germline BRCA mutations to PARP1/2 blockade owes to inherent defects of the BRCA-dependent homologous recombination machinery, which are unleashed by interruption of PARP DNA repair activity and lead to DNA damage overload and cell death.  Conversely, aspirant BRCA-like tumors harboring somatic DNA repair dysfunctions (a vast entity of genetic and epigenetic defects known as "BRCAness") not always align with the familial counterpart and appear not to be equally sensitive to PARP inhibition.  The acquisition of secondary resistance in initially responsive patients and the lack of standardized biomarkers to identify "BRCAness" pose serious threats to the clin. advance of PARP inhibitors; a feeling is also emerging that a BRCA-centered perspective might have missed the influence of addnl., not negligible and DNA repair-independent PARP contributions onto therapy outcome.  While regulatory approval for PARP1/2 inhibitors is still pending, novel therapeutic opportunities are sprouting from different branches of the PARP family, although they remain immature for clin. extrapolation.  This review is an endeavor to provide a comprehensive appraisal of the multifaceted biol. of PARPs and their evolving impact on cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqebmjv_GlsGrVg90H21EOLACvtfcHk0ljjrSSfQ2hTKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrrN&md5=222390f25fa1763853fdaf8da34b1d14</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2014.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2014.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DLupo%26aufirst%3DB.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribosyl%2529ation%2520in%2520cancer%253A%2520old%2520and%2520new%2520paradigms%2520revisited%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1846%26spage%3D201%26epage%3D215%26doi%3D10.1016%2Fj.bbcan.2014.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span> </span><span class="NLM_article-title">4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+W.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+B.+Martin&title=4-%5B3-%284-cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+A+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0liWR1wCr9LUQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%2BW.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3D4-%255B3-%25284-cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520A%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.-Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial&doi=10.1158%2F1535-7163.MCT-06-0552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0liWR1wCr9LUQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956%26doi%3D10.1158%2F1535-7163.MCT-06-0552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Canan-Koch, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoresen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tikhe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zook, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span> </span><span class="NLM_article-title">Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4961</span><span class="NLM_x">–</span> <span class="NLM_lpage">4974</span><span class="refDoi"> DOI: 10.1021/jm020259n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020259n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4961-4974&author=S.+S.+Canan-Kochauthor=L.+H.+Thoresenauthor=J.+G.+Tikheauthor=K.+A.+Maegleyauthor=X.-H.+Yuauthor=S.+E.+Zookauthor=R.+A.+Kumpfauthor=C.+Zhangauthor=T.+J.+Boritzkiauthor=R.+N.+Mansourauthor=K.+E.+Zhangauthor=A.+Ekkerauthor=C.+R.+Calabreseauthor=N.+J.+Curtinauthor=S.+Kyleauthor=H.+D.+Thomasauthor=L.-Z.+Wangauthor=A.+H.+Calvertauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=D.+R.+Newellauthor=S.+E.+Webberauthor=Z.+Hostomsky&title=Novel+tricyclic+poly%28ADP-ribose%29+polymerase-1+inhibitors+with+potent+anticancer+chemopotentiating+activity%3A+Design%2C+synthesis%2C+and+X-ray+cocrystal+structure&doi=10.1021%2Fjm020259n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm020259n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020259n%26sid%3Dliteratum%253Aachs%26aulast%3DCanan-Koch%26aufirst%3DS.%2BS.%26aulast%3DThoresen%26aufirst%3DL.%2BH.%26aulast%3DTikhe%26aufirst%3DJ.%2BG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DYu%26aufirst%3DX.-H.%26aulast%3DZook%26aufirst%3DS.%2BE.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DMansour%26aufirst%3DR.%2BN.%26aulast%3DZhang%26aufirst%3DK.%2BE.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DHostomsky%26aufirst%3DZ.%26atitle%3DNovel%2520tricyclic%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%2520with%2520potent%2520anticancer%2520chemopotentiating%2520activity%253A%2520Design%252C%2520synthesis%252C%2520and%2520X-ray%2520cocrystal%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4961%26epage%3D4974%26doi%3D10.1021%2Fjm020259n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and −2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">–</span> <span class="NLM_lpage">7185</span><span class="refDoi"> DOI: 10.1021/jm901188v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+A+novel+oral+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA-1+and+%E2%88%922+mutant+tumors&doi=10.1021%2Fjm901188v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520A%2520novel%2520oral%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA-1%2520and%2520%25E2%2588%25922%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185%26doi%3D10.1021%2Fjm901188v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span> </span><span class="NLM_article-title">Niraparib: a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3302</span><span class="NLM_x">–</span> <span class="NLM_lpage">3314</span><span class="refDoi"> DOI: 10.1021/jm5018237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3302-3314&author=P.+Jonesauthor=K.+Wilcoxenauthor=M.+Rowleyauthor=C.+Toniatti&title=Niraparib%3A+a+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+for+the+treatment+of+tumors+with+defective+homologous+recombination&doi=10.1021%2Fjm5018237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26atitle%3DNiraparib%253A%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520tumors%2520with%2520defective%2520homologous%2520recombination%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3302%26epage%3D3314%26doi%3D10.1021%2Fjm5018237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeWeese, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillehay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holley-Shanks, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hristov, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idler, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasko, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigal, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meulbroek, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palma, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsurutani, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span> </span><span class="NLM_article-title">ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2728</span><span class="NLM_x">–</span> <span class="NLM_lpage">2737</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-3039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1078-0432.CCR-06-3039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=17473206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2728-2737&author=C.+K.+Donawhoauthor=Y.+Luoauthor=Y.+Luoauthor=T.+D.+Penningauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=V.+D.+Bontcheva-Diazauthor=B.+F.+Coxauthor=T.+L.+DeWeeseauthor=L.+E.+Dillehayauthor=D.+C.+Fergusonauthor=N.+S.+Ghoreishi-Haackauthor=D.+R.+Grimmauthor=R.+Guanauthor=E.+K.+Hanauthor=R.+R.+Holley-Shanksauthor=B.+Hristovauthor=K.+B.+Idlerauthor=K.+Jarvisauthor=E.+F.+Johnsonauthor=L.+R.+Kleinbergauthor=V.+Klinghoferauthor=L.+M.+Laskoauthor=X.+Liuauthor=K.+C.+Marshauthor=T.+P.+McGonigalauthor=J.+A.+Meulbroekauthor=A.+M.+Olsonauthor=J.+P.+Palmaauthor=L.+E.+Rodriguezauthor=Y.+Shiauthor=J.+A.+Stavropoulosauthor=A.+C.+Tsurutaniauthor=G.+D.+Zhuauthor=S.+Rosenbergauthor=V.+L.+Girandaauthor=D.+J.+Frost&title=ABT-888%2C+an+orally+active+poly%28ADP-ribose%29+polymerase+inhibitor+that+potentiates+DNA-damaging+agents+in+preclinical+tumor+models&doi=10.1158%2F1078-0432.CCR-06-3039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models</span></div><div class="casAuthors">Donawho, Cherrie K.; Luo, Yan; Luo, Yanping; Penning, Thomas D.; Bauch, Joy L.; Bouska, Jennifer J.; Bontcheva-Diaz, Velitchka D.; Cox, Bryan F.; DeWeese, Theodore L.; Dillehay, Larry E.; Ferguson, Debra C.; Ghoreishi-Haack, Nayereh S.; Grimm, David R.; Guan, Ran; Han, Edward K.; Holley-Shanks, Rhonda R.; Hristov, Boris; Idler, Kenneth B.; Jarvis, Ken; Johnson, Eric F.; Kleinberg, Lawrence R.; Klinghofer, Vered; Lasko, Loren M.; Liu, Xuesong; Marsh, Kennan C.; McGonigal, Thomas P.; Meulbroek, Jonathan A.; Olson, Amanda M.; Palma, Joann P.; Rodriguez, Luis E.; Shi, Yan; Stavropoulos, Jason A.; Tsurutani, Alan C.; Zhu, Gui-Dong; Rosenberg, Saul H.; Giranda, Vincent L.; Frost, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2728-2737</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose is to evaluate the preclin. pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888.  In vitro potency was detd. in a PARP-1 and PARP-2 enzyme assay.  In vivo efficacy was evaluated in syngeneic and xenograft models in combination with temozolomide, platinums, cyclophosphamide, and ionizing radiation.  ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2 and 2.9 nmol/L, resp.  The compd. has good oral bioavailability and crosses the blood-brain barrier.  ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model.  PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d.  In the 9L orthotopic rat glioma model, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression.  In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited.  Finally, ABT-888 potentiated radiation (2 Gy/d × 10) in an HCT-116 colon carcinoma model.  In each model, ABT-888 did not display single-agent activity.  ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.  This broad spectrum of chemopotentiation and radiopotentiation makes this compd. an attractive candidate for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2xiIRsPurHLVg90H21EOLACvtfcHk0lgda9zIIMsnIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D&md5=4769ee3eec82465993eb9e1443095894</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3039%26sid%3Dliteratum%253Aachs%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%2BD.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DDeWeese%26aufirst%3DT.%2BL.%26aulast%3DDillehay%26aufirst%3DL.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%2BC.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DGrimm%26aufirst%3DD.%2BR.%26aulast%3DGuan%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DE.%2BK.%26aulast%3DHolley-Shanks%26aufirst%3DR.%2BR.%26aulast%3DHristov%26aufirst%3DB.%26aulast%3DIdler%26aufirst%3DK.%2BB.%26aulast%3DJarvis%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DKleinberg%26aufirst%3DL.%2BR.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DLasko%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMcGonigal%26aufirst%3DT.%2BP.%26aulast%3DMeulbroek%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DPalma%26aufirst%3DJ.%2BP.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DTsurutani%26aufirst%3DA.%2BC.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DRosenberg%26aufirst%3DS.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26atitle%3DABT-888%252C%2520an%2520orally%2520active%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520that%2520potentiates%2520DNA-damaging%2520agents%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2728%26epage%3D2737%26doi%3D10.1158%2F1078-0432.CCR-06-3039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubisch, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carbox-amide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">6965</span><span class="NLM_x">–</span> <span class="NLM_lpage">6975</span><span class="refDoi"> DOI: 10.1016/j.bmc.2008.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.bmc.2008.05.044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6965-6975&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=S.+Thomasauthor=W.+Lubischauthor=R.+Grandelauthor=W.+Wernetauthor=C.+H.+Parkauthor=E.+H.+Fryauthor=Y.+Luoauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=D.+J.+Frostauthor=C.+K.+Donawhoauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=S.+H.+Rosenbergauthor=V.+L.+Giranda&title=Discovery+and+SAR+of+2-%281-propylpiperidin-4-yl%29-1H-benzimidazole-4-carbox-amide%3A+A+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmc.2008.05.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DLubisch%26aufirst%3DW.%26aulast%3DGrandel%26aufirst%3DR.%26aulast%3DWernet%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25202-%25281-propylpiperidin-4-yl%2529-1H-benzimidazole-4-carbox-amide%253A%2520A%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6965%26epage%3D6975%26doi%3D10.1016%2Fj.bmc.2008.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">523</span><span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. I·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., I·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0ljeOPBMode9Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boshuizen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">–</span> <span class="NLM_lpage">5015</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1078-0432.CCR-13-1391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23881923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5003-5015&author=Y.+Shenauthor=F.+L.+Rehmanauthor=Y.+Fengauthor=J.+Boshuizenauthor=I.+Bajramiauthor=R.+Elliottauthor=B.+Wangauthor=C.+J.+Lordauthor=L.+E.+Postauthor=A.+Ashworth&title=BMN+673%2C+a+novel+and+highly+potent+PARP1%2F2+inhibitor+for+the+treatment+of+human+cancers+with+DNA+repair+deficiency&doi=10.1158%2F1078-0432.CCR-13-1391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency</span></div><div class="casAuthors">Shen, Yuqiao; Rehman, Farah L.; Feng, Ying; Boshuizen, Julia; Bajrami, Ilirjana; Elliott, Richard; Wang, Bing; Lord, Christopher J.; Post, Leonard E.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5003-5015</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.  Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  Exptl. Design: Potency and selectivity of BMN 673 was detd. by biochem. assays.  Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models.  Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested.  BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concns. than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib).  In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors.  BMN 673 is readily orally bioavailable, with more than 40% abs. oral bioavailability in rats when dosed in carboxylmethyl cellulose.  Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice.  Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs.  Conclusion: BMN 673 is currently in early-phase clin. development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.  Clin Cancer Res; 19(18); 5003-15. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdmHIVEuoz7Vg90H21EOLACvtfcHk0ljeOPBMode9Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J&md5=f58b67f14784c0a0fa1197caffd8d96d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1391%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBoshuizen%26aufirst%3DJ.%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBMN%2520673%252C%2520a%2520novel%2520and%2520highly%2520potent%2520PARP1%252F2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%2520with%2520DNA%2520repair%2520deficiency%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5003%26epage%3D5015%26doi%3D10.1158%2F1078-0432.CCR-13-1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimshaw, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiryanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, P.</span><span> </span><span class="NLM_article-title">Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4501</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.bmcl.2013.06.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4501-4505&author=A.+R.+Gangloffauthor=J.+Brownauthor=R.+de+Jongauthor=D.+R.+Douganauthor=C.+E.+Grimshawauthor=M.+Hixonauthor=A.+Jenningsauthor=R.+Kamranauthor=A.+Kiryanovauthor=S.+O%E2%80%99Connellauthor=E.+Taylorauthor=P.+Vu&title=Discovery+of+novel+benzo%5Bb%5D%5B1%2C4%5Doxazin-3%284H%29-ones+as+poly%28ADP-ribose%29polymerase+inhibitors&doi=10.1016%2Fj.bmcl.2013.06.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.055%26sid%3Dliteratum%253Aachs%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3Dde%2BJong%26aufirst%3DR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DHixon%26aufirst%3DM.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DKamran%26aufirst%3DR.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DVu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%2520benzo%255Bb%255D%255B1%252C4%255Doxazin-3%25284H%2529-ones%2520as%2520poly%2528ADP-ribose%2529polymerase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4501%26epage%3D4505%26doi%3D10.1016%2Fj.bmcl.2013.06.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2885</span><span class="NLM_x">–</span> <span class="NLM_lpage">2903</span><span class="refDoi"> DOI: 10.1021/jm301825t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301825t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslGhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2885-2903&author=N.+Yeauthor=C.+H.+Chenauthor=T.+Chenauthor=Z.+Songauthor=J.+X.+Heauthor=X.+J.+Huanauthor=S.+S.+Songauthor=Q.+Liuauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Xuauthor=Z.+H.+Miaoauthor=A.+Zhang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+benzo%5Bde%5D%5B1%2C7%5Dnaphthyridin-7%288H%29-ones+bearing+a+functionalized+longer+chain+appendage+as+novel+PARP1+inhibitors&doi=10.1021%2Fjm301825t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors</span></div><div class="casAuthors">Ye, Na; Chen, Chuan-Huizi; Chen, TianTian; Song, Zilan; He, Jin-Xue; Huan, Xia-Juan; Song, Shan-Shan; Liu, Qiufeng; Chen, Yi; Ding, Jian; Xu, Yechun; Miao, Ze-Hong; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2885-2903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors.  The initial effort led to the first-generation PARP1 inhibitor I (X = NH) bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell.  Further effort generated the second-generation lead, cyclopenta[ij]isoquinolinone I [X = nothing; (II)], showing high potency against both the PARP1 enzyme and BRCA-deficient cells, esp. for the BRCA1-deficient MDA-MB-436 cells (CC50 < 0.26 nM).  Mechanistic studies revealed that the new PARP1 inhibitors significantly inhibited H2O2-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells.  Significant potentiation on the cytotoxicity of Temozolomide was also obsd.  The unique structural character and exceptionally high potency of II made it stand out as a promising drug candidate worthy for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFCnCaPH54gbVg90H21EOLACvtfcHk0lhPxHKqFjYQ1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslGhtL8%253D&md5=6f13946d5bb17bcfd8c1c00ae5b9a589</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301825t%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%2BX.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520benzo%255Bde%255D%255B1%252C7%255Dnaphthyridin-7%25288H%2529-ones%2520bearing%2520a%2520functionalized%2520longer%2520chain%2520appendage%2520as%2520novel%2520PARP1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2885%26epage%3D2903%26doi%3D10.1021%2Fjm301825t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busel, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caprera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khvat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasavin, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzetta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainoldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span> </span><span class="NLM_article-title">Discovery of 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): a Potent, Orally Available and Highly Selective PARP-1 Inhibitor for Cancer Therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6875</span><span class="NLM_x">–</span> <span class="NLM_lpage">6898</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6875-6898&author=G.+Papeoauthor=H.+Posteriauthor=D.+Borghiauthor=A.+A.+Buselauthor=F.+Capreraauthor=E.+Casaleauthor=M.+Ciomeiauthor=A.+Cirlaauthor=E.+Cortiauthor=M.+D%E2%80%99Anelloauthor=M.+Fasoliniauthor=B.+Forteauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Khvatauthor=M.+Y.+Krasavinauthor=R.+Lupiauthor=P.+Orsiniauthor=R.+Peregoauthor=E.+Pesentiauthor=D.+Pezzettaauthor=S.+Rainoldiauthor=F.+Riccardi-Sirtoriauthor=A.+Scolaroauthor=F.+Solaauthor=F.+Zuccottoauthor=E.+R.+Felderauthor=D.+Donatiauthor=A.+Montagnoli&title=Discovery+of+2-%5B1-%284%2C4-difluorocyclohexyl%29piperidin-4-yl%5D-6-fluoro-3-oxo-2%2C3-dihydro-1H-isoindole-4-carboxamide+%28NMS-P118%29%3A+a+Potent%2C+Orally+Available+and+Highly+Selective+PARP-1+Inhibitor+for+Cancer+Therapy&doi=10.1021%2Facs.jmedchem.5b00680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBusel%26aufirst%3DA.%2BA.%26aulast%3DCaprera%26aufirst%3DF.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DCirla%26aufirst%3DA.%26aulast%3DCorti%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Anello%26aufirst%3DM.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DKhvat%26aufirst%3DA.%26aulast%3DKrasavin%26aufirst%3DM.%2BY.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPezzetta%26aufirst%3DD.%26aulast%3DRainoldi%26aufirst%3DS.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMontagnoli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25202-%255B1-%25284%252C4-difluorocyclohexyl%2529piperidin-4-yl%255D-6-fluoro-3-oxo-2%252C3-dihydro-1H-isoindole-4-carboxamide%2520%2528NMS-P118%2529%253A%2520a%2520Potent%252C%2520Orally%2520Available%2520and%2520Highly%2520Selective%2520PARP-1%2520Inhibitor%2520for%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6875%26epage%3D6898%26doi%3D10.1021%2Facs.jmedchem.5b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Shalinsky, D. R.</span>; <span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Preclinical chemosensitization by PARP inhibitors</span>. In  <span class="citation_source-book">PARP Inhibitors for Cancer Therapy</span>; <span class="NLM_contrib-group">Curtin, N.; Sharma, R.</span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">260</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1007%2F978-3-319-14151-0_9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=225-260&author=D.+R.+Shalinskyauthor=N.+Curtin&author=R.+Sharma&title=PARP+Inhibitors+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-14151-0_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-14151-0_9%26sid%3Dliteratum%253Aachs%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26atitle%3DPreclinical%2520chemosensitization%2520by%2520PARP%2520inhibitors%26btitle%3DPARP%2520Inhibitors%2520for%2520Cancer%2520Therapy%26aulast%3DCurtin%26aufirst%3DN.%26pub%3DHumana%2520Press%26date%3D2015%26spage%3D225%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span><span class="refDoi"> DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lhPxHKqFjYQ1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span><span class="refDoi"> DOI: 10.1038/nature03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+J.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&doi=10.1038%2Fnature03445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0lg6DxHr5QIpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921%26doi%3D10.1038%2Fnature03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3785</span><span class="NLM_x">–</span> <span class="NLM_lpage">3790</span><span class="refDoi"> DOI: 10.1200/JCO.2008.16.0812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1200%2FJCO.2008.16.0812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=18591545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGjs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3785-3790&author=A.+Ashworth&title=A+synthetic+lethal+therapeutic+approach%3A+poly%28ADP%29+ribose+polymerase+inhibitors+for+the+treatment+of+cancers+deficient+in+DNA+double-strand+break+repair&doi=10.1200%2FJCO.2008.16.0812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair</span></div><div class="casAuthors">Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3785-3790</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability.  This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically.  Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCA2, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase.  This provides the basis for a novel synthetic lethal approach to cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXrRHAispvD7Vg90H21EOLACvtfcHk0lg6DxHr5QIpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGjs7rL&md5=ae9227ee9c2fd4367264e738921fec2c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.16.0812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.16.0812%26sid%3Dliteratum%253Aachs%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DA%2520synthetic%2520lethal%2520therapeutic%2520approach%253A%2520poly%2528ADP%2529%2520ribose%2520polymerase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancers%2520deficient%2520in%2520DNA%2520double-strand%2520break%2520repair%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3785%26epage%3D3790%26doi%3D10.1200%2FJCO.2008.16.0812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span><span class="refDoi"> DOI: 10.1016/j.molonc.2011.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.molonc.2011.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=21821475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=387-393&author=T.+Helleday&title=The+underlying+mechanism+for+the+PARP+and+BRCA+synthetic+lethality%3A+clearing+up+the+misunderstandings&doi=10.1016%2Fj.molonc.2011.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings</span></div><div class="casAuthors">Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-393</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) polymerase (PARP) inhibitors effectively kill tumors defective in the BRCA1 or BRCA2 genes through the concept of synthetic lethality.  It is suggested that PARP inhibitors cause an increase in DNA single-strand breaks (SSBs), which are converted during replication to irreparable toxic DNA double-strand breaks (DSBs) in BRCA1/2 defective cells.  There are a no. of recent reports challenging this model.  Here, alternative models that are not mutually exclusive are presented to explain the synthetic lethality between BRCA1/2 and PARP inhibitors.  One such model proposes that PARP inhibition causes PARP-1 to be trapped onto DNA repair intermediates, esp. during base excision repair.  This may in turn cause obstruction to replication forks, which require BRCA-dependent homologous recombination to be resolved.  In another model, PARP is directly involved in catalyzing replication repair in a distinct pathway from homologous recombination.  Exptl. evidence supporting these novel models to explain the PARP-BRCA synthetic lethality are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUCIzO2NudrVg90H21EOLACvtfcHk0lg6DxHr5QIpIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO&md5=1b64dde39e08d863e774de91a0fbe1e9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2011.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2011.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DThe%2520underlying%2520mechanism%2520for%2520the%2520PARP%2520and%2520BRCA%2520synthetic%2520lethality%253A%2520clearing%2520up%2520the%2520misunderstandings%26jtitle%3DMol.%2520Oncol.%26date%3D2011%26volume%3D5%26spage%3D387%26epage%3D393%26doi%3D10.1016%2Fj.molonc.2011.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Biomarkers of PARP inhibitor sensitivity</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1007/s10549-011-1375-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1007%2Fs10549-011-1375-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=21301956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A280%3ADC%252BC3MvitVOqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=283-286&author=N.+C.+Turnerauthor=A.+Ashworth&title=Biomarkers+of+PARP+inhibitor+sensitivity&doi=10.1007%2Fs10549-011-1375-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers of PARP inhibitor sensitivity</span></div><div class="casAuthors">Turner Nicholas C; Ashworth Alan</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research and treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqvWEtOUv36LJzI8owOhpDfW6udTcc2ebycD66YaFH17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvitVOqsQ%253D%253D&md5=9d5a04417162585c252a39156f6650f4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1375-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1375-8%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBiomarkers%2520of%2520PARP%2520inhibitor%2520sensitivity%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D127%26spage%3D283%26epage%3D286%26doi%3D10.1007%2Fs10549-011-1375-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP2 by clinical PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5588</span><span class="NLM_x">–</span> <span class="NLM_lpage">5599</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23118055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.+Y.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP2+by+clinical+PARP+inhibitors&doi=10.1158%2F0008-5472.CAN-12-2753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-yin N.; Das, Benu Brata; Renaud, Amelie; Zhang, Yiping; Doroshow, James H.; Ji, Jiuping; Takeda, Shunichi; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5588-5599</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings indicate that PARP inhibitors in clin. trials not only block catalytic function but also trap PARP enzymes on DNA, illuminating the mechanistic basis for their cytotoxic activity in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3m55HXn9ObVg90H21EOLACvtfcHk0ljTVNUOLDeEmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE&md5=81c590b6a4fbb9efc9c64f7de5e89524</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP2%2520by%2520clinical%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599%26doi%3D10.1158%2F0008-5472.CAN-12-2753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="refDoi"> DOI: 10.3389/fonc.2013.00228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.3389%2Ffonc.2013.00228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=24062981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt1yqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=228&author=S.+B.+De+Lorenzoauthor=A.+G.+Patelauthor=R.+M.+Hurleyauthor=S.+H.+Kaufmann&title=The+elephant+and+the+blind+men%3A+making+sense+of+PARP+inhibitors+in+homologous+recombination+deficient+tumor+cells&doi=10.3389%2Ffonc.2013.00228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells</span></div><div class="casAuthors">De Lorenzo Silvana B; Patel Anand G; Hurley Rachel M; Kaufmann Scott H</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Poly(ADP-ribose) polymerase 1 (PARP1) is an important component of the base excision repair (BER) pathway as well as a regulator of homologous recombination (HR) and non-homologous end-joining (NHEJ).  Previous studies have demonstrated that treatment of HR-deficient cells with PARP inhibitors results in stalled and collapsed replication forks.  Consequently, HR-deficient cells are extremely sensitive to PARP inhibitors.  Several explanations have been advanced to explain this so-called synthetic lethality between HR deficiency and PARP inhibition: (i) reduction of BER activity leading to enhanced DNA double-strand breaks, which accumulate in the absence of HR; (ii) trapping of inhibited PARP1 at sites of DNA damage, which prevents access of other repair proteins; (iii) failure to initiate HR by poly(ADP-ribose) polymer-dependent BRCA1 recruitment; and (iv) activation of the NHEJ pathway, which selectively induces error-prone repair in HR-deficient cells.  Here we review evidence regarding these various explanations for the ability of PARP inhibitors to selectively kill HR-deficient cancer cells and discuss their potential implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiyQIXPBx6kVm8bhe6roZYfW6udTcc2ebycD66YaFH17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt1yqtA%253D%253D&md5=3dc80d23dca912a20c717677a3e31ed8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00228%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DHurley%26aufirst%3DR.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DThe%2520elephant%2520and%2520the%2520blind%2520men%253A%2520making%2520sense%2520of%2520PARP%2520inhibitors%2520in%2520homologous%2520recombination%2520deficient%2520tumor%2520cells%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D228%26doi%3D10.3389%2Ffonc.2013.00228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.+Y.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+trapping+by+BMN+673+and+comparison+with+olaparib+and+rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0ljdjRDosEnOYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520trapping%2520by%2520BMN%2520673%2520and%2520comparison%2520with%2520olaparib%2520and%2520rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span> </span><span class="NLM_article-title">Trapping poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1124/jpet.114.222448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1124%2Fjpet.114.222448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25758918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=446-457&author=J.+Shenauthor=M.+Aoyagi-Scharberauthor=B.+Wang&title=Trapping+poly%28ADP-ribose%29+polymerase&doi=10.1124%2Fjpet.114.222448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Shen, Yuqiao; Aoyagi-Scharber, Mika; Wang, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-457</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage.  The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.  Several clin.-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.  Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells.  In this article, we review the available data on mol. interactions between these clin.-stage PARP inhibitors and PARP proteins, and discuss how their biol. differences might be explained by the trapping mechanism.  We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7H8kc8UmXLVg90H21EOLACvtfcHk0ljdjRDosEnOYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D&md5=36ceb95db0a63ab9ce002906df555482</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.222448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.222448%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DTrapping%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D446%26epage%3D457%26doi%3D10.1124%2Fjpet.114.222448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of poly(ADP-ribose) polymerase inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">–</span> <span class="NLM_lpage">4584</span><span class="refDoi"> DOI: 10.1021/jm100012m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+poly%28ADP-ribose%29+polymerase+inhibitors.+From+concept+to+clinic&doi=10.1021%2Fjm100012m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584%26doi%3D10.1021%2Fjm100012m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Optimization of phenyl-substituted benzimidazole carboxamide poly (ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3142</span><span class="NLM_x">–</span> <span class="NLM_lpage">3153</span><span class="refDoi"> DOI: 10.1021/jm901775y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901775y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3142-3153&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=J.+Gongauthor=S.+Thomasauthor=V.+B.+Gandhiauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+H.+Parkauthor=E.+H.+Fryauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=F.+G.+Buchananauthor=G.+T.+Bukofzerauthor=L.+E.+Rodriguezauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Optimization+of+phenyl-substituted+benzimidazole+carboxamide+poly+%28ADP-ribose%29+polymerase+inhibitors%3A+identification+of+%28S%29-2-%282-fluoro-4-%28pyrrolidin-2-yl%29phenyl%29-1H-benzimidazole-4-carboxamide+%28A-966492%29%2C+a+highly+potent+and+efficacious+inhibitor&doi=10.1021%2Fjm901775y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901775y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901775y%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBuchanan%26aufirst%3DF.%2BG.%26aulast%3DBukofzer%26aufirst%3DG.%2BT.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DOptimization%2520of%2520phenyl-substituted%2520benzimidazole%2520carboxamide%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitors%253A%2520identification%2520of%2520%2528S%2529-2-%25282-fluoro-4-%2528pyrrolidin-2-yl%2529phenyl%2529-1H-benzimidazole-4-carboxamide%2520%2528A-966492%2529%252C%2520a%2520highly%2520potent%2520and%2520efficacious%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3142%26epage%3D3153%26doi%3D10.1021%2Fjm901775y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, P. A.</span><span> </span><span class="NLM_article-title">Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from tetrahydropyridophthalazinone</span> <span class="citation_source-journal">Acta Crystallogr., Sect. F: Struct. Biol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1107/S2053230X14015088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1107%2FS2053230X14015088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25195882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=1143-1149&author=M.+Aoyagi-Scharberauthor=A.+S.+Gardbergauthor=B.+K.+Yipauthor=B.+Wangauthor=Y.+Shenauthor=P.+A.+Fitzpatrick&title=Structural+basis+for+the+inhibition+of+poly%28ADP-ribose%29+polymerases+1+and+2+by+BMN+673%2C+a+potent+inhibitor+derived+from+tetrahydropyridophthalazinone&doi=10.1107%2FS2053230X14015088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone</span></div><div class="casAuthors">Aoyagi-Scharber, Mika; Gardberg, Anna S.; Yip, Bryan K.; Wang, Bing; Shen, Yuqiao; Fitzpatrick, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1143-1149</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2), which are involved in DNA damage response, are targets of anticancer therapeutics.  BMN 673 is a novel PARP1/2 inhibitor with substantially increased PARP-mediated tumor cytotoxicity and is now in later-stage clin. development for BRCA-deficient breast cancers.  Here, in co-crystal structures, BMN 673 was anchored to the nicotinamide-binding pocket via an extensive network of H-bonding and π-stacking interactions, including those mediated by active site water mols.  The novel di-branched scaffold of BMN 673 extended the binding interactions toward the outer edges of the pocket, which exhibited the least sequence homol. among PARP enzymes.  The crystallog. structural analyses reported here therefore not only provide crit. insights into the mol. basis for the exceptionally high potency of the clin. development candidate BMN 673, but also new opportunities for increasing inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3neiOqbsUprVg90H21EOLACvtfcHk0lg_cgpjA4MSOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I&md5=6d75628ad833fa618eac02e72f326666</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS2053230X14015088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X14015088%26sid%3Dliteratum%253Aachs%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DGardberg%26aufirst%3DA.%2BS.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFitzpatrick%26aufirst%3DP.%2BA.%26atitle%3DStructural%2520basis%2520for%2520the%2520inhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerases%25201%2520and%25202%2520by%2520BMN%2520673%252C%2520a%2520potent%2520inhibitor%2520derived%2520from%2520tetrahydropyridophthalazinone%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2014%26volume%3D70%26spage%3D1143%26epage%3D1149%26doi%3D10.1107%2FS2053230X14015088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">de Bono, J.; Mina, L. A.; Gonzalez, M.; Curtin, N. J.; Wang, E.; Henshaw, J. W.; Chadha, M.; Sachdev, J. C.; Matei, D.; Jameson, G. S.; Ong, M.; Basu, B.; Wainberg, Z. A.; Byers, L.; Chugh, R.</span><span> </span><span class="NLM_article-title">First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 31–June 4</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract 2580.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=ASCO&author=J.+de+Bono&author=L.+A.+Mina&author=M.+Gonzalez&author=N.+J.+Curtin&author=E.+Wang&author=J.+W.+Henshaw&author=M.+Chadha&author=J.+C.+Sachdev&author=D.+Matei&author=G.+S.+Jameson&author=M.+Ong&author=B.+Basu&author=Z.+A.+Wainberg&author=L.+Byers&author=R.+Chugh&title=First-in-human+trial+of+novel+oral+PARP+inhibitor+BMN+673+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBono%26aufirst%3DJ.%26atitle%3DFirst-in-human%2520trial%2520of%2520novel%2520oral%2520PARP%2520inhibitor%2520BMN%2520673%2520in%2520patients%2520with%2520solid%2520tumors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Wainberg, Z. A.; Rafii, S.; Ramanathan, R. K.; Mina, L. A.; Byers, L. A.; Chugh, R.; Goldman, J. W.; Sachdev, J.; Matei, D.; Wheler, J. J.; Henshaw, J. W.; Zhang, C.; Gallant, G. J. A.; de Bono, J. S.</span><span> </span><span class="NLM_article-title">Safety and antitumor activity of the PARP inhibitor BMN 673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA mutation carrier cancer patients</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 30–June 3</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Abstract 7522.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&conference=ASCO&author=Z.+A.+Wainberg&author=S.+Rafii&author=R.+K.+Ramanathan&author=L.+A.+Mina&author=L.+A.+Byers&author=R.+Chugh&author=J.+W.+Goldman&author=J.+Sachdev&author=D.+Matei&author=J.+J.+Wheler&author=J.+W.+Henshaw&author=C.+Zhang&author=G.+J.+A.+Gallant&author=J.+S.+de+Bono&title=Safety+and+antitumor+activity+of+the+PARP+inhibitor+BMN+673+in+a+phase+1+trial+recruiting+metastatic+small-cell+lung+cancer+%28SCLC%29+and+germline+BRCA+mutation+carrier+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520the%2520PARP%2520inhibitor%2520BMN%2520673%2520in%2520a%2520phase%25201%2520trial%2520recruiting%2520metastatic%2520small-cell%2520lung%2520cancer%2520%2528SCLC%2529%2520and%2520germline%2520BRCA%2520mutation%2520carrier%2520cancer%2520patients%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billups, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyalin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurmasheva, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">Synergistic activity of PARP inhibition by talazoparib (BMN 673) with Temozolomide in pediatric cancer models in the pediatric preclinical testing program</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1078-0432.CCR-14-2572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25500058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=819-832&author=M.+A.+Smithauthor=C.+P.+Reynoldsauthor=M.+H.+Kangauthor=E.+A.+Kolbauthor=R.+Gorlickauthor=H.+Carolauthor=R.+B.+Lockauthor=S.+T.+Keirauthor=J.+M.+Marisauthor=C.+A.+Billupsauthor=D.+Lyalinauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghton&title=Synergistic+activity+of+PARP+inhibition+by+talazoparib+%28BMN+673%29+with+Temozolomide+in+pediatric+cancer+models+in+the+pediatric+preclinical+testing+program&doi=10.1158%2F1078-0432.CCR-14-2572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program</span></div><div class="casAuthors">Smith, Malcolm A.; Reynolds, C. Patrick; Kang, Min H.; Kolb, E. Anders; Gorlick, Richard; Carol, Hernan; Lock, Richard B.; Keir, Stephen T.; Maris, John M.; Billups, Catherine A.; Lyalin, Dmitry; Kurmasheva, Raushan T.; Houghton, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">819-832</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Inhibitors of PARP, an enzyme involved in base excision repair, have demonstrated single-agent activity against tumors deficient in homologous repair processes.  Ewing sarcoma cells are also sensitive to PARP inhibitors, although the mechanism is not understood.  Here, we evaluated the stereo-selective PARP inhibitor, talazoparib (BMN 673), combined with temozolomide or topotecan.  Exptl. Design: Talazoparib was tested in vitro in combination with temozolomide (0.3-1,000 μmol/L) or topotecan (0.03-100 nmol/L) and in vivo at a dose of 0.1 mg/kg administered twice daily for 5 days combined with temozolomide (30 mg/kg/daily x 5; combination A) or 0.25 mg/kg administered twice daily for 5 days combined with temozolomide (12 mg/kg/daily x 5; combination B).  Pharmacodynamic studies were undertaken after 1 or 5 days of treatment.  Results: In vitro talazoparib potentiated the toxicity of temozolomide up to 85-fold, with marked potentiation in Ewing sarcoma and leukemia lines (30-50-fold).  There was less potentiation for topotecan.  In vivo, talazoparib potentiated the toxicity of temozolomide, and combination A and combination B represent the MTDs when combined with low-dose or high-dose talazoparib, resp.  Both combinations demonstrated significant synergism against 5 of 10 Ewing sarcoma xenografts.  The combination demonstrated modest activity against most other xenograft models.  Pharmacodynamic studies showed a treatment-induced complete loss of PARP only in tumor models sensitive to either talazoparib alone or talazoparib plus temozolomide.  Conclusions: The high level of activity obsd. for talazoparib plus temozolomide in Ewing sarcoma xenografts makes this an interesting combination to consider for pediatric evaluation.  Clin Cancer Res; 21(4); 819-32. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRSU7OIbk0urVg90H21EOLACvtfcHk0lg_cgpjA4MSOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGgsL4%253D&md5=eb7b7d7224fa3700fd624d6074712a69</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2572%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DLyalin%26aufirst%3DD.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DSynergistic%2520activity%2520of%2520PARP%2520inhibition%2520by%2520talazoparib%2520%2528BMN%2520673%2529%2520with%2520Temozolomide%2520in%2520pediatric%2520cancer%2520models%2520in%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D819%26epage%3D832%26doi%3D10.1158%2F1078-0432.CCR-14-2572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Stewart, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goshorn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benavente, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twarog, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caufield, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahrami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlström, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsurkan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatfield, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiagarajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirinifard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sablauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelat, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, M. A.</span><span> </span><span class="NLM_article-title">Targeting the DNA Repair Pathway in Ewing Sarcoma</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1016/j.celrep.2014.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.celrep.2014.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25437539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVantbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=829-840&author=E.+Stewartauthor=R.+Goshornauthor=C.+Bradleyauthor=L.+M.+Griffithsauthor=C.+Benaventeauthor=N.+R.+Twarogauthor=G.+M.+Millerauthor=W.+Caufieldauthor=B.+B.+Freemanauthor=A.+Bahramiauthor=A.+Pappoauthor=J.+Wuauthor=A.+Lohauthor=%C3%85.+Karlstr%C3%B6mauthor=C.+Calabreseauthor=B.+Gordonauthor=L.+Tsurkanauthor=M.+J.+Hatfieldauthor=P.+M.+Potterauthor=S.+E.+Snyderauthor=S.+Thiagarajanauthor=A.+Shirinifardauthor=A.+Sablauerauthor=A.+A.+Shelatauthor=M.+A.+Dyer&title=Targeting+the+DNA+Repair+Pathway+in+Ewing+Sarcoma&doi=10.1016%2Fj.celrep.2014.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Repair Pathway in Ewing Sarcoma</span></div><div class="casAuthors">Stewart, Elizabeth; Goshorn, Ross; Bradley, Cori; Griffiths, Lyra M.; Benavente, Claudia; Twarog, Nathaniel R.; Miller, Gregory M.; Caufield, William; Freeman, Burgess B. III; Bahrami, Armita; Pappo, Alberto; Wu, Jianrong; Loh, Amos; Karlstrom, Asa; Calabrese, Chris; Gordon, Brittney; Tsurkan, Lyudmila; Hatfield, M. Jason; Potter, Philip M.; Snyder, Scott E.; Thiagarajan, Suresh; Shirinifard, Abbas; Sablauer, Andras; Shelat, Anang A.; Dyer, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">829-840</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ewing sarcoma (EWS) is a tumor of the bone and soft tissue that primarily affects adolescents and young adults.  With current therapies, 70% of patients with localized disease survive, but patients with metastatic or recurrent disease have a poor outcome.  We found that EWS cell lines are defective in DNA break repair and are sensitive to PARP inhibitors (PARPis).  PARPi-induced cytotoxicity in EWS cells was 10- to 1,000-fold higher after administration of the DNA-damaging agents irinotecan or temozolomide.  We developed an orthotopic EWS mouse model and performed pharmacokinetic and pharmacodynamic studies using three different PARPis that are in clin. development for pediatric cancer.  Irinotecan administered on a low-dose, protracted schedule previously optimized for pediatric patients was an effective DNA-damaging agent when combined with PARPis; it was also better tolerated than combinations with temozolomide.  Combining PARPis with irinotecan and temozolomide gave complete and durable responses in more than 80% of the mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXVo1kI7i2vLVg90H21EOLACvtfcHk0lhN6uaEzleVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVantbbN&md5=ed18f79a51857f793b95d25af21270ff</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DE.%26aulast%3DGoshorn%26aufirst%3DR.%26aulast%3DBradley%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DL.%2BM.%26aulast%3DBenavente%26aufirst%3DC.%26aulast%3DTwarog%26aufirst%3DN.%2BR.%26aulast%3DMiller%26aufirst%3DG.%2BM.%26aulast%3DCaufield%26aufirst%3DW.%26aulast%3DFreeman%26aufirst%3DB.%2BB.%26aulast%3DBahrami%26aufirst%3DA.%26aulast%3DPappo%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLoh%26aufirst%3DA.%26aulast%3DKarlstr%25C3%25B6m%26aufirst%3D%25C3%2585.%26aulast%3DCalabrese%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DB.%26aulast%3DTsurkan%26aufirst%3DL.%26aulast%3DHatfield%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DP.%2BM.%26aulast%3DSnyder%26aufirst%3DS.%2BE.%26aulast%3DThiagarajan%26aufirst%3DS.%26aulast%3DShirinifard%26aufirst%3DA.%26aulast%3DSablauer%26aufirst%3DA.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BA.%26atitle%3DTargeting%2520the%2520DNA%2520Repair%2520Pathway%2520in%2520Ewing%2520Sarcoma%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D829%26epage%3D840%26doi%3D10.1016%2Fj.celrep.2014.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Flack, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardinelli, G.</span><span> </span><span class="NLM_article-title">Reporting and evaluating absolute-structure and absolute-configuration determinations</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span><span class="refDoi"> DOI: 10.1107/S0021889800007184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1107%2FS0021889800007184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsl2isbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2000&pages=1143-1148&author=H.+D.+Flackauthor=G.+Bernardinelli&title=Reporting+and+evaluating+absolute-structure+and+absolute-configuration+determinations&doi=10.1107%2FS0021889800007184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Reporting and evaluating absolute-structure and absolute-configuration determinations</span></div><div class="casAuthors">Flack, H. D.; Bernardinelli, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1143-1148</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A discussion, with ∼34 refs.  Detailed practical and numerical information is provided for undertaking and evaluating abs.-structure and abs.-configuration detns.  The interpretation of numerical values of x, the Flack parameter, and its std. uncertainty u are explained in terms of the inversion-distinguishing power.  Also, the conditions to obtain reliable values of x(u) are detailed.  Further explanatory material is provided on the use of right-handed axes, valid intensity data, the application to macromol. structures, the dangers of polar-dispersion errors, Euclidean normalizers of space groups, the detection and reporting of mol. symmetry, enantiopurity and optical activity in soln.  New CIF data names are introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yJBh7Ya8arVg90H21EOLACvtfcHk0lhN6uaEzleVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsl2isbY%253D&md5=b69fce3ec144b7ad60344bcf1c164afe</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0021889800007184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889800007184%26sid%3Dliteratum%253Aachs%26aulast%3DFlack%26aufirst%3DH.%2BD.%26aulast%3DBernardinelli%26aufirst%3DG.%26atitle%3DReporting%2520and%2520evaluating%2520absolute-structure%2520and%2520absolute-configuration%2520determinations%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2000%26volume%3D33%26spage%3D1143%26epage%3D1148%26doi%3D10.1107%2FS0021889800007184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Integration, scaling, space-group assignment and post-refinement</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1107/S0907444909047374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1107%2FS0907444909047374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=20124693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=133-144&author=W.+Kabsch&title=Integration%2C+scaling%2C+space-group+assignment+and+post-refinement&doi=10.1107%2FS0907444909047374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Integration, scaling, space-group assignment and post-refinement</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Important steps in the processing of rotation data are described that are common to most software packages.  These programs differ in the details and in the methods implemented to carry out the tasks.  Here, the working principles underlying the data-redn. package XDS are explained, including the new features of automatic detn. of spot size and reflecting range, recognition and assignment of crystal symmetry and a highly efficient algorithm for the detn. of correction/scaling factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGW7t3Bb1P_rVg90H21EOLACvtfcHk0lhN6uaEzleVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D&md5=eb1db34f3c959b4921771eb9f57b2159</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047374%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DIntegration%252C%2520scaling%252C%2520space-group%2520assignment%2520and%2520post-refinement%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D133%26epage%3D144%26doi%3D10.1107%2FS0907444909047374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Litton, J. K.; Blum, J. L.; Im, Y. H.; Martin, M.; Mina, L.; Roche, H.; Rugo, H. S.; Visco, F.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Eiermann, W.</span><span> </span><span class="NLM_article-title">A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRCA)</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 29–Jun 2</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>Poster TPS1107.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&conference=ASCO&author=J.+K.+Litton&author=J.+L.+Blum&author=Y.+H.+Im&author=M.+Martin&author=L.+Mina&author=H.+Roche&author=H.+S.+Rugo&author=F.+Visco&author=C.+Zhang&author=N.+A.+Lokker&author=D.+L.+Lounsbury&author=W.+Eiermann&title=A+phase+3%2C+open-label%2C+randomized%2C+parallel%2C+2-arm+international+study+of+the+oral+PARP+inhibitor+talazoparib+%28BMN+673%29+in+germline+BRCA+mutation+subjects+with+locally+advanced+and%2For+metastatic+breast+cancer+%28EMBRCA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26atitle%3DA%2520phase%25203%252C%2520open-label%252C%2520randomized%252C%2520parallel%252C%25202-arm%2520international%2520study%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520talazoparib%2520%2528BMN%2520673%2529%2520in%2520germline%2520BRCA%2520mutation%2520subjects%2520with%2520locally%2520advanced%2520and%252For%2520metastatic%2520breast%2520cancer%2520%2528EMBRCA%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Turner, N. C.; Balmaña, J.; Fasching, P. A.; Hurvitz, S. A.; Telli, M. L.; Visco, F.; Wardley, A. M.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Robson, M. E.</span><span> </span><span class="NLM_article-title">A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 29–Jun 2</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>Poster TPS1108.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&conference=ASCO&author=N.+C.+Turner&author=J.+Balma%C3%B1a&author=P.+A.+Fasching&author=S.+A.+Hurvitz&author=M.+L.+Telli&author=F.+Visco&author=A.+M.+Wardley&author=C.+Zhang&author=N.+A.+Lokker&author=D.+L.+Lounsbury&author=M.+E.+Robson&title=A+phase+2+study+%282-stage%2C+2-cohort%29+of+the+oral+PARP+inhibitor+talazoparib+%28BMN+673%29+in+patients+with+germline+BRCA+mutation+and+locally+advanced+and%2For+metastatic+breast+cancer+%28ABRAZO%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DA%2520phase%25202%2520study%2520%25282-stage%252C%25202-cohort%2529%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520talazoparib%2520%2528BMN%2520673%2529%2520in%2520patients%2520with%2520germline%2520BRCA%2520mutation%2520and%2520locally%2520advanced%2520and%252For%2520metastatic%2520breast%2520cancer%2520%2528ABRAZO%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Case, D. A.</span>; <span class="NLM_etal"></span>AMBER 10; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+A.+Case&title=AMBER+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26jtitle%3DAMBER%252010%26pub%3DUniversity%2520of%2520California%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 67 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K. Rajanna, Hemant Bhutani, Atish T. Paul, <span class="NLM_string-name hlFld-ContribAuthor">Raj Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">U.S. FDA Approved Drugs from 2015–June 2020: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2339-2381. <a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DU.S.%252BFDA%252BApproved%252BDrugs%252Bfrom%252B2015%2525E2%252580%252593June%252B2020%25253A%252BA%252BPerspective%26aulast%3DBhutani%26aufirst%3DPriyadeep%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hexiang Wang, Bo Ren, Ye Liu, Beibei Jiang, Yin Guo, Min Wei, Lusong Luo, Xianzhao Kuang, Ming Qiu, Lei Lv, Hong Xu, Ruipeng Qi, Huibin Yan, Dexu Xu, Zhiwei Wang, Chang-Xin Huo, Yutong Zhu, Yuan Zhao, Yiyuan Wu, Zhen Qin, Dan Su, Tristin Tang, Fan Wang, Xuebing Sun, Yingcai Feng, Hao Peng, Xing Wang, Yajuan Gao, Yong Liu, Wenfeng Gong, Fenglong Yu, Xuesong Liu, Lai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Changyou Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15541-15563. <a href="https://doi.org/10.1021/acs.jmedchem.0c01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPamiparib%252B%252528BGB-290%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BPoly%252B%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252BInhibitor%252Bin%252BClinical%252BDevelopment%26aulast%3DWang%26aufirst%3DHexiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01082020%26date%3D02122020%26volume%3D63%26issue%3D24%26spage%3D15541%26epage%3D15563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Yungen Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 122-139. <a href="https://doi.org/10.1021/acs.jmedchem.9b00622" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00622%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BDual%252BPoly%252528ADP-ribose%252529polymerase%252Band%252BPhosphoinositide%252B3-Kinase%252BInhibitors%252Bas%252Ba%252BPromising%252BStrategy%252Bfor%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11042019%26date%3D27122019%26date%3D17122019%26volume%3D63%26issue%3D1%26spage%3D122%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zoufeng Xu, Cai Li, Qiyuan Zhou, Zhiqin Deng, Zixuan Tong, Man-Kit Tse, <span class="NLM_string-name hlFld-ContribAuthor">Guangyu Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (23)
                                     , 16279-16291. <a href="https://doi.org/10.1021/acs.inorgchem.9b02839" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.9b02839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.9b02839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.9b02839%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252BCytotoxicity%25252C%252Band%252BMechanistic%252BInvestigation%252Bof%252BPlatinum%252528IV%252529%252BAnticancer%252BComplexes%252BConjugated%252Bwith%252BPoly%252528ADP-ribose%252529%252BPolymerase%252BInhibitors%26aulast%3DXu%26aufirst%3DZoufeng%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23092019%26date%3D18112019%26volume%3D58%26issue%3D23%26spage%3D16279%26epage%3D16291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Uday Kiran Velagapudi, Marie-France Langelier, Cristina Delgado-Martin, Morgan E. Diolaiti, Sietske Bakker, Alan Ashworth, Bhargav A. Patel, Xuwei Shao, John M. Pascal, <span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (11)
                                     , 5330-5357. <a href="https://doi.org/10.1021/acs.jmedchem.8b01709" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01709</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01709%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase%252BInhibitors%25253A%252BImpact%252Bof%252BAdenosine%252BPocket-Binding%252BMotif%252BAppendage%252Bto%252Bthe%252B3-Oxo-2%25252C3-dihydrobenzofuran-7-carboxamide%252Bon%252BPotency%252Band%252BSelectivity%26aulast%3DVelagapudi%26aufirst%3DUday%2BKiran%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D01112018%26date%3D24052019%26date%3D01052019%26volume%3D62%26issue%3D11%26spage%3D5330%26epage%3D5357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lik Hang Yuen, Srikanta Dana, Yu Liu, Samuel I. Bloom, Ann-Gerd Thorsell, Dario Neri, Anthony J. Donato, Dmitri Kireev, Herwig Schüler, <span class="NLM_string-name hlFld-ContribAuthor">Raphael M. Franzini</span>. </span><span class="cited-content_cbyCitation_article-title">A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (13)
                                     , 5169-5181. <a href="https://doi.org/10.1021/jacs.8b08039" title="DOI URL">https://doi.org/10.1021/jacs.8b08039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b08039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b08039%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DA%252BFocused%252BDNA-Encoded%252BChemical%252BLibrary%252Bfor%252Bthe%252BDiscovery%252Bof%252BInhibitors%252Bof%252BNAD%25252B-Dependent%252BEnzymes%26aulast%3DYuen%26aufirst%3DLik%2BHang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D28072018%26date%3D19032019%26date%3D11032019%26volume%3D141%26issue%3D13%26spage%3D5169%26epage%3D5181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chuanlong Guo, Lijun Wang, Xiuxue Li, Shuaiyu Wang, Xuemin Yu, Kuo Xu, Yue Zhao, Jiao Luo, Xiangqian Li, Bo Jiang, <span class="NLM_string-name hlFld-ContribAuthor">Dayong Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 3051-3067. <a href="https://doi.org/10.1021/acs.jmedchem.8b01946" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01946%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BBromophenol%2525E2%252580%252593Thiosemicarbazone%252BHybrids%252Bas%252BPotent%252BSelective%252BInhibitors%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252B%252528PARP-1%252529%252Bfor%252BUse%252Bin%252BCancer%26aulast%3DGuo%26aufirst%3DChuanlong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13122018%26date%3D19032019%26date%3D07032019%26volume%3D62%26issue%3D6%26spage%3D3051%26epage%3D3067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Ping-Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, and <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>  . </span><span class="cited-content_cbyCitation_article-title">An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9575-9598. <a href="https://doi.org/10.1021/acs.jmedchem.6b00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BPoly%252528ADP-ribose%252529polymerase-1%252B%252528PARP-1%252529%252BInhibitors%25253A%252BOpportunities%252Band%252BChallenges%252Bin%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DYing-Qing%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D13012016%26date%3D27072016%26date%3D10112016%26date%3D14072016%26volume%3D59%26issue%3D21%26spage%3D9575%26epage%3D9598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor T.  Sabe</span>, <span class="hlFld-ContribAuthor ">Thandokuhle  Ntombela</span>, <span class="hlFld-ContribAuthor ">Lindiwe A.  Jhamba</span>, <span class="hlFld-ContribAuthor ">Glenn E.M.  Maguire</span>, <span class="hlFld-ContribAuthor ">Thavendran  Govender</span>, <span class="hlFld-ContribAuthor ">Tricia  Naicker</span>, <span class="hlFld-ContribAuthor ">Hendrik G.  Kruger</span>. </span><span class="cited-content_cbyCitation_article-title">Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113705. <a href="https://doi.org/10.1016/j.ejmech.2021.113705" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113705%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Btrends%252Bin%252Bcomputer%252Baided%252Bdrug%252Bdesign%252Band%252Ba%252Bhighlight%252Bof%252Bdrugs%252Bdiscovered%252Bvia%252Bcomputational%252Btechniques%25253A%252BA%252Breview%26aulast%3DSabe%26aufirst%3DVictor%2BT.%26date%3D2021%26volume%3D224%26spage%3D113705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Shen</span>, <span class="hlFld-ContribAuthor ">Yiran  Ge</span>, <span class="hlFld-ContribAuthor ">Junwei  Wang</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Qihua  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128169. <a href="https://doi.org/10.1016/j.bmcl.2021.128169" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128169%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bmolecules%252Bas%252Bpotent%252BPARP-1%252Binhibitors%26aulast%3DShen%26aufirst%3DHui%26date%3D2021%26volume%3D47%26spage%3D128169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Evthokia A.  Hobbs</span>, <span class="hlFld-ContribAuthor ">Jennifer K.  Litton</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Yap</span>. </span><span class="cited-content_cbyCitation_article-title">Development of the PARP inhibitor talazoparib for the treatment of advanced
              BRCA1
              and
              BRCA2
              mutated breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2021,</strong> <em>18 </em>, 1-13. <a href="https://doi.org/10.1080/14656566.2021.1952181" title="DOI URL">https://doi.org/10.1080/14656566.2021.1952181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2021.1952181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2021.1952181%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DDevelopment%252Bof%252Bthe%252BPARP%252Binhibitor%252Btalazoparib%252Bfor%252Bthe%252Btreatment%252Bof%252Badvanced%252BBRCA1%252Band%252BBRCA2%252Bmutated%252Bbreast%252Bcancer%26aulast%3DHobbs%26aufirst%3DEvthokia%2BA.%26date%3D2021%26date%3D2021%26volume%3D18%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uday Kiran  Velagapudi</span>, <span class="hlFld-ContribAuthor ">Bhargav A.  Patel</span>, <span class="hlFld-ContribAuthor ">Xuwei  Shao</span>, <span class="hlFld-ContribAuthor ">Sanjai Kumar  Pathak</span>, <span class="hlFld-ContribAuthor ">Dana V.  Ferraris</span>, <span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (7)
                                     , 609-623. <a href="https://doi.org/10.1080/13543776.2021.1886275" title="DOI URL">https://doi.org/10.1080/13543776.2021.1886275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1886275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1886275%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRecent%252Bdevelopment%252Bin%252Bthe%252Bdiscovery%252Bof%252BPARP%252Binhibitors%252Bas%252Banticancer%252Bagents%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282016-2020%252529%26aulast%3DVelagapudi%26aufirst%3DUday%2BKiran%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D7%26spage%3D609%26epage%3D623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueqian  Zuo</span>, <span class="hlFld-ContribAuthor ">Haibo  Zhao</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Recognition</span><span> <strong>2021,</strong> <em>34 </em>
                                    (7)
                                     <a href="https://doi.org/10.1002/jmr.2891" title="DOI URL">https://doi.org/10.1002/jmr.2891</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jmr.2891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjmr.2891%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Recognition%26atitle%3DSystematic%252Binhibitor%252Bselectivity%252Bbetween%252BPARP1%252Band%252BPARP2%252Benzymes%25253A%252BMolecular%252Bimplications%252Bfor%252Bovarian%252Bcancer%252Bpersonalized%252Btherapy%26aulast%3DZuo%26aufirst%3DXueqian%26date%3D2021%26date%3D2021%26volume%3D34%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph M.  Gozgit</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Vasbinder</span>, <span class="hlFld-ContribAuthor ">Ryan P.  Abo</span>, <span class="hlFld-ContribAuthor ">Kaiko  Kunii</span>, <span class="hlFld-ContribAuthor ">Kristy G.  Kuplast-Barr</span>, <span class="hlFld-ContribAuthor ">Bin  Gui</span>, <span class="hlFld-ContribAuthor ">Alvin Z.  Lu</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Molina</span>, <span class="hlFld-ContribAuthor ">Elena  Minissale</span>, <span class="hlFld-ContribAuthor ">Kerren K.  Swinger</span>, <span class="hlFld-ContribAuthor ">Tim J.  Wigle</span>, <span class="hlFld-ContribAuthor ">Danielle J.  Blackwell</span>, <span class="hlFld-ContribAuthor ">Christina R.  Majer</span>, <span class="hlFld-ContribAuthor ">Yue  Ren</span>, <span class="hlFld-ContribAuthor ">Mario  Niepel</span>, <span class="hlFld-ContribAuthor ">Zacharenia A.  Varsamis</span>, <span class="hlFld-ContribAuthor ">Sunaina P.  Nayak</span>, <span class="hlFld-ContribAuthor ">Ellen  Bamberg</span>, <span class="hlFld-ContribAuthor ">Jan-Rung  Mo</span>, <span class="hlFld-ContribAuthor ">W. David  Church</span>, <span class="hlFld-ContribAuthor ">Ahmed S.A.  Mady</span>, <span class="hlFld-ContribAuthor ">Jeff  Song</span>, <span class="hlFld-ContribAuthor ">Luke  Utley</span>, <span class="hlFld-ContribAuthor ">Patricia E.  Rao</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Mitchison</span>, <span class="hlFld-ContribAuthor ">Kevin W.  Kuntz</span>, <span class="hlFld-ContribAuthor ">Victoria M.  Richon</span>, <span class="hlFld-ContribAuthor ">Heike  Keilhack</span>. </span><span class="cited-content_cbyCitation_article-title">PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.ccell.2021.06.018" title="DOI URL">https://doi.org/10.1016/j.ccell.2021.06.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2021.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2021.06.018%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DPARP7%252Bnegatively%252Bregulates%252Bthe%252Btype%252BI%252Binterferon%252Bresponse%252Bin%252Bcancer%252Bcells%252Band%252Bits%252Binhibition%252Btriggers%252Bantitumor%252Bimmunity%26aulast%3DGozgit%26aufirst%3DJoseph%2BM.%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vinayak  Palve</span>, <span class="hlFld-ContribAuthor ">Claire E.  Knezevic</span>, <span class="hlFld-ContribAuthor ">Daniel S.  Bejan</span>, <span class="hlFld-ContribAuthor ">Yunting  Luo</span>, <span class="hlFld-ContribAuthor ">Xueli  Li</span>, <span class="hlFld-ContribAuthor ">Silvia  Novakova</span>, <span class="hlFld-ContribAuthor ">Eric A.  Welsh</span>, <span class="hlFld-ContribAuthor ">Bin  Fang</span>, <span class="hlFld-ContribAuthor ">Fumi  Kinose</span>, <span class="hlFld-ContribAuthor ">Eric B.  Haura</span>, <span class="hlFld-ContribAuthor ">Alvaro N.  Monteiro</span>, <span class="hlFld-ContribAuthor ">John M.  Koomen</span>, <span class="hlFld-ContribAuthor ">Michael S.  Cohen</span>, <span class="hlFld-ContribAuthor ">Harshani R.  Lawrence</span>, <span class="hlFld-ContribAuthor ">Uwe  Rix</span>. </span><span class="cited-content_cbyCitation_article-title">The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>5 </em><a href="https://doi.org/10.1016/j.chembiol.2021.07.008" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.07.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.07.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DThe%252Bnon-canonical%252Btarget%252BPARP16%252Bcontributes%252Bto%252Bpolypharmacology%252Bof%252Bthe%252BPARP%252Binhibitor%252Btalazoparib%252Band%252Bits%252Bsynergy%252Bwith%252BWEE1%252Binhibitors%26aulast%3DPalve%26aufirst%3DVinayak%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maninder  Singh</span>, <span class="hlFld-ContribAuthor ">Jyotika  Rajawat</span>, <span class="hlFld-ContribAuthor ">Jitendra  Kuldeep</span>, <span class="hlFld-ContribAuthor ">Nidhi  Shukla</span>, <span class="hlFld-ContribAuthor ">Durga Prasad  Mishra</span>, <span class="hlFld-ContribAuthor ">Mohammad Imran  Siddiqi</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>45 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2021.1913229" title="DOI URL">https://doi.org/10.1080/07391102.2021.1913229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1913229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1913229%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIntegrated%252Bsupport%252Bvector%252Bmachine%252Band%252Bpharmacophore%252Bbased%252Bvirtual%252Bscreening%252Bdriven%252Bidentification%252Bof%252Bthiophene%252Bcarboxamide%252Bscaffold%252Bcontaining%252Bcompound%252Bas%252Bpotential%252BPARP1%252Binhibitor%26aulast%3DSingh%26aufirst%3DManinder%26date%3D2021%26date%3D2021%26volume%3D45%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Zhou</span>, <span class="hlFld-ContribAuthor ">Huaping  Chen</span>, <span class="hlFld-ContribAuthor ">Cedric  Mpoy</span>, <span class="hlFld-ContribAuthor ">Sadia  Afrin</span>, <span class="hlFld-ContribAuthor ">Buck E.  Rogers</span>, <span class="hlFld-ContribAuthor ">Joel R.  Garbow</span>, <span class="hlFld-ContribAuthor ">John A.  Katzenellenbogen</span>, <span class="hlFld-ContribAuthor ">Jinbin  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2021,</strong> <em>9 </em>
                                    (5)
                                     , 565. <a href="https://doi.org/10.3390/biomedicines9050565" title="DOI URL">https://doi.org/10.3390/biomedicines9050565</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines9050565&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines9050565%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DRadiosynthesis%252Band%252BEvaluation%252Bof%252BTalazoparib%252Band%252BIts%252BDerivatives%252Bas%252BPARP-1-Targeting%252BAgents%26aulast%3DZhou%26aufirst%3DDong%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D5%26spage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonardo L.G.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Adriano D.  Andricopulo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-54. <a href="https://doi.org/10.1002/0471266949.bmc141.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc141.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc141.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc141.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%2525E2%252580%252590Based%252BDrug%252BDesign%26aulast%3DFerreira%26aufirst%3DLeonardo%2BL.G.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D54%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asha  Sinha</span>, <span class="hlFld-ContribAuthor ">Sachin  Katyal</span>, <span class="hlFld-ContribAuthor ">Tiina M.  Kauppinen</span>. </span><span class="cited-content_cbyCitation_article-title">PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2021,</strong> <em>187 </em>, 108502. <a href="https://doi.org/10.1016/j.neuropharm.2021.108502" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2021.108502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2021.108502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2021.108502%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DPARP-DNA%252Btrapping%252Bability%252Bof%252BPARP%252Binhibitors%252Bjeopardizes%252Bastrocyte%252Bviability%25253A%252BImplications%252Bfor%252BCNS%252Bdisease%252Btherapeutics%26aulast%3DSinha%26aufirst%3DAsha%26date%3D2021%26volume%3D187%26spage%3D108502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junwei  Wang</span>, <span class="hlFld-ContribAuthor ">Guangchao  He</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Yiran  Ge</span>, <span class="hlFld-ContribAuthor ">Shuping  Wang</span>, <span class="hlFld-ContribAuthor ">Yungen  Xu</span>, <span class="hlFld-ContribAuthor ">Qihua  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113054. <a href="https://doi.org/10.1016/j.ejmech.2020.113054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BPARP%25252FPI3K%252Bdual%252Binhibitors%252Bwith%252Bhigh%252Befficiency%252Bagainst%252BBRCA-proficient%252Btriple%252Bnegative%252Bbreast%252Bcancer%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2021%26volume%3D213%26spage%3D113054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaun D.  Fontaine</span>, <span class="hlFld-ContribAuthor ">Gary W.  Ashley</span>, <span class="hlFld-ContribAuthor ">Peter J.  Houghton</span>, <span class="hlFld-ContribAuthor ">Raushan T.  Kurmasheva</span>, <span class="hlFld-ContribAuthor ">Morgan  Diolaiti</span>, <span class="hlFld-ContribAuthor ">Alan  Ashworth</span>, <span class="hlFld-ContribAuthor ">Cody J.  Peer</span>, <span class="hlFld-ContribAuthor ">Ryan  Nguyen</span>, <span class="hlFld-ContribAuthor ">William D.  Figg</span>, <span class="hlFld-ContribAuthor ">Denis R.  Beckford-Vera</span>, <span class="hlFld-ContribAuthor ">Daniel V.  Santi</span>. </span><span class="cited-content_cbyCitation_article-title">A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2021,</strong> <em>81 </em>
                                    (4)
                                     , 1076-1086. <a href="https://doi.org/10.1158/0008-5472.CAN-20-1741" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-20-1741</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-20-1741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-20-1741%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DA%252BVery%252BLong-Acting%252BPARP%252BInhibitor%252BSuppresses%252BCancer%252BCell%252BGrowth%252Bin%252BDNA%252BRepair-Deficient%252BTumor%252BModels%26aulast%3DFontaine%26aufirst%3DShaun%2BD.%26date%3D2021%26date%3D2020%26volume%3D81%26issue%3D4%26spage%3D1076%26epage%3D1086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Basavarajaiah Suliphuldevara  Matada</span>, <span class="hlFld-ContribAuthor ">Raviraj  Pattanashettar</span>, <span class="hlFld-ContribAuthor ">Nagesh Gunavanthrao  Yernale</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review on the biological interest of quinoline and its derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>32 </em>, 115973. <a href="https://doi.org/10.1016/j.bmc.2020.115973" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115973</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115973%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Breview%252Bon%252Bthe%252Bbiological%252Binterest%252Bof%252Bquinoline%252Band%252Bits%252Bderivatives%26aulast%3DMatada%26aufirst%3DBasavarajaiah%2BSuliphuldevara%26date%3D2021%26volume%3D32%26spage%3D115973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Young Min  Kim</span>, <span class="hlFld-ContribAuthor ">Hyung‐Seok  Yoo</span>, <span class="hlFld-ContribAuthor ">Seung Hwan  Son</span>, <span class="hlFld-ContribAuthor ">Ga Yeong  Kim</span>, <span class="hlFld-ContribAuthor ">Hyu Jeong  Jang</span>, <span class="hlFld-ContribAuthor ">Dong Hwan  Kim</span>, <span class="hlFld-ContribAuthor ">Soo Dong  Kim</span>, <span class="hlFld-ContribAuthor ">Boyoung Y.  Park</span>, <span class="hlFld-ContribAuthor ">Nam‐Jung  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel Approach to
              N
              ‐Tf 2‐Aryl‐2,3‐Dihydroquinolin‐ 4(1
              H
              )‐ones via a Ligand‐Free Pd(II)‐Catalyzed Oxidative Aza‐Michael Cyclization. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (4)
                                     , 618-622. <a href="https://doi.org/10.1002/ejoc.202001425" title="DOI URL">https://doi.org/10.1002/ejoc.202001425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001425%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BNovel%252BApproach%252Bto%252BN%252B%2525E2%252580%252590Tf%252B2%2525E2%252580%252590Aryl%2525E2%252580%2525902%25252C3%2525E2%252580%252590Dihydroquinolin%2525E2%252580%252590%252B4%2525281%252BH%252B%252529%2525E2%252580%252590ones%252Bvia%252Ba%252BLigand%2525E2%252580%252590Free%252BPd%252528II%252529%2525E2%252580%252590Catalyzed%252BOxidative%252BAza%2525E2%252580%252590Michael%252BCyclization%26aulast%3DKim%26aufirst%3DYoung%2BMin%26date%3D2021%26date%3D2020%26volume%3D2021%26issue%3D4%26spage%3D618%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claire  Fritz</span>, <span class="hlFld-ContribAuthor ">Scott M.  Portwood</span>, <span class="hlFld-ContribAuthor ">Amanda  Przespolewski</span>, <span class="hlFld-ContribAuthor ">Eunice S.  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. </span><span class="cited-content_cbyCitation_journal-name">Blood Reviews</span><span> <strong>2021,</strong> <em>45 </em>, 100696. <a href="https://doi.org/10.1016/j.blre.2020.100696" title="DOI URL">https://doi.org/10.1016/j.blre.2020.100696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.blre.2020.100696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.blre.2020.100696%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Reviews%26atitle%3DPARP%252Bgoes%252Bthe%252Bweasel%252521%252BEmerging%252Brole%252Bof%252BPARP%252Binhibitors%252Bin%252Bacute%252Bleukemias%26aulast%3DFritz%26aufirst%3DClaire%26date%3D2021%26volume%3D45%26spage%3D100696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Navnath P.  Karche</span>, <span class="hlFld-ContribAuthor ">Mandar  Bhonde</span>, <span class="hlFld-ContribAuthor ">Neelima  Sinha</span>, <span class="hlFld-ContribAuthor ">Gourhari  Jana</span>, <span class="hlFld-ContribAuthor ">Gagan  Kukreja</span>, <span class="hlFld-ContribAuthor ">Sanjay P.  Kurhade</span>, <span class="hlFld-ContribAuthor ">Arun R.  Jagdale</span>, <span class="hlFld-ContribAuthor ">Ajay R.  Tilekar</span>, <span class="hlFld-ContribAuthor ">Anil K.  Hajare</span>, <span class="hlFld-ContribAuthor ">Ganesh R.  Jadhav</span>, <span class="hlFld-ContribAuthor ">Nishant R.  Gupta</span>, <span class="hlFld-ContribAuthor ">Rohan  Limaye</span>, <span class="hlFld-ContribAuthor ">Nilesh  Khedkar</span>, <span class="hlFld-ContribAuthor ">Baban R.  Thube</span>, <span class="hlFld-ContribAuthor ">Javed S.  Shaikh</span>, <span class="hlFld-ContribAuthor ">Nageswara  Rao Irlapati</span>, <span class="hlFld-ContribAuthor ">Samiron  Phukan</span>, <span class="hlFld-ContribAuthor ">Gopal  Gole</span>, <span class="hlFld-ContribAuthor ">Apparao  Bommakanti</span>, <span class="hlFld-ContribAuthor ">Harshal  Khanwalkar</span>, <span class="hlFld-ContribAuthor ">Yogesh  Pawar</span>, <span class="hlFld-ContribAuthor ">Ramesh  Kale</span>, <span class="hlFld-ContribAuthor ">Rakesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Rajesh  Gupta</span>, <span class="hlFld-ContribAuthor ">V.R.  Praveen Kumar</span>, <span class="hlFld-ContribAuthor ">Saif  Wahid</span>, <span class="hlFld-ContribAuthor ">Albi  Francis</span>, <span class="hlFld-ContribAuthor ">Tariq  Bhat</span>, <span class="hlFld-ContribAuthor ">Nivrutti  Kamble</span>, <span class="hlFld-ContribAuthor ">Vinod  Patil</span>, <span class="hlFld-ContribAuthor ">Prashant B.  Nigade</span>, <span class="hlFld-ContribAuthor ">Dipak  Modi</span>, <span class="hlFld-ContribAuthor ">Shashikant  Pawar</span>, <span class="hlFld-ContribAuthor ">Sneha  Naidu</span>, <span class="hlFld-ContribAuthor ">Harish  Volam</span>, <span class="hlFld-ContribAuthor ">Vamsi  Pagdala</span>, <span class="hlFld-ContribAuthor ">Sadanand  Mallurwar</span>, <span class="hlFld-ContribAuthor ">Hemant  Goyal</span>, <span class="hlFld-ContribAuthor ">Pushpak  Bora</span>, <span class="hlFld-ContribAuthor ">Prajakta  Ahirrao</span>, <span class="hlFld-ContribAuthor ">Minakshi  Singh</span>, <span class="hlFld-ContribAuthor ">Prabhakaran  Kamalakannan</span>, <span class="hlFld-ContribAuthor ">Kumar Ram  Naik</span>, <span class="hlFld-ContribAuthor ">Pradipta  Kumar</span>, <span class="hlFld-ContribAuthor ">Rajendra G.  Powar</span>, <span class="hlFld-ContribAuthor ">Rajesh B.  Shankar</span>, <span class="hlFld-ContribAuthor ">Peter R.  Bernstein</span>, <span class="hlFld-ContribAuthor ">Jayasagar  Gundu</span>, <span class="hlFld-ContribAuthor ">Kumar  Nemmani</span>, <span class="hlFld-ContribAuthor ">Lakshmi  Narasimham</span>, <span class="hlFld-ContribAuthor ">Kochumalayil Shaji  George</span>, <span class="hlFld-ContribAuthor ">Sharad  Sharma</span>, <span class="hlFld-ContribAuthor ">Dhananjay  Bakhle</span>, <span class="hlFld-ContribAuthor ">Rajender Kumar  Kamboj</span>, <span class="hlFld-ContribAuthor ">Venkata P.  Palle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (24)
                                     , 115819. <a href="https://doi.org/10.1016/j.bmc.2020.115819" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115819</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115819%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bisoquinolinone%252Band%252Bnaphthyridinone-based%252Binhibitors%252Bof%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252B%252528PARP1%252529%252Bas%252Banticancer%252Bagents%25253A%252BStructure%252Bactivity%252Brelationship%252Band%252Bpreclinical%252Bcharacterization%26aulast%3DKarche%26aufirst%3DNavnath%2BP.%26date%3D2020%26volume%3D28%26issue%3D24%26spage%3D115819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiu-Juan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Xu</span>, <span class="hlFld-ContribAuthor ">Hong-Xia  Mou</span>, <span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Shu-Yi  Hao</span>, <span class="hlFld-ContribAuthor ">Shi-Wu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis and anti‐tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127556. <a href="https://doi.org/10.1016/j.bmcl.2020.127556" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127556</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127556%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bsynthesis%252Band%252Banti%2525E2%252580%252590tumour%252Bproperties%252Bof%252Bnovel%252B4-substituted%252Bphthalazinones%252Bas%252BAurora%252BB%252Bkinase%252Binhibitors%26aulast%3DZhang%26aufirst%3DXiu-Juan%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miguel Angel  Galván Morales</span>, <span class="hlFld-ContribAuthor ">Raúl  Barrera Rodríguez</span>, <span class="hlFld-ContribAuthor ">Julio Raúl  Santiago Cruz</span>, <span class="hlFld-ContribAuthor ">Luis M.  Teran</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (23)
                                     , 5686. <a href="https://doi.org/10.3390/molecules25235686" title="DOI URL">https://doi.org/10.3390/molecules25235686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25235686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25235686%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOverview%252Bof%252BNew%252BTreatments%252Bwith%252BImmunotherapy%252Bfor%252BBreast%252BCancer%252Band%252Ba%252BProposal%252Bof%252Ba%252BCombination%252BTherapy%26aulast%3DGalv%25C3%25A1n%2BMorales%26aufirst%3DMiguel%2BAngel%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D23%26spage%3D5686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ye  Han</span>, <span class="hlFld-ContribAuthor ">Xiaopeng  Yu</span>, <span class="hlFld-ContribAuthor ">Shuqiang  Li</span>, <span class="hlFld-ContribAuthor ">Ye  Tian</span>, <span class="hlFld-ContribAuthor ">Caigang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.578095" title="DOI URL">https://doi.org/10.3389/fonc.2020.578095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.578095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.578095%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DNew%252BPerspectives%252Bfor%252BResistance%252Bto%252BPARP%252BInhibitors%252Bin%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DHan%26aufirst%3DYe%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jyoti  Singh</span>, <span class="hlFld-ContribAuthor ">Amruta  Suryan</span>, <span class="hlFld-ContribAuthor ">Sandeep  Kumar</span>, <span class="hlFld-ContribAuthor ">Shweta  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Phthalazinone Scaffold: Emerging Tool in the Development of Target Based Novel Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (18)
                                     , 2228-2245. <a href="https://doi.org/10.2174/1871520620666200807220146" title="DOI URL">https://doi.org/10.2174/1871520620666200807220146</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520620666200807220146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520620666200807220146%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DPhthalazinone%252BScaffold%25253A%252BEmerging%252BTool%252Bin%252Bthe%252BDevelopment%252Bof%252BTarget%252BBased%252BNovel%252BAnticancer%252BAgents%26aulast%3DSingh%26aufirst%3DJyoti%26date%3D2020%26volume%3D20%26issue%3D18%26spage%3D2228%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.K.  Litton</span>, <span class="hlFld-ContribAuthor ">S.A.  Hurvitz</span>, <span class="hlFld-ContribAuthor ">L.A.  Mina</span>, <span class="hlFld-ContribAuthor ">H.S.  Rugo</span>, <span class="hlFld-ContribAuthor ">K.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">A.  Gonçalves</span>, <span class="hlFld-ContribAuthor ">S.  Diab</span>, <span class="hlFld-ContribAuthor ">N.  Woodward</span>, <span class="hlFld-ContribAuthor ">A.  Goodwin</span>, <span class="hlFld-ContribAuthor ">R.  Yerushalmi</span>, <span class="hlFld-ContribAuthor ">H.  Roché</span>, <span class="hlFld-ContribAuthor ">Y.-H.  Im</span>, <span class="hlFld-ContribAuthor ">W.  Eiermann</span>, <span class="hlFld-ContribAuthor ">R.G.W.  Quek</span>, <span class="hlFld-ContribAuthor ">T.  Usari</span>, <span class="hlFld-ContribAuthor ">S.  Lanzalone</span>, <span class="hlFld-ContribAuthor ">A.  Czibere</span>, <span class="hlFld-ContribAuthor ">J.L.  Blum</span>, <span class="hlFld-ContribAuthor ">M.  Martin</span>, <span class="hlFld-ContribAuthor ">J.  Ettl</span>. </span><span class="cited-content_cbyCitation_article-title">Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2020,</strong> <em>31 </em>
                                    (11)
                                     , 1526-1535. <a href="https://doi.org/10.1016/j.annonc.2020.08.2098" title="DOI URL">https://doi.org/10.1016/j.annonc.2020.08.2098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.annonc.2020.08.2098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.annonc.2020.08.2098%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DTalazoparib%252Bversus%252Bchemotherapy%252Bin%252Bpatients%252Bwith%252Bgermline%252BBRCA1%25252F2-mutated%252BHER2-negative%252Badvanced%252Bbreast%252Bcancer%25253A%252Bfinal%252Boverall%252Bsurvival%252Bresults%252Bfrom%252Bthe%252BEMBRACA%252Btrial%26aulast%3DLitton%26aufirst%3DJ.K.%26date%3D2020%26volume%3D31%26issue%3D11%26spage%3D1526%26epage%3D1535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Zhao</span>, <span class="hlFld-ContribAuthor ">Liu-Xia  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Jiang</span>, <span class="hlFld-ContribAuthor ">Jing  Long</span>, <span class="hlFld-ContribAuthor ">Zhong-Ye  Ma</span>, <span class="hlFld-ContribAuthor ">Ai-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Yan  Cheng</span>, <span class="hlFld-ContribAuthor ">Dong-Sheng  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112570. <a href="https://doi.org/10.1016/j.ejmech.2020.112570" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112570%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bups%252Band%252Bdowns%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252Binhibitors%252Bin%252Bcancer%252Btherapy%2525E2%252580%252593Current%252Bprogress%252Band%252Bfuture%252Bdirection%26aulast%3DZhao%26aufirst%3DYue%26date%3D2020%26volume%3D203%26spage%3D112570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaviarasan  Lakshmanan</span>, <span class="hlFld-ContribAuthor ">Gowramma  Byran</span>, <span class="hlFld-ContribAuthor ">Manal  Mohammed</span>. </span><span class="cited-content_cbyCitation_article-title">A Brief Review on Dual Target of PARP1 and STAT3 for Cancer Therapy: A Novel Perception. </span><span class="cited-content_cbyCitation_journal-name">Current Enzyme Inhibition</span><span> <strong>2020,</strong> <em>16 </em>
                                    (2)
                                     , 115-134. <a href="https://doi.org/10.2174/1573408016666200316114209" title="DOI URL">https://doi.org/10.2174/1573408016666200316114209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573408016666200316114209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573408016666200316114209%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Enzyme%2520Inhibition%26atitle%3DA%252BBrief%252BReview%252Bon%252BDual%252BTarget%252Bof%252BPARP1%252Band%252BSTAT3%252Bfor%252BCancer%252BTherapy%25253A%252BA%252BNovel%252BPerception%26aulast%3DLakshmanan%26aufirst%3DKaviarasan%26date%3D2020%26volume%3D16%26issue%3D2%26spage%3D115%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  King</span>, <span class="hlFld-ContribAuthor ">Xiao Dun  Li</span>, <span class="hlFld-ContribAuthor ">Gilberto S.  Almeida</span>, <span class="hlFld-ContribAuthor ">Colin  Kwok</span>, <span class="hlFld-ContribAuthor ">Polly  Gravells</span>, <span class="hlFld-ContribAuthor ">Daniel  Harrison</span>, <span class="hlFld-ContribAuthor ">Saoirse  Burke</span>, <span class="hlFld-ContribAuthor ">Albert  Hallsworth</span>, <span class="hlFld-ContribAuthor ">Yann  Jamin</span>, <span class="hlFld-ContribAuthor ">Sally  George</span>, <span class="hlFld-ContribAuthor ">Simon P.  Robinson</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Lord</span>, <span class="hlFld-ContribAuthor ">Evon  Poon</span>, <span class="hlFld-ContribAuthor ">Daniel  Yeomanson</span>, <span class="hlFld-ContribAuthor ">Louis  Chesler</span>, <span class="hlFld-ContribAuthor ">Helen E.  Bryant</span>. </span><span class="cited-content_cbyCitation_article-title">MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2020,</strong> <em>11 </em>
                                    (23)
                                     , 2141-2159. <a href="https://doi.org/10.18632/oncotarget.27329" title="DOI URL">https://doi.org/10.18632/oncotarget.27329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27329%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DMYCN%252Bexpression%252Binduces%252Breplication%252Bstress%252Band%252Bsensitivity%252Bto%252BPARP%252Binhibition%252Bin%252Bneuroblastoma%26aulast%3DKing%26aufirst%3DDavid%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D23%26spage%3D2141%26epage%3D2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. Shaheer  Malik</span>, <span class="hlFld-ContribAuthor ">Saleh A.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Ismail I.  Althagafi</span>, <span class="hlFld-ContribAuthor ">Mohammed Azam  Ansari</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 327-348. <a href="https://doi.org/10.1039/C9MD00458K" title="DOI URL">https://doi.org/10.1039/C9MD00458K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00458K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00458K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252Btriazoles%252Bas%252Bbioisosteres%252Band%252Blinkers%252Bin%252Bthe%252Bdevelopment%252Bof%252Bmicrotubule%252Btargeting%252Bagents%26aulast%3DMalik%26aufirst%3DM.%2BShaheer%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D3%26spage%3D327%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaofang  Wu</span>, <span class="hlFld-ContribAuthor ">Feng  Gao</span>, <span class="hlFld-ContribAuthor ">Siyuan  Zheng</span>, <span class="hlFld-ContribAuthor ">Chen  Zhang</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Martinez-Ledesma</span>, <span class="hlFld-ContribAuthor ">Ravesanker  Ezhilarasan</span>, <span class="hlFld-ContribAuthor ">Jie  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaolong  Li</span>, <span class="hlFld-ContribAuthor ">Ningping  Feng</span>, <span class="hlFld-ContribAuthor ">Asha  Multani</span>, <span class="hlFld-ContribAuthor ">Erik P.  Sulman</span>, <span class="hlFld-ContribAuthor ">Roel G.  Verhaak</span>, <span class="hlFld-ContribAuthor ">John F.  de Groot</span>, <span class="hlFld-ContribAuthor ">Tim P.  Heffernan</span>, <span class="hlFld-ContribAuthor ">W.K. Alfred  Yung</span>, <span class="hlFld-ContribAuthor ">Dimpy  Koul</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR
              Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2020,</strong> <em>26 </em>
                                    (6)
                                     , 1395-1407. <a href="https://doi.org/10.1158/1078-0432.CCR-19-2549" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-19-2549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-19-2549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-19-2549%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DEGFR%252BAmplification%252BInduces%252BIncreased%252BDNA%252BDamage%252BResponse%252Band%252BRenders%252BSelective%252BSensitivity%252Bto%252BTalazoparib%252B%252528PARP%252BInhibitor%252529%252Bin%252BGlioblastoma%26aulast%3DWu%26aufirst%3DShaofang%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D1395%26epage%3D1407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David S.  Lakomy</span>, <span class="hlFld-ContribAuthor ">Diana L.  Urbauer</span>, <span class="hlFld-ContribAuthor ">Shannon N.  Westin</span>, <span class="hlFld-ContribAuthor ">Lilie L.  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Radiation Oncology</span><span> <strong>2020,</strong> <em>21 </em>, 56-61. <a href="https://doi.org/10.1016/j.ctro.2019.12.005" title="DOI URL">https://doi.org/10.1016/j.ctro.2019.12.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctro.2019.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctro.2019.12.005%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Radiation%2520Oncology%26atitle%3DPhase%252BI%252Bstudy%252Bof%252Bthe%252BPARP%252Binhibitor%252Btalazoparib%252Bwith%252Bradiation%252Btherapy%252Bfor%252Blocally%252Brecurrent%252Bgynecologic%252Bcancers%26aulast%3DLakomy%26aufirst%3DDavid%2BS.%26date%3D2020%26volume%3D21%26spage%3D56%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dea  Slade</span>. </span><span class="cited-content_cbyCitation_article-title">PARP and PARG inhibitors in cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Genes & Development</span><span> <strong>2020,</strong> <em>34 </em>
                                    (5-6)
                                     , 360-394. <a href="https://doi.org/10.1101/gad.334516.119" title="DOI URL">https://doi.org/10.1101/gad.334516.119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/gad.334516.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fgad.334516.119%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%2520%2526%2520Development%26atitle%3DPARP%252Band%252BPARG%252Binhibitors%252Bin%252Bcancer%252Btreatment%26aulast%3DSlade%26aufirst%3DDea%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D5-6%26spage%3D360%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuliya V.  Sherstyuk</span>, <span class="hlFld-ContribAuthor ">Nikita V.  Ivanisenko</span>, <span class="hlFld-ContribAuthor ">Alexandra L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">Maria V.  Sukhanova</span>, <span class="hlFld-ContribAuthor ">Roman Y.  Peshkov</span>, <span class="hlFld-ContribAuthor ">Ilia V.  Eltsov</span>, <span class="hlFld-ContribAuthor ">Mikhail M.  Kutuzov</span>, <span class="hlFld-ContribAuthor ">Tatiana A.  Kurgina</span>, <span class="hlFld-ContribAuthor ">Ekaterina A.  Belousova</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Ivanisenko</span>, <span class="hlFld-ContribAuthor ">Olga I.  Lavrik</span>, <span class="hlFld-ContribAuthor ">Vladimir N.  Silnikov</span>, <span class="hlFld-ContribAuthor ">Tatyana V.  Abramova</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (1)
                                     , 214. <a href="https://doi.org/10.3390/ijms21010214" title="DOI URL">https://doi.org/10.3390/ijms21010214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21010214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21010214%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BMolecular%252BModeling%252BStudy%252Bof%252BConjugates%252Bof%252BADP%252Band%252BMorpholino%252BNucleosides%252Bas%252BA%252BNovel%252BClass%252Bof%252BInhibitors%252Bof%252BPARP-1%25252C%252BPARP-2%252Band%252BPARP-3%26aulast%3DSherstyuk%26aufirst%3DYuliya%2BV.%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaguo  Li</span>, <span class="hlFld-ContribAuthor ">Dian  Xiao</span>, <span class="hlFld-ContribAuthor ">Lianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Fei  Xie</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Yang</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 407. <a href="https://doi.org/10.3390/molecules25020407" title="DOI URL">https://doi.org/10.3390/molecules25020407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25020407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25020407%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BIn%252BVitro%252BEvaluation%252Bof%252Bthe%252BPhotoactivatable%252BProdrug%252Bof%252Bthe%252BPARP%252BInhibitor%252BTalazoparib%26aulast%3DLi%26aufirst%3DJiaguo%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Mercedes  Medio‐Simon</span>, <span class="hlFld-ContribAuthor ">Daniel M.  Sedgwick</span>, <span class="hlFld-ContribAuthor ">Claudio  Santi</span>, <span class="hlFld-ContribAuthor ">Renzo  Ruzziconi</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine‐Containing Drugs Approved by the FDA in 2018. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (51)
                                     , 11797-11819. <a href="https://doi.org/10.1002/chem.201901840" title="DOI URL">https://doi.org/10.1002/chem.201901840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201901840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201901840%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DFluorine%2525E2%252580%252590Containing%252BDrugs%252BApproved%252Bby%252Bthe%252BFDA%252Bin%252B2018%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D51%26spage%3D11797%26epage%3D11819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hua-Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Chuan-Huizi  Chen</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Ne  Guo</span>, <span class="hlFld-ContribAuthor ">Yu-Nan  Tian</span>, <span class="hlFld-ContribAuthor ">Xia-Juan  Huan</span>, <span class="hlFld-ContribAuthor ">Shan-Shan  Song</span>, <span class="hlFld-ContribAuthor ">Jin-Xue  He</span>, <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2019,</strong> <em>145 </em>
                                    (3)
                                     , 714-727. <a href="https://doi.org/10.1002/ijc.32131" title="DOI URL">https://doi.org/10.1002/ijc.32131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.32131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.32131%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DIncreased%252BPARP1-DNA%252Bbinding%252Bdue%252Bto%252BautoPARylation%252Binhibition%252Bof%252BPARP1%252Bon%252BDNA%252Brather%252Bthan%252BPARP1-DNA%252Btrapping%252Bis%252Bcorrelated%252Bwith%252BPARP1%252Binhibitor%252527s%252Bcytotoxicity%26aulast%3DChen%26aufirst%3DHua-Dong%26date%3D2019%26date%3D2019%26volume%3D145%26issue%3D3%26spage%3D714%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monika  Toma</span>, <span class="hlFld-ContribAuthor ">Tomasz  Skorski</span>, <span class="hlFld-ContribAuthor ">Tomasz  Sliwinski</span>. </span><span class="cited-content_cbyCitation_article-title">DNA Double Strand Break Repair - Related Synthetic Lethality. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2019,</strong> <em>26 </em>
                                    (8)
                                     , 1446-1482. <a href="https://doi.org/10.2174/0929867325666180201114306" title="DOI URL">https://doi.org/10.2174/0929867325666180201114306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180201114306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180201114306%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DDNA%252BDouble%252BStrand%252BBreak%252BRepair%252B-%252BRelated%252BSynthetic%252BLethality%26aulast%3DToma%26aufirst%3DMonika%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D1446%26epage%3D1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paige  Baldwin</span>, <span class="hlFld-ContribAuthor ">Anders W.  Ohman</span>, <span class="hlFld-ContribAuthor ">Jamie E.  Medina</span>, <span class="hlFld-ContribAuthor ">Eric T.  McCarthy</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Dinulescu</span>, <span class="hlFld-ContribAuthor ">Srinivas  Sridhar</span>. </span><span class="cited-content_cbyCitation_article-title">Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.00353" title="DOI URL">https://doi.org/10.3389/fonc.2019.00353</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.00353%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DNanoformulation%252Bof%252BTalazoparib%252BDelays%252BTumor%252BProgression%252Band%252BAscites%252BFormation%252Bin%252Ba%252BLate%252BStage%252BCancer%252BModel%26aulast%3DBaldwin%26aufirst%3DPaige%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lawrence B.  Mensah</span>, <span class="hlFld-ContribAuthor ">Stephen W.  Morton</span>, <span class="hlFld-ContribAuthor ">Jiahe  Li</span>, <span class="hlFld-ContribAuthor ">Haihua  Xiao</span>, <span class="hlFld-ContribAuthor ">Mohiuddin A.  Quadir</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Elias</span>, <span class="hlFld-ContribAuthor ">Emily  Penn</span>, <span class="hlFld-ContribAuthor ">Aysen K.  Richson</span>, <span class="hlFld-ContribAuthor ">Paiman Peter  Ghoroghchian</span>, <span class="hlFld-ContribAuthor ">Joyce  Liu</span>, <span class="hlFld-ContribAuthor ">Paula T.  Hammond</span>. </span><span class="cited-content_cbyCitation_article-title">Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioengineering & Translational Medicine</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     <a href="https://doi.org/10.1002/btm2.10131" title="DOI URL">https://doi.org/10.1002/btm2.10131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/btm2.10131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbtm2.10131%26sid%3Dliteratum%253Aachs%26jtitle%3DBioengineering%2520%2526%2520Translational%2520Medicine%26atitle%3DLayer%2525E2%252580%252590by%2525E2%252580%252590layer%252Bnanoparticles%252Bfor%252Bnovel%252Bdelivery%252Bof%252Bcisplatin%252Band%252BPARP%252Binhibitors%252Bfor%252Bplatinum%2525E2%252580%252590based%252Bdrug%252Bresistance%252Btherapy%252Bin%252Bovarian%252Bcancer%26aulast%3DMensah%26aufirst%3DLawrence%2BB.%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binfang  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Guo</span>, <span class="hlFld-ContribAuthor ">Guangzhao  Wang</span>, <span class="hlFld-ContribAuthor ">Huisheng  Huang</span>, <span class="hlFld-ContribAuthor ">Fulan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianhua  Xu</span>, <span class="hlFld-ContribAuthor ">Rongxing  He</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical investigation on the mechanism of Cu(
              ii
              )-catalyzed synthesis of 4-quinolones: effects of additives HOTf
              vs.
              HOTs. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2019,</strong> <em>43 </em>
                                    (10)
                                     , 4291-4305. <a href="https://doi.org/10.1039/C9NJ00082H" title="DOI URL">https://doi.org/10.1039/C9NJ00082H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ00082H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ00082H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DTheoretical%252Binvestigation%252Bon%252Bthe%252Bmechanism%252Bof%252BCu%252528%252Bii%252B%252529-catalyzed%252Bsynthesis%252Bof%252B4-quinolones%25253A%252Beffects%252Bof%252Badditives%252BHOTf%252Bvs.%252BHOTs%26aulast%3DYuan%26aufirst%3DBinfang%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D10%26spage%3D4291%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brandon  Carney</span>, <span class="hlFld-ContribAuthor ">Susanne  Kossatz</span>, <span class="hlFld-ContribAuthor ">Benjamin H.  Lok</span>, <span class="hlFld-ContribAuthor ">Valentina  Schneeberger</span>, <span class="hlFld-ContribAuthor ">Kishore K.  Gangangari</span>, <span class="hlFld-ContribAuthor ">Naga Vara Kishore  Pillarsetty</span>, <span class="hlFld-ContribAuthor ">Wolfgang A.  Weber</span>, <span class="hlFld-ContribAuthor ">Charles M.  Rudin</span>, <span class="hlFld-ContribAuthor ">John T.  Poirier</span>, <span class="hlFld-ContribAuthor ">Thomas  Reiner</span>. </span><span class="cited-content_cbyCitation_article-title">Target engagement imaging of PARP inhibitors in small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-017-02096-w" title="DOI URL">https://doi.org/10.1038/s41467-017-02096-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-017-02096-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-017-02096-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DTarget%252Bengagement%252Bimaging%252Bof%252BPARP%252Binhibitors%252Bin%252Bsmall-cell%252Blung%252Bcancer%26aulast%3DCarney%26aufirst%3DBrandon%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Lesueur</span>, <span class="hlFld-ContribAuthor ">François  Chevalier</span>, <span class="hlFld-ContribAuthor ">Elias A.  El-Habr</span>, <span class="hlFld-ContribAuthor ">Marie-Pierre  Junier</span>, <span class="hlFld-ContribAuthor ">Hervé  Chneiweiss</span>, <span class="hlFld-ContribAuthor ">Laurent  Castera</span>, <span class="hlFld-ContribAuthor ">Etienne  Müller</span>, <span class="hlFld-ContribAuthor ">Dinu  Stefan</span>, <span class="hlFld-ContribAuthor ">Yannick  Saintigny</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-22022-4" title="DOI URL">https://doi.org/10.1038/s41598-018-22022-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-22022-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-22022-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DRadiosensitization%252BEffect%252Bof%252BTalazoparib%25252C%252Ba%252BParp%252BInhibitor%25252C%252Bon%252BGlioblastoma%252BStem%252BCells%252BExposed%252Bto%252BLow%252Band%252BHigh%252BLinear%252BEnergy%252BTransfer%252BRadiation%26aulast%3DLesueur%26aufirst%3DPaul%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gamze  Guney Eskiler</span>, <span class="hlFld-ContribAuthor ">Gulsah  Cecener</span>, <span class="hlFld-ContribAuthor ">Unal  Egeli</span>, <span class="hlFld-ContribAuthor ">Berrin  Tunca</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2018,</strong> <em>35 </em>
                                    (11)
                                     <a href="https://doi.org/10.1007/s11095-018-2502-6" title="DOI URL">https://doi.org/10.1007/s11095-018-2502-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-018-2502-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-018-2502-6%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DSynthetically%252BLethal%252BBMN%252B673%252B%252528Talazoparib%252529%252BLoaded%252BSolid%252BLipid%252BNanoparticles%252Bfor%252BBRCA1%252BMutant%252BTriple%252BNegative%252BBreast%252BCancer%26aulast%3DGuney%2BEskiler%26aufirst%3DGamze%26date%3D2018%26date%3D2018%26volume%3D35%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aashish  Soni</span>, <span class="hlFld-ContribAuthor ">Fanghua  Li</span>, <span class="hlFld-ContribAuthor ">You  Wang</span>, <span class="hlFld-ContribAuthor ">Martha  Grabos</span>, <span class="hlFld-ContribAuthor ">Lisa Marie  Krieger</span>, <span class="hlFld-ContribAuthor ">Shipra  Chaudhary</span>, <span class="hlFld-ContribAuthor ">Mohammad Sharif Mortoga  Hasan</span>, <span class="hlFld-ContribAuthor ">Mansoor  Ahmed</span>, <span class="hlFld-ContribAuthor ">C. Norman  Coleman</span>, <span class="hlFld-ContribAuthor ">Beverly A.  Teicher</span>, <span class="hlFld-ContribAuthor ">Richard L.  Piekarz</span>, <span class="hlFld-ContribAuthor ">Dian  Wang</span>, <span class="hlFld-ContribAuthor ">George E.  Iliakis</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (10)
                                     , 2206-2216. <a href="https://doi.org/10.1158/1535-7163.MCT-17-0836" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-0836</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-0836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-0836%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DInhibition%252Bof%252BParp1%252Bby%252BBMN673%252BEffectively%252BSensitizes%252BCells%252Bto%252BRadiotherapy%252Bby%252BUpsetting%252Bthe%252BBalance%252Bof%252BRepair%252BPathways%252BProcessing%252BDNA%252BDouble-Strand%252BBreaks%26aulast%3DSoni%26aufirst%3DAashish%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D2206%26epage%3D2216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Lan  Zhao</span>, <span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Chun-Hao  Yang</span>, <span class="hlFld-ContribAuthor ">Jun-An  Xiao</span>, <span class="hlFld-ContribAuthor ">Peng-Ju  Xia</span>, <span class="hlFld-ContribAuthor ">Xiao-Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Straightforward Synthesis of Novel Difluorinated 2-Hydroxyl-Substituted Dihydroquinolones Through Selectfluor-triggered Annulation of 2-Aminoarylenaminones. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2018,</strong> <em>3 </em>
                                    (32)
                                     , 9218-9221. <a href="https://doi.org/10.1002/slct.201801951" title="DOI URL">https://doi.org/10.1002/slct.201801951</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201801951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201801951%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DStraightforward%252BSynthesis%252Bof%252BNovel%252BDifluorinated%252B2-Hydroxyl-Substituted%252BDihydroquinolones%252BThrough%252BSelectfluor-triggered%252BAnnulation%252Bof%252B2-Aminoarylenaminones%26aulast%3DZhao%26aufirst%3DQing-Lan%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D32%26spage%3D9218%26epage%3D9221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hadia  Almahli</span>, <span class="hlFld-ContribAuthor ">Elie  Hadchity</span>, <span class="hlFld-ContribAuthor ">Maiy Y.  Jaballah</span>, <span class="hlFld-ContribAuthor ">Racha  Daher</span>, <span class="hlFld-ContribAuthor ">Hazem A.  Ghabbour</span>, <span class="hlFld-ContribAuthor ">Maha M.  Kabil</span>, <span class="hlFld-ContribAuthor ">Nasser S.  Al-shakliah</span>, <span class="hlFld-ContribAuthor ">Wagdy M.  Eldehna</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>77 </em>, 443-456. <a href="https://doi.org/10.1016/j.bioorg.2018.01.034" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.01.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.01.034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252Bsynthesized%252Bphthalazinone-based%252BPARP-1%252Binhibitors%252Bwith%252Bapoptosis%252Binducing%252Bmechanism%252Bin%252Blung%252Bcancer%26aulast%3DAlmahli%26aufirst%3DHadia%26date%3D2018%26volume%3D77%26spage%3D443%26epage%3D456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahendra Kumar  Hidau</span>, <span class="hlFld-ContribAuthor ">Srikanth  Kolluru</span>, <span class="hlFld-ContribAuthor ">Srinath  Palakurthi</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Chromatography</span><span> <strong>2018,</strong> <em>32 </em>
                                    (2)
                                     , e4046. <a href="https://doi.org/10.1002/bmc.4046" title="DOI URL">https://doi.org/10.1002/bmc.4046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bmc.4046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbmc.4046%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Chromatography%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252Ba%252Bhigh-performance%252Bliquid%252Bchromatography%252Bmethod%252Bfor%252Bthe%252Bquantification%252Bof%252Btalazoparib%252Bin%252Brat%252Bplasma%25253A%252BApplication%252Bto%252Bplasma%252Bprotein%252Bbinding%252Bstudies%26aulast%3DHidau%26aufirst%3DMahendra%2BKumar%26date%3D2018%26date%3D2017%26volume%3D32%26issue%3D2%26spage%3De4046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuxing  Chen</span>, <span class="hlFld-ContribAuthor ">Xiajuan  Huan</span>, <span class="hlFld-ContribAuthor ">Qiufeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yuqin  Wang</span>, <span class="hlFld-ContribAuthor ">Qian  He</span>, <span class="hlFld-ContribAuthor ">Cun  Tan</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yechun  Xu</span>, <span class="hlFld-ContribAuthor ">Zehong  Miao</span>, <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 389-403. <a href="https://doi.org/10.1016/j.ejmech.2018.01.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B2-%2525284%25252C5%25252C6%25252C7-tetrahydrothienopyridin-2-yl%252529-benzoimidazole%252Bcarboxamides%252Bas%252Bnovel%252Borally%252Befficacious%252BPoly%252528ADP-ribose%252529polymerase%252B%252528PARP%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DXuxing%26date%3D2018%26volume%3D145%26spage%3D389%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Haiping  Yao</span>, <span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Hailong  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of quinazoline-2,4(1
              H
              ,3
              H
              )-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (17)
                                     , 3189-3202. <a href="https://doi.org/10.1039/C8OB00286J" title="DOI URL">https://doi.org/10.1039/C8OB00286J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB00286J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB00286J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bquinazoline-2%25252C4%2525281%252BH%252B%25252C3%252BH%252B%252529-dione%252Bderivatives%252Bas%252Bnovel%252BPARP-1%25252F2%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Btheir%252Bantitumor%252Bactivity%26aulast%3DZhou%26aufirst%3DJie%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D17%26spage%3D3189%26epage%3D3202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imke H.  Bartelink</span>, <span class="hlFld-ContribAuthor ">Brendan  Prideaux</span>, <span class="hlFld-ContribAuthor ">Gregor  Krings</span>, <span class="hlFld-ContribAuthor ">Lisa  Wilmes</span>, <span class="hlFld-ContribAuthor ">Pei Rong Evelyn  Lee</span>, <span class="hlFld-ContribAuthor ">Pan  Bo</span>, <span class="hlFld-ContribAuthor ">Byron  Hann</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Coppé</span>, <span class="hlFld-ContribAuthor ">Diane  Heditsian</span>, <span class="hlFld-ContribAuthor ">Lamorna  Swigart-Brown</span>, <span class="hlFld-ContribAuthor ">Ella F.  Jones</span>, <span class="hlFld-ContribAuthor ">Sergey  Magnitsky</span>, <span class="hlFld-ContribAuthor ">Ron J  Keizer</span>, <span class="hlFld-ContribAuthor ">Niels  de Vries</span>, <span class="hlFld-ContribAuthor ">Hilde  Rosing</span>, <span class="hlFld-ContribAuthor ">Nela  Pawlowska</span>, <span class="hlFld-ContribAuthor ">Scott  Thomas</span>, <span class="hlFld-ContribAuthor ">Mallika  Dhawan</span>, <span class="hlFld-ContribAuthor ">Rahul  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Pamela N.  Munster</span>, <span class="hlFld-ContribAuthor ">Laura J.  Esserman</span>, <span class="hlFld-ContribAuthor ">Weiming  Ruan</span>, <span class="hlFld-ContribAuthor ">Alan H. B.  Wu</span>, <span class="hlFld-ContribAuthor ">Douglas  Yee</span>, <span class="hlFld-ContribAuthor ">Véronique  Dartois</span>, <span class="hlFld-ContribAuthor ">Radojka M.  Savic</span>, <span class="hlFld-ContribAuthor ">Denise M.  Wolf</span>, <span class="hlFld-ContribAuthor ">Laura  van ’t Veer</span>. </span><span class="cited-content_cbyCitation_article-title">Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research</span><span> <strong>2017,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13058-017-0896-4" title="DOI URL">https://doi.org/10.1186/s13058-017-0896-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13058-017-0896-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13058-017-0896-4%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%26atitle%3DHeterogeneous%252Bdrug%252Bpenetrance%252Bof%252Bveliparib%252Band%252Bcarboplatin%252Bmeasured%252Bin%252Btriple%252Bnegative%252Bbreast%252Btumors%26aulast%3DBartelink%26aufirst%3DImke%2BH.%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hideki  Minami</span>, <span class="hlFld-ContribAuthor ">Noriko  Okamoto</span>, <span class="hlFld-ContribAuthor ">Takuya  Sueda</span>, <span class="hlFld-ContribAuthor ">Takatsugu  Sakaguchi</span>, <span class="hlFld-ContribAuthor ">Minoru  Ishikura</span>, <span class="hlFld-ContribAuthor ">Reiko  Yanada</span>. </span><span class="cited-content_cbyCitation_article-title">Reaction of 2-propargylphenylcarbamates with diphenyliodonium salts via Meyer-Schuster rearrangement. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (45)
                                     , 4277-4280. <a href="https://doi.org/10.1016/j.tetlet.2017.09.079" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.09.079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.09.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.09.079%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DReaction%252Bof%252B2-propargylphenylcarbamates%252Bwith%252Bdiphenyliodonium%252Bsalts%252Bvia%252BMeyer-Schuster%252Brearrangement%26aulast%3DMinami%26aufirst%3DHideki%26date%3D2017%26volume%3D58%26issue%3D45%26spage%3D4277%26epage%3D4280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mallika S.  Dhawan</span>, <span class="hlFld-ContribAuthor ">Imke H.  Bartelink</span>, <span class="hlFld-ContribAuthor ">Rahul Raj  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Jim  Leng</span>, <span class="hlFld-ContribAuthor ">Jenna Z.  Zhang</span>, <span class="hlFld-ContribAuthor ">Nela  Pawlowska</span>, <span class="hlFld-ContribAuthor ">Manuela  Terranova-Barberio</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Grabowsky</span>, <span class="hlFld-ContribAuthor ">Andrew  Gewitz</span>, <span class="hlFld-ContribAuthor ">Amy J.  Chien</span>, <span class="hlFld-ContribAuthor ">Mark  Moasser</span>, <span class="hlFld-ContribAuthor ">Robin K.  Kelley</span>, <span class="hlFld-ContribAuthor ">Tayeba  Maktabi</span>, <span class="hlFld-ContribAuthor ">Scott  Thomas</span>, <span class="hlFld-ContribAuthor ">Pamela N.  Munster</span>. </span><span class="cited-content_cbyCitation_article-title">Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2017,</strong> <em>23 </em>
                                    (21)
                                     , 6400-6410. <a href="https://doi.org/10.1158/1078-0432.CCR-17-0703" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-0703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-0703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-0703%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DDifferential%252BToxicity%252Bin%252BPatients%252Bwith%252Band%252Bwithout%252BDNA%252BRepair%252BMutations%25253A%252BPhase%252BI%252BStudy%252Bof%252BCarboplatin%252Band%252BTalazoparib%252Bin%252BAdvanced%252BSolid%252BTumors%26aulast%3DDhawan%26aufirst%3DMallika%2BS.%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D21%26spage%3D6400%26epage%3D6410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prashant B.  Nigade</span>, <span class="hlFld-ContribAuthor ">Jayasagar  Gundu</span>, <span class="hlFld-ContribAuthor ">K.  Sreedhara Pai</span>, <span class="hlFld-ContribAuthor ">Kumar V. S.  Nemmani</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of Tissue-to-Plasma Ratios of Basic Compounds in Mice. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Drug Metabolism and Pharmacokinetics</span><span> <strong>2017,</strong> <em>42 </em>
                                    (5)
                                     , 835-847. <a href="https://doi.org/10.1007/s13318-017-0402-5" title="DOI URL">https://doi.org/10.1007/s13318-017-0402-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13318-017-0402-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13318-017-0402-5%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Drug%2520Metabolism%2520and%2520Pharmacokinetics%26atitle%3DPrediction%252Bof%252BTissue-to-Plasma%252BRatios%252Bof%252BBasic%252BCompounds%252Bin%252BMice%26aulast%3DNigade%26aufirst%3DPrashant%2BB.%26date%3D2017%26date%3D2017%26volume%3D42%26issue%3D5%26spage%3D835%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beverly A.  Teicher</span>, <span class="hlFld-ContribAuthor ">Thomas  Silvers</span>, <span class="hlFld-ContribAuthor ">Michael  Selby</span>, <span class="hlFld-ContribAuthor ">Rene  Delosh</span>, <span class="hlFld-ContribAuthor ">Julie  Laudeman</span>, <span class="hlFld-ContribAuthor ">Chad  Ogle</span>, <span class="hlFld-ContribAuthor ">Russell  Reinhart</span>, <span class="hlFld-ContribAuthor ">Ralph  Parchment</span>, <span class="hlFld-ContribAuthor ">Julia  Krushkal</span>, <span class="hlFld-ContribAuthor ">Dmitriy  Sonkin</span>, <span class="hlFld-ContribAuthor ">Larry  Rubinstein</span>, <span class="hlFld-ContribAuthor ">Joel  Morris</span>, <span class="hlFld-ContribAuthor ">David  Evans</span>. </span><span class="cited-content_cbyCitation_article-title">Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. </span><span class="cited-content_cbyCitation_journal-name">Cancer Medicine</span><span> <strong>2017,</strong> <em>6 </em>
                                    (8)
                                     , 1952-1964. <a href="https://doi.org/10.1002/cam4.1131" title="DOI URL">https://doi.org/10.1002/cam4.1131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cam4.1131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcam4.1131%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Medicine%26atitle%3DSmall%252Bcell%252Blung%252Bcarcinoma%252Bcell%252Bline%252Bscreen%252Bof%252Betoposide%25252Fcarboplatin%252Bplus%252Ba%252Bthird%252Bagent%26aulast%3DTeicher%26aufirst%3DBeverly%2BA.%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D8%26spage%3D1952%26epage%3D1964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hailong  Zhao</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Guonan  Cui</span>, <span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Fangfang  Lai</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinazoline-2,4(1 H ,3 H )-dione derivatives as potent PARP-2 selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (15)
                                     , 4045-4054. <a href="https://doi.org/10.1016/j.bmc.2017.05.052" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.05.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.05.052%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinazoline-2%25252C4%2525281%252BH%252B%25252C3%252BH%252B%252529-dione%252Bderivatives%252Bas%252Bpotent%252BPARP-2%252Bselective%252Binhibitors%26aulast%3DZhao%26aufirst%3DHailong%26date%3D2017%26volume%3D25%26issue%3D15%26spage%3D4045%26epage%3D4054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angiolo  Gadducci</span>, <span class="hlFld-ContribAuthor ">Maria Elena  Guerrieri</span>. </span><span class="cited-content_cbyCitation_article-title">PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2017,</strong> <em>114 </em>, 153-165. <a href="https://doi.org/10.1016/j.critrevonc.2017.04.006" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2017.04.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2017.04.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DPARP%252Binhibitors%252Balone%252Band%252Bin%252Bcombination%252Bwith%252Bother%252Bbiological%252Bagents%252Bin%252Bhomologous%252Brecombination%252Bdeficient%252Bepithelial%252Bovarian%252Bcancer%25253A%252BFrom%252Bthe%252Bbasic%252Bresearch%252Bto%252Bthe%252Bclinic%26aulast%3DGadducci%26aufirst%3DAngiolo%26date%3D2017%26volume%3D114%26spage%3D153%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>132 </em>, 26-41. <a href="https://doi.org/10.1016/j.ejmech.2017.03.013" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.013%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-substituted%252B1%252BH%252B-benzo%25255B%252Bd%252B%25255Dimmidazole-4-carboxamide%252Bderivatives%252Bas%252Bnovel%252Bpoly%252528ADP-ribose%252529polymerase-1%252Binhibitors%252Bwith%252Bin%2525C2%2525A0vivo%252Banti-tumor%252Bactivity%26aulast%3DZhou%26aufirst%3DJie%26date%3D2017%26volume%3D132%26spage%3D26%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Jiwei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenlu  Li</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Changjun  Chen</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">PARP inhibitors as antitumor agents: a patent update (2013-2015). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (3)
                                     , 363-382. <a href="https://doi.org/10.1080/13543776.2017.1259413" title="DOI URL">https://doi.org/10.1080/13543776.2017.1259413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1259413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1259413%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPARP%252Binhibitors%252Bas%252Bantitumor%252Bagents%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282013-2015%252529%26aulast%3DYuan%26aufirst%3DZigao%26date%3D2017%26date%3D2016%26volume%3D27%26issue%3D3%26spage%3D363%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Shang</span>, <span class="hlFld-ContribAuthor ">Juechen  Ni</span>, <span class="hlFld-ContribAuthor ">Xinyu  Gao</span>, <span class="hlFld-ContribAuthor ">Chengren  Li</span>, <span class="hlFld-ContribAuthor ">Xiaomeng  Lin</span>, <span class="hlFld-ContribAuthor ">Zhinan  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Du</span>, <span class="hlFld-ContribAuthor ">Shuang  Li</span>, <span class="hlFld-ContribAuthor ">Yongheng  Xing</span>. </span><span class="cited-content_cbyCitation_article-title">Various structures of complexes fabricated using transition metals and triazole ligands and their inhibition effects on xanthine luminescence. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2016,</strong> <em>40 </em>
                                    (9)
                                     , 8100-8109. <a href="https://doi.org/10.1039/C6NJ01503D" title="DOI URL">https://doi.org/10.1039/C6NJ01503D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6NJ01503D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6NJ01503D%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DVarious%252Bstructures%252Bof%252Bcomplexes%252Bfabricated%252Busing%252Btransition%252Bmetals%252Band%252Btriazole%252Bligands%252Band%252Btheir%252Binhibition%252Beffects%252Bon%252Bxanthine%252Bluminescence%26aulast%3DShang%26aufirst%3DDi%26date%3D2016%26date%3D2016%26volume%3D40%26issue%3D9%26spage%3D8100%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PARP inhibitors currently undergoing clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Planned Synthetic Route to <b>5</b> and the Synthesis of <b>13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) EA, 10% Pd/C, H<sub>2</sub>, 1 atm, rt, 2 h; (ii) PhCHO, MeONa, ethyl propionate, reflux, 18 h; (iii) H<sub>2</sub>NNH<sub>2</sub>, H<sub>2</sub>O, reflux, 3 h; (iv) NBS; (v) deprotection–cyclization–oxidation.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>15</b>–<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) RCHO, MeONa, ethyl propionate, reflux, 18 h; (ii) H<sub>2</sub>NNH<sub>2</sub>, H<sub>2</sub>O, reflux, 3 h; (iii) PtO<sub>2</sub>, 20 atm H<sub>2</sub>, MeOH, 50 °C, 24 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>24</b>–<b>57</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) R<sub>1</sub>CHO, MgSO<sub>4</sub>, MeOH, reflux, 24 h; (ii) R<sub>2</sub>CHO, R<sub>3</sub>ONa = EtONa (except for <b>22a</b>–<b>c</b>, <b>22m</b>, and <b>23e</b>, wherein R<sub>3</sub>ONa = MeONa), ethyl propionate, rt, 18 h; (iii) H<sub>2</sub>NNH<sub>2</sub>, H<sub>2</sub>O, MeOH, rt to reflux, 3–18 h; (iv) 3 <i>N</i> HCl, rt; (v) amine, NaBH<sub>4</sub>.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>47</b>, <b>61</b>–<b>64</b>, and (8<i>S</i>,9<i>R</i>)-<b>47</b> (BMN 673)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (i) 1-methyl-1<i>H</i>-1,2,4-triazole-5-carbaldehyde, Et<sub>3</sub>N, Ac<sub>2</sub>O, 2-Me-THF, rt to 80 °C, 2 h; (ii) MeOH, rt, overnight; (iii) R<sub>1</sub>CHO, TiCl<sub>3</sub>, THF, MeOH, 0 °C to rt, (iv) H<sub>2</sub>NNH<sub>2</sub>, MeOH, rt, overnight; (v) <b>47</b>, SFC chiral separation.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. ORTEP diagram of BMN 673 ((8<i>S</i>,9<i>R</i>)-<b>47</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Predicted ligand binding poses relative to <i>cat</i>PARP1: (8<i>S</i>,9<i>R</i>)-<b>47</b> (talazoparib; BMN 673) co-crystal structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT">4PJT</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (A) Overlay of the calculated (cyan) and co-crystallized (magenta) binding poses of (8<i>S</i>,9<i>R</i>)-<b>47</b> validates that the induced-fit docking protocol reproduces the inhibitor binding mode of the co-crystal structure. (B) Overlay of the binding poses of (8<i>R</i>,9<i>S</i>)-<b>47</b> calculated (cyan) and (8<i>S</i>,9<i>R</i>)-<b>47</b> co-crystallized (magenta) suggests that the (8<i>R</i>,9<i>S</i>) stereoconfiguration could impose steric strains to nearby PARP1 residues (arrows). (C) Overlay of the binding pose of (8<i>S</i>,9<i>R</i>)-<b>39</b> calculated (cyan) and (8<i>S</i>,9<i>R</i>)-<b>47</b> co-crystallized (magenta) suggests that inhibitor interactions with the NAD<sup>+</sup>-binding residues and/or ordered water molecule (arrow) could be affected by the absence of a hydrogen-bonding N atom on the 9<i>R</i>-substituent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. BMN 673 ((8<i>S</i>,9<i>R</i>)-<b>47</b>) exhibits antitumor activity against a <i>BRCA1</i> mutant tumor model in mice.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (A) Pharmacodynamic activity in <i>BRCA1</i> mutant mouse xenograft model following a single dose (1 mg/kg, po) by measuring MX-1 tumor PAR levels using ELISA at 2, 8, and 24 h after treatment. (B) Antitumor efficacy in <i>BRCA1</i> mutant (MX-1) mouse xenograft model following once-daily (QD) oral dosing. (C) BMN 673 is more effective in mouse xenograft models with 0.165 mg/kg twice-daily (BID) dosing than 0.33 mg/kg once-daily (QD) dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/medium/jm-2015-014985_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. BMN 673 ((8<i>S</i>,9<i>R</i>)-<b>47</b>) potentiates the effects of DNA-damaging cytotoxic agents in a BRCA1 mutant MX-1 xenograft mouse model.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (A) BMN 673 in combination with cisplatin. BMN 673 and olaparib were dosed orally once-daily (QD) from days 1–8; cisplatin was dosed by intraperitoneal injection (ip) at 6 mg/kg on day 3. (B) BMN 673 in combination with carboplatin. BMN 673 was dosed orally QD at 0.33 mg/kg for 5 or 8 days starting from day 1. Carboplatin was dosed ip at a 35 mg/kg dosage on day 1 half of an hour after BMN 673 administration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01498/20160113/images/large/jm-2015-014985_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01498&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i159">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hottiger, M. O.</span><span> </span><span class="NLM_article-title">The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases</span> <span class="citation_source-journal">Front. Biosci., Landmark Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3046</span><span class="NLM_x">–</span> <span class="NLM_lpage">3082</span><span class="refDoi"> DOI: 10.2741/2909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.2741%2F2909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=17981777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=3046-3082&author=P.+O.+Hassaauthor=M.+O.+Hottiger&title=The+diverse+biological+roles+of+mammalian+PARPS%2C+a+small+but+powerful+family+of+poly-ADP-ribose+polymerases&doi=10.2741%2F2909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases</span></div><div class="casAuthors">Hassa, Paul O.; Hottiger, Michael O.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3046-3082</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Poly-ADP-ribose metab. plays a mayor role in a wide range of biol. processes, such as maintenance of genomic stability, transcriptional regulation, energy metab., and cell death.  Poly-ADP-ribose polymerases (PARPs) are an ancient family of enzymes, as evidenced by the poly-ADP-ribosylating activities reported in dinoflagellates and archaebacteria and by the identification of Parp-like genes in eubacterial and archaeabacterial genomes.  Six genes encoding "bona fide" PARP enzymes have been identified in mammalians: PARP1, PARP2, PARP3, PARP4/vPARP, PARP5/Tankyrases-1, and PARP6/Tankyrases-2.  The best studied of these enzymes, PARP1, plays a primary role in the process of poly-ADP-ribosylation.  PARP1-mediated poly-ADP-ribosylation has been implicated in the pathogenesis of cancer, inflammatory, and neurodegenerative disorders.  Here, the authors summarize novel findings and concepts for PARP enzymes and their poly-ADP-ribosylation activity in the regulation of physiol. and pathophysiol. processes.  A special focus is placed on the proposed mol. mechanisms involved in these processes, such as signaling, regulation of telomere dynamics, remodeling of chromatin structure, and transcriptional regulation.  A potential functional cross-talk between PARP family members and other NAD-consuming enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoNyzgIk1gtrVg90H21EOLACvtfcHk0ljJoYFsiwqrpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhs1Cntrk%253D&md5=1e62c4597ec219b0797a29c1458b98b4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2741%2F2909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F2909%26sid%3Dliteratum%253Aachs%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26atitle%3DThe%2520diverse%2520biological%2520roles%2520of%2520mammalian%2520PARPS%252C%2520a%2520small%2520but%2520powerful%2520family%2520of%2520poly-ADP-ribose%2520polymerases%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2008%26volume%3D13%26spage%3D3046%26epage%3D3082%26doi%3D10.2741%2F2909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Rouleau, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendzel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, G. G.</span><span> </span><span class="NLM_article-title">PARP inhibition: PARP1 and beyond</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">301</span><span class="refDoi"> DOI: 10.1038/nrc2812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnrc2812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=20200537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=293-301&author=M.+Rouleauauthor=A.+Patelauthor=M.+J.+Hendzelauthor=S.+H.+Kaufmannauthor=G.+G.+Poirier&title=PARP+inhibition%3A+PARP1+and+beyond&doi=10.1038%2Fnrc2812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibition: PARP1 and beyond</span></div><div class="casAuthors">Rouleau, Michele; Patel, Anand; Hendzel, Michael J.; Kaufmann, Scott H.; Poirier, Guy G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">293-301</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets.  To provide a framework for understanding these recent observations, the authors have reviewed what is known about the structures and functions of the family of PARP enzymes, and then outlined a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOiY_n1IClmbVg90H21EOLACvtfcHk0ljJoYFsiwqrpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yms7w%253D&md5=fa3e3964e84229317dadbd505f11ad86</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2812%26sid%3Dliteratum%253Aachs%26aulast%3DRouleau%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DHendzel%26aufirst%3DM.%2BJ.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DPoirier%26aufirst%3DG.%2BG.%26atitle%3DPARP%2520inhibition%253A%2520PARP1%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D293%26epage%3D301%26doi%3D10.1038%2Fnrc2812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Therapeutic applications of PARP inhibitors: anticancer therapy and beyond</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span><span class="refDoi"> DOI: 10.1016/j.mam.2013.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.mam.2013.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23370117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1217-1256&author=N.+J.+Curtinauthor=C.+Szabo&title=Therapeutic+applications+of+PARP+inhibitors%3A+anticancer+therapy+and+beyond&doi=10.1016%2Fj.mam.2013.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span></div><div class="casAuthors">Curtin, Nicola J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1256</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this article is to describe the current and potential clin. translation of pharmacol. inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases.  The first section of the present review summarizes the available preclin. and clin. data with PARP inhibitors in various forms of cancer.  In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-assocd. lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer.  HRR defects are classically assocd. with BRCA1 and 2 mutations assocd. with familial breast and ovarian cancer, but there may be many other causes of HRR defects.  Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects.  Multiple lines of preclin. data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation.  Both single agent and combination clin. trials are underway.  The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clin. development.  The second section of the present review summarizes the role of PARP in selected non-oncol. indications.  In a no. of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clin. translatability of PARP inhibition is supported by multiple lines of preclin. data, as well as observational data demonstrating PARP activation in human tissue samples.  In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathol.  Accordingly, multiple lines of preclin. data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses.  As the clin. trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clin. investigations, aimed at testing of PARP inhibitors for various non-oncol. indications, will be initiated, as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4INVXcZ0zbVg90H21EOLACvtfcHk0lhFZGjJ5r0d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D&md5=6a514e160666b5dde38e1365211cd41e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DTherapeutic%2520applications%2520of%2520PARP%2520inhibitors%253A%2520anticancer%2520therapy%2520and%2520beyond%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1217%26epage%3D1256%26doi%3D10.1016%2Fj.mam.2013.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Krishnakumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.molcel.2010.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=20603072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8-24&author=R.+Krishnakumarauthor=W.+L.+Kraus&title=The+PARP+side+of+the+nucleus%3A+molecular+actions%2C+physiological+outcomes%2C+and+clinical+targets&doi=10.1016%2Fj.molcel.2010.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span></div><div class="casAuthors">Krishnakumar, Raga; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-24</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The abundant nuclear enzyme PARP-1, a multifunctional regulator of chromatin structure, transcription, and genomic integrity, plays key roles in a wide variety of processes in the nucleus.  Recent studies have begun to connect the mol. functions of PARP-1 to specific physiol. and pathol. outcomes, many of which can be altered by an expanding array of chem. inhibitors of PARP enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy5Mj-wajemLVg90H21EOLACvtfcHk0lhFZGjJ5r0d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D&md5=afb9423e09ed68d2bfa589ed0d7b9f13</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnakumar%26aufirst%3DR.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DThe%2520PARP%2520side%2520of%2520the%2520nucleus%253A%2520molecular%2520actions%252C%2520physiological%2520outcomes%252C%2520and%2520clinical%2520targets%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D39%26spage%3D8%26epage%3D24%26doi%3D10.1016%2Fj.molcel.2010.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Langelier, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascal, J. M.</span><span> </span><span class="NLM_article-title">PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1016/j.sbi.2013.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.sbi.2013.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23333033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=134-143&author=M.+F.+Langelierauthor=J.+M.+Pascal&title=PARP-1+mechanism+for+coupling+DNA+damage+detection+to+poly%28ADP-ribose%29+synthesis&doi=10.1016%2Fj.sbi.2013.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis</span></div><div class="casAuthors">Langelier, Marie-France; Pascal, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-143</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase 1 (PARP-1) regulates gene transcription, cell death signaling, and DNA repair through prodn. of the posttranslational modification poly(ADP-ribose).  During the cellular response to genotoxic stress PARP-1 rapidly assocs. with DNA damage, which robustly stimulates poly(ADP-ribose) prodn. over a low basal level of PARP-1 activity.  DNA damage-dependent PARP-1 activity is central to understanding PARP-1 biol. function, but structural insights into the mechanisms underlying this mode of regulation have remained elusive, in part due to the highly modular six-domain architecture of PARP-1.  Recent structural studies have illustrated how PARP-1 uses specialized zinc fingers to detect DNA breaks through sequence-independent interaction with exposed nucleotide bases, a common feature of damaged and abnormal DNA structures.  The mechanism of coupling DNA damage detection to elevated poly(ADP-ribose) prodn. has been elucidated based on a crystal structure of the essential domains of PARP-1 in complex with a DNA strand break.  The multiple domains of PARP-1 collapse onto damaged DNA, forming a network of interdomain contacts that introduce destabilizing alterations in the catalytic domain leading to an enhanced rate of poly(ADP-ribose) prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraHOp_vs_b0rVg90H21EOLACvtfcHk0lhFZGjJ5r0d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qu7w%253D&md5=b0c94b832353bcda25e0ad4dc982cbce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2013.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2013.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DLangelier%26aufirst%3DM.%2BF.%26aulast%3DPascal%26aufirst%3DJ.%2BM.%26atitle%3DPARP-1%2520mechanism%2520for%2520coupling%2520DNA%2520damage%2520detection%2520to%2520poly%2528ADP-ribose%2529%2520synthesis%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2013%26volume%3D23%26spage%3D134%26epage%3D143%26doi%3D10.1016%2Fj.sbi.2013.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">DNA repair dysregulation from cancer driver to therapeutic target</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1038/nrc3399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnrc3399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23175119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslagsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=801-817&author=N.+J.+Curtin&title=DNA+repair+dysregulation+from+cancer+driver+to+therapeutic+target&doi=10.1038%2Fnrc3399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair dysregulation from cancer driver to therapeutic target</span></div><div class="casAuthors">Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">801-817</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulation of DNA damage repair and signalling to cell cycle checkpoints, known as the DNA damage response (DDR), is assocd. with a predisposition to cancer and affects responses to DNA-damaging anticancer therapy.  Dysfunction of one DNA repair pathway may be compensated for by the function of another compensatory DDR pathway, which may be increased and contribute to resistance to DNA-damaging chemotherapy and radiotherapy.  Therefore, DDR pathways make an ideal target for therapeutic intervention; first, to prevent or reverse therapy resistance; and second, using a synthetic lethal approach to specifically kill cancer cells that are dependent on a compensatory DNA repair pathway for survival in the context of cancer-assocd. oxidative and replicative stress.  These hypotheses are currently being tested in the lab. and are being translated into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNDBV6krLGBbVg90H21EOLACvtfcHk0lhFZGjJ5r0d1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslagsb3N&md5=1bcb90d4742e46696c8a30a4fce2400c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3399%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DDNA%2520repair%2520dysregulation%2520from%2520cancer%2520driver%2520to%2520therapeutic%2520target%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D801%26epage%3D817%26doi%3D10.1038%2Fnrc3399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Amé, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niedergang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apiou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Höger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ménissier-de Murcia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">17860</span><span class="NLM_x">–</span> <span class="NLM_lpage">17868</span><span class="refDoi"> DOI: 10.1074/jbc.274.25.17860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1074%2Fjbc.274.25.17860" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=17860-17868&author=J.+C.+Am%C3%A9author=V.+Rolliauthor=V.+Schreiberauthor=C.+Niedergangauthor=F.+Apiouauthor=P.+Deckerauthor=S.+Mullerauthor=T.+H%C3%B6gerauthor=J.+M%C3%A9nissier-de+Murciaauthor=G.+de+Murcia&title=PARP-2%2C+A+novel+mammalian+DNA+damage-dependent+poly%28ADP-ribose%29+polymerase&doi=10.1074%2Fjbc.274.25.17860"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.25.17860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.25.17860%26sid%3Dliteratum%253Aachs%26aulast%3DAm%25C3%25A9%26aufirst%3DJ.%2BC.%26aulast%3DRolli%26aufirst%3DV.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DNiedergang%26aufirst%3DC.%26aulast%3DApiou%26aufirst%3DF.%26aulast%3DDecker%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DH%25C3%25B6ger%26aufirst%3DT.%26aulast%3DM%25C3%25A9nissier-de%2BMurcia%26aufirst%3DJ.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPARP-2%252C%2520A%2520novel%2520mammalian%2520DNA%2520damage-dependent%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D17860%26epage%3D17868%26doi%3D10.1074%2Fjbc.274.25.17860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ame, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose): novel functions for an old molecule</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/nrm1963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnrm1963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=16829982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=517-528&author=V.+Schreiberauthor=F.+Dantzerauthor=J.+C.+Ameauthor=G.+de+Murcia&title=Poly%28ADP-ribose%29%3A+novel+functions+for+an+old+molecule&doi=10.1038%2Fnrm1963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose): novel functions for an old molecule</span></div><div class="casAuthors">Schreiber, Valerie; Dantzer, Francoise; Ame, Jean-Christophe; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The addn. to proteins of the neg. charged polymer of ADP-ribose, which is synthesized by poly(ADP-ribose) polymerase (PARPs) from NAD, is a unique post-translational modification.  It regulates not only cell survival and cell-death programs, but also an increasing no. of other biol. functions with which novel members of the PARP family have been assocd.  These functions include transcriptional regulation, telomere cohesion and mitotic spindle formation during cell division, intracellular trafficking, and energy metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLsI4_BKfjdrVg90H21EOLACvtfcHk0lii-ETJkdpeOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1Ohsb4%253D&md5=676e83755491500f3bf2137f348dfa1b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrm1963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1963%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3DAme%26aufirst%3DJ.%2BC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DPoly%2528ADP-ribose%2529%253A%2520novel%2520functions%2520for%2520an%2520old%2520molecule%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2006%26volume%3D7%26spage%3D517%26epage%3D528%26doi%3D10.1038%2Fnrm1963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">The DNA damage response and cancer therapy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">481</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1038/nature10760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnature10760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=22258607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=481&publication_year=2012&pages=287-294&author=C.+J.+Lordauthor=A.+Ashworth&title=The+DNA+damage+response+and+cancer+therapy&doi=10.1038%2Fnature10760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The DNA damage response and cancer therapy</span></div><div class="casAuthors">Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">481</span>
        (<span class="NLM_cas:issue">7381</span>),
    <span class="NLM_cas:pages">287-294</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Genomic instability is one of the most pervasive characteristics of tumor cells and is probably the combined effect of DNA damage, tumor-specific DNA repair defects, and a failure to stop or stall the cell cycle before the damaged DNA is passed on to daughter cells.  Although these processes drive genomic instability and ultimately the disease process, they also provide therapeutic opportunities.  A better understanding of the cellular response to DNA damage will not only inform our knowledge of cancer development but also help to refine the classification as well as the treatment of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS1sAbqFhmrVg90H21EOLACvtfcHk0lii-ETJkdpeOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1GmsQ%253D%253D&md5=75d12cdb52e8c9a39bced1611bf90298</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature10760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10760%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DThe%2520DNA%2520damage%2520response%2520and%2520cancer%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D481%26spage%3D287%26epage%3D294%26doi%3D10.1038%2Fnature10760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors: polypharmacology versus selective inhibition</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3575</span><span class="refDoi"> DOI: 10.1111/febs.12298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1111%2Ffebs.12298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23601167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFWksbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=3563-3575&author=T.+Ekbladauthor=E.+Camaioniauthor=H.+Sch%C3%BClerauthor=A.+Macchiarulo&title=PARP+inhibitors%3A+polypharmacology+versus+selective+inhibition&doi=10.1111%2Ffebs.12298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors: polypharmacology versus selective inhibition</span></div><div class="casAuthors">Ekblad, Torun; Camaioni, Emidio; Schueler, Herwig; Macchiarulo, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3563-3575</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Inhibition of ADP-ribosyltransferases with diphtheria toxin homol. (ARTD), widely known as the poly(ADP-ribose) polymerase (PARP) family, is a strategy under development for treatment of various conditions, including cancers and ischemia.  Here, we give a brief summary of ARTD enzyme functions and the implications for their potential as therapeutic targets.  We present an overview of the PARP inhibitors that have been used in clin. trials.  Finally, we summarize recent insights from structural biol., and discuss the mol. aspects of PARP inhibitors in terms of broad-range vs. selective inhibition of ARTD family enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_9XKFIi3olbVg90H21EOLACvtfcHk0lii-ETJkdpeOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFWksbjP&md5=ec08e437f8b0150a44df2f9dda7cd5f7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12298%26sid%3Dliteratum%253Aachs%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%253A%2520polypharmacology%2520versus%2520selective%2520inhibition%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D3563%26epage%3D3575%26doi%3D10.1111%2Ffebs.12298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lupo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trusolino, L.</span><span> </span><span class="NLM_article-title">Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1846</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1016/j.bbcan.2014.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.bbcan.2014.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25026313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1846&publication_year=2014&pages=201-215&author=B.+Lupoauthor=L.+Trusolino&title=Inhibition+of+poly%28ADP-ribosyl%29ation+in+cancer%3A+old+and+new+paradigms+revisited&doi=10.1016%2Fj.bbcan.2014.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited</span></div><div class="casAuthors">Lupo, Barbara; Trusolino, Livio</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1846</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-215</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inhibitors of poly(ADP-ribose) polymerases actualized the biol. concept of synthetic lethality in the clin. practice, yielding a paradigmatic example of translational medicine.  The profound sensitivity of tumors with germline BRCA mutations to PARP1/2 blockade owes to inherent defects of the BRCA-dependent homologous recombination machinery, which are unleashed by interruption of PARP DNA repair activity and lead to DNA damage overload and cell death.  Conversely, aspirant BRCA-like tumors harboring somatic DNA repair dysfunctions (a vast entity of genetic and epigenetic defects known as "BRCAness") not always align with the familial counterpart and appear not to be equally sensitive to PARP inhibition.  The acquisition of secondary resistance in initially responsive patients and the lack of standardized biomarkers to identify "BRCAness" pose serious threats to the clin. advance of PARP inhibitors; a feeling is also emerging that a BRCA-centered perspective might have missed the influence of addnl., not negligible and DNA repair-independent PARP contributions onto therapy outcome.  While regulatory approval for PARP1/2 inhibitors is still pending, novel therapeutic opportunities are sprouting from different branches of the PARP family, although they remain immature for clin. extrapolation.  This review is an endeavor to provide a comprehensive appraisal of the multifaceted biol. of PARPs and their evolving impact on cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqebmjv_GlsGrVg90H21EOLACvtfcHk0lg5Mtc7sXGQ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OqsrrN&md5=222390f25fa1763853fdaf8da34b1d14</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2014.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2014.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DLupo%26aufirst%3DB.%26aulast%3DTrusolino%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520poly%2528ADP-ribosyl%2529ation%2520in%2520cancer%253A%2520old%2520and%2520new%2520paradigms%2520revisited%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2014%26volume%3D1846%26spage%3D201%26epage%3D215%26doi%3D10.1016%2Fj.bbcan.2014.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M. B.</span><span> </span><span class="NLM_article-title">4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+W.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+M.+Smithauthor=N.+M.+B.+Martin&title=4-%5B3-%284-cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+A+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0lg5Mtc7sXGQ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%2BW.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%2BM.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26atitle%3D4-%255B3-%25284-cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520A%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.-Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial&doi=10.1158%2F1535-7163.MCT-06-0552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0ljLmp7lW80gbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956%26doi%3D10.1158%2F1535-7163.MCT-06-0552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Canan-Koch, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoresen, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tikhe, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zook, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpf, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boritzki, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span> </span><span class="NLM_article-title">Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4961</span><span class="NLM_x">–</span> <span class="NLM_lpage">4974</span><span class="refDoi"> DOI: 10.1021/jm020259n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020259n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4961-4974&author=S.+S.+Canan-Kochauthor=L.+H.+Thoresenauthor=J.+G.+Tikheauthor=K.+A.+Maegleyauthor=X.-H.+Yuauthor=S.+E.+Zookauthor=R.+A.+Kumpfauthor=C.+Zhangauthor=T.+J.+Boritzkiauthor=R.+N.+Mansourauthor=K.+E.+Zhangauthor=A.+Ekkerauthor=C.+R.+Calabreseauthor=N.+J.+Curtinauthor=S.+Kyleauthor=H.+D.+Thomasauthor=L.-Z.+Wangauthor=A.+H.+Calvertauthor=B.+T.+Goldingauthor=R.+J.+Griffinauthor=D.+R.+Newellauthor=S.+E.+Webberauthor=Z.+Hostomsky&title=Novel+tricyclic+poly%28ADP-ribose%29+polymerase-1+inhibitors+with+potent+anticancer+chemopotentiating+activity%3A+Design%2C+synthesis%2C+and+X-ray+cocrystal+structure&doi=10.1021%2Fjm020259n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm020259n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020259n%26sid%3Dliteratum%253Aachs%26aulast%3DCanan-Koch%26aufirst%3DS.%2BS.%26aulast%3DThoresen%26aufirst%3DL.%2BH.%26aulast%3DTikhe%26aufirst%3DJ.%2BG.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DYu%26aufirst%3DX.-H.%26aulast%3DZook%26aufirst%3DS.%2BE.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBoritzki%26aufirst%3DT.%2BJ.%26aulast%3DMansour%26aufirst%3DR.%2BN.%26aulast%3DZhang%26aufirst%3DK.%2BE.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DHostomsky%26aufirst%3DZ.%26atitle%3DNovel%2520tricyclic%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%2520with%2520potent%2520anticancer%2520chemopotentiating%2520activity%253A%2520Design%252C%2520synthesis%252C%2520and%2520X-ray%2520cocrystal%2520structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4961%26epage%3D4974%26doi%3D10.1021%2Fjm020259n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and −2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">–</span> <span class="NLM_lpage">7185</span><span class="refDoi"> DOI: 10.1021/jm901188v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+A+novel+oral+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA-1+and+%E2%88%922+mutant+tumors&doi=10.1021%2Fjm901188v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520A%2520novel%2520oral%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA-1%2520and%2520%25E2%2588%25922%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185%26doi%3D10.1021%2Fjm901188v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span> </span><span class="NLM_article-title">Niraparib: a poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3302</span><span class="NLM_x">–</span> <span class="NLM_lpage">3314</span><span class="refDoi"> DOI: 10.1021/jm5018237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3302-3314&author=P.+Jonesauthor=K.+Wilcoxenauthor=M.+Rowleyauthor=C.+Toniatti&title=Niraparib%3A+a+poly+%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+for+the+treatment+of+tumors+with+defective+homologous+recombination&doi=10.1021%2Fjm5018237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26atitle%3DNiraparib%253A%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520tumors%2520with%2520defective%2520homologous%2520recombination%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3302%26epage%3D3314%26doi%3D10.1021%2Fjm5018237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeWeese, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillehay, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holley-Shanks, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hristov, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Idler, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasko, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGonigal, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meulbroek, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palma, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsurutani, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span> </span><span class="NLM_article-title">ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2728</span><span class="NLM_x">–</span> <span class="NLM_lpage">2737</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-3039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1078-0432.CCR-06-3039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=17473206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2728-2737&author=C.+K.+Donawhoauthor=Y.+Luoauthor=Y.+Luoauthor=T.+D.+Penningauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=V.+D.+Bontcheva-Diazauthor=B.+F.+Coxauthor=T.+L.+DeWeeseauthor=L.+E.+Dillehayauthor=D.+C.+Fergusonauthor=N.+S.+Ghoreishi-Haackauthor=D.+R.+Grimmauthor=R.+Guanauthor=E.+K.+Hanauthor=R.+R.+Holley-Shanksauthor=B.+Hristovauthor=K.+B.+Idlerauthor=K.+Jarvisauthor=E.+F.+Johnsonauthor=L.+R.+Kleinbergauthor=V.+Klinghoferauthor=L.+M.+Laskoauthor=X.+Liuauthor=K.+C.+Marshauthor=T.+P.+McGonigalauthor=J.+A.+Meulbroekauthor=A.+M.+Olsonauthor=J.+P.+Palmaauthor=L.+E.+Rodriguezauthor=Y.+Shiauthor=J.+A.+Stavropoulosauthor=A.+C.+Tsurutaniauthor=G.+D.+Zhuauthor=S.+Rosenbergauthor=V.+L.+Girandaauthor=D.+J.+Frost&title=ABT-888%2C+an+orally+active+poly%28ADP-ribose%29+polymerase+inhibitor+that+potentiates+DNA-damaging+agents+in+preclinical+tumor+models&doi=10.1158%2F1078-0432.CCR-06-3039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models</span></div><div class="casAuthors">Donawho, Cherrie K.; Luo, Yan; Luo, Yanping; Penning, Thomas D.; Bauch, Joy L.; Bouska, Jennifer J.; Bontcheva-Diaz, Velitchka D.; Cox, Bryan F.; DeWeese, Theodore L.; Dillehay, Larry E.; Ferguson, Debra C.; Ghoreishi-Haack, Nayereh S.; Grimm, David R.; Guan, Ran; Han, Edward K.; Holley-Shanks, Rhonda R.; Hristov, Boris; Idler, Kenneth B.; Jarvis, Ken; Johnson, Eric F.; Kleinberg, Lawrence R.; Klinghofer, Vered; Lasko, Loren M.; Liu, Xuesong; Marsh, Kennan C.; McGonigal, Thomas P.; Meulbroek, Jonathan A.; Olson, Amanda M.; Palma, Joann P.; Rodriguez, Luis E.; Shi, Yan; Stavropoulos, Jason A.; Tsurutani, Alan C.; Zhu, Gui-Dong; Rosenberg, Saul H.; Giranda, Vincent L.; Frost, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2728-2737</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose is to evaluate the preclin. pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888.  In vitro potency was detd. in a PARP-1 and PARP-2 enzyme assay.  In vivo efficacy was evaluated in syngeneic and xenograft models in combination with temozolomide, platinums, cyclophosphamide, and ionizing radiation.  ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2 and 2.9 nmol/L, resp.  The compd. has good oral bioavailability and crosses the blood-brain barrier.  ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model.  PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d.  In the 9L orthotopic rat glioma model, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression.  In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited.  Finally, ABT-888 potentiated radiation (2 Gy/d × 10) in an HCT-116 colon carcinoma model.  In each model, ABT-888 did not display single-agent activity.  ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models.  This broad spectrum of chemopotentiation and radiopotentiation makes this compd. an attractive candidate for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2xiIRsPurHLVg90H21EOLACvtfcHk0ljsumx2JUX-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslOhurg%253D&md5=4769ee3eec82465993eb9e1443095894</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3039%26sid%3Dliteratum%253Aachs%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%2BD.%26aulast%3DCox%26aufirst%3DB.%2BF.%26aulast%3DDeWeese%26aufirst%3DT.%2BL.%26aulast%3DDillehay%26aufirst%3DL.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%2BC.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DGrimm%26aufirst%3DD.%2BR.%26aulast%3DGuan%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DE.%2BK.%26aulast%3DHolley-Shanks%26aufirst%3DR.%2BR.%26aulast%3DHristov%26aufirst%3DB.%26aulast%3DIdler%26aufirst%3DK.%2BB.%26aulast%3DJarvis%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DKleinberg%26aufirst%3DL.%2BR.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DLasko%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMcGonigal%26aufirst%3DT.%2BP.%26aulast%3DMeulbroek%26aufirst%3DJ.%2BA.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DPalma%26aufirst%3DJ.%2BP.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DTsurutani%26aufirst%3DA.%2BC.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DRosenberg%26aufirst%3DS.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26atitle%3DABT-888%252C%2520an%2520orally%2520active%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520that%2520potentiates%2520DNA-damaging%2520agents%2520in%2520preclinical%2520tumor%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2728%26epage%3D2737%26doi%3D10.1158%2F1078-0432.CCR-06-3039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubisch, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernet, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carbox-amide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">6965</span><span class="NLM_x">–</span> <span class="NLM_lpage">6975</span><span class="refDoi"> DOI: 10.1016/j.bmc.2008.05.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.bmc.2008.05.044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=6965-6975&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=S.+Thomasauthor=W.+Lubischauthor=R.+Grandelauthor=W.+Wernetauthor=C.+H.+Parkauthor=E.+H.+Fryauthor=Y.+Luoauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=D.+J.+Frostauthor=C.+K.+Donawhoauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=S.+H.+Rosenbergauthor=V.+L.+Giranda&title=Discovery+and+SAR+of+2-%281-propylpiperidin-4-yl%29-1H-benzimidazole-4-carbox-amide%3A+A+potent+inhibitor+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmc.2008.05.044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.05.044%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DLubisch%26aufirst%3DW.%26aulast%3DGrandel%26aufirst%3DR.%26aulast%3DWernet%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25202-%25281-propylpiperidin-4-yl%2529-1H-benzimidazole-4-carbox-amide%253A%2520A%2520potent%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D6965%26epage%3D6975%26doi%3D10.1016%2Fj.bmc.2008.05.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">523</span><span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. I·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., I·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0ljsumx2JUX-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boshuizen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">–</span> <span class="NLM_lpage">5015</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1078-0432.CCR-13-1391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23881923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5003-5015&author=Y.+Shenauthor=F.+L.+Rehmanauthor=Y.+Fengauthor=J.+Boshuizenauthor=I.+Bajramiauthor=R.+Elliottauthor=B.+Wangauthor=C.+J.+Lordauthor=L.+E.+Postauthor=A.+Ashworth&title=BMN+673%2C+a+novel+and+highly+potent+PARP1%2F2+inhibitor+for+the+treatment+of+human+cancers+with+DNA+repair+deficiency&doi=10.1158%2F1078-0432.CCR-13-1391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency</span></div><div class="casAuthors">Shen, Yuqiao; Rehman, Farah L.; Feng, Ying; Boshuizen, Julia; Bajrami, Ilirjana; Elliott, Richard; Wang, Bing; Lord, Christopher J.; Post, Leonard E.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5003-5015</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.  Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  Exptl. Design: Potency and selectivity of BMN 673 was detd. by biochem. assays.  Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models.  Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested.  BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concns. than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib).  In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors.  BMN 673 is readily orally bioavailable, with more than 40% abs. oral bioavailability in rats when dosed in carboxylmethyl cellulose.  Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice.  Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs.  Conclusion: BMN 673 is currently in early-phase clin. development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.  Clin Cancer Res; 19(18); 5003-15. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdmHIVEuoz7Vg90H21EOLACvtfcHk0lhwiupWw0iGKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J&md5=f58b67f14784c0a0fa1197caffd8d96d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1391%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBoshuizen%26aufirst%3DJ.%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBMN%2520673%252C%2520a%2520novel%2520and%2520highly%2520potent%2520PARP1%252F2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%2520with%2520DNA%2520repair%2520deficiency%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5003%26epage%3D5015%26doi%3D10.1158%2F1078-0432.CCR-13-1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimshaw, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hixon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiryanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, P.</span><span> </span><span class="NLM_article-title">Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4501</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.bmcl.2013.06.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4501-4505&author=A.+R.+Gangloffauthor=J.+Brownauthor=R.+de+Jongauthor=D.+R.+Douganauthor=C.+E.+Grimshawauthor=M.+Hixonauthor=A.+Jenningsauthor=R.+Kamranauthor=A.+Kiryanovauthor=S.+O%E2%80%99Connellauthor=E.+Taylorauthor=P.+Vu&title=Discovery+of+novel+benzo%5Bb%5D%5B1%2C4%5Doxazin-3%284H%29-ones+as+poly%28ADP-ribose%29polymerase+inhibitors&doi=10.1016%2Fj.bmcl.2013.06.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.055%26sid%3Dliteratum%253Aachs%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3Dde%2BJong%26aufirst%3DR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DHixon%26aufirst%3DM.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DKamran%26aufirst%3DR.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DE.%26aulast%3DVu%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%2520benzo%255Bb%255D%255B1%252C4%255Doxazin-3%25284H%2529-ones%2520as%2520poly%2528ADP-ribose%2529polymerase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4501%26epage%3D4505%26doi%3D10.1016%2Fj.bmcl.2013.06.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ye, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huan, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2885</span><span class="NLM_x">–</span> <span class="NLM_lpage">2903</span><span class="refDoi"> DOI: 10.1021/jm301825t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301825t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslGhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2885-2903&author=N.+Yeauthor=C.+H.+Chenauthor=T.+Chenauthor=Z.+Songauthor=J.+X.+Heauthor=X.+J.+Huanauthor=S.+S.+Songauthor=Q.+Liuauthor=Y.+Chenauthor=J.+Dingauthor=Y.+Xuauthor=Z.+H.+Miaoauthor=A.+Zhang&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+benzo%5Bde%5D%5B1%2C7%5Dnaphthyridin-7%288H%29-ones+bearing+a+functionalized+longer+chain+appendage+as+novel+PARP1+inhibitors&doi=10.1021%2Fjm301825t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors</span></div><div class="casAuthors">Ye, Na; Chen, Chuan-Huizi; Chen, TianTian; Song, Zilan; He, Jin-Xue; Huan, Xia-Juan; Song, Shan-Shan; Liu, Qiufeng; Chen, Yi; Ding, Jian; Xu, Yechun; Miao, Ze-Hong; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2885-2903</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors.  The initial effort led to the first-generation PARP1 inhibitor I (X = NH) bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell.  Further effort generated the second-generation lead, cyclopenta[ij]isoquinolinone I [X = nothing; (II)], showing high potency against both the PARP1 enzyme and BRCA-deficient cells, esp. for the BRCA1-deficient MDA-MB-436 cells (CC50 < 0.26 nM).  Mechanistic studies revealed that the new PARP1 inhibitors significantly inhibited H2O2-triggered PARylation in SKOV3 cells, induced cellular accumulation of DNA double-strand breaks, and impaired cell-cycle progression in BRCA2-deficient cells.  Significant potentiation on the cytotoxicity of Temozolomide was also obsd.  The unique structural character and exceptionally high potency of II made it stand out as a promising drug candidate worthy for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFCnCaPH54gbVg90H21EOLACvtfcHk0lhwiupWw0iGKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslGhtL8%253D&md5=6f13946d5bb17bcfd8c1c00ae5b9a589</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm301825t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301825t%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DJ.%2BX.%26aulast%3DHuan%26aufirst%3DX.%2BJ.%26aulast%3DSong%26aufirst%3DS.%2BS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DMiao%26aufirst%3DZ.%2BH.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520benzo%255Bde%255D%255B1%252C7%255Dnaphthyridin-7%25288H%2529-ones%2520bearing%2520a%2520functionalized%2520longer%2520chain%2520appendage%2520as%2520novel%2520PARP1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2885%26epage%3D2903%26doi%3D10.1021%2Fjm301825t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busel, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caprera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Anello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khvat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasavin, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzetta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rainoldi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sola, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span> </span><span class="NLM_article-title">Discovery of 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): a Potent, Orally Available and Highly Selective PARP-1 Inhibitor for Cancer Therapy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6875</span><span class="NLM_x">–</span> <span class="NLM_lpage">6898</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00680</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00680" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6875-6898&author=G.+Papeoauthor=H.+Posteriauthor=D.+Borghiauthor=A.+A.+Buselauthor=F.+Capreraauthor=E.+Casaleauthor=M.+Ciomeiauthor=A.+Cirlaauthor=E.+Cortiauthor=M.+D%E2%80%99Anelloauthor=M.+Fasoliniauthor=B.+Forteauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+Khvatauthor=M.+Y.+Krasavinauthor=R.+Lupiauthor=P.+Orsiniauthor=R.+Peregoauthor=E.+Pesentiauthor=D.+Pezzettaauthor=S.+Rainoldiauthor=F.+Riccardi-Sirtoriauthor=A.+Scolaroauthor=F.+Solaauthor=F.+Zuccottoauthor=E.+R.+Felderauthor=D.+Donatiauthor=A.+Montagnoli&title=Discovery+of+2-%5B1-%284%2C4-difluorocyclohexyl%29piperidin-4-yl%5D-6-fluoro-3-oxo-2%2C3-dihydro-1H-isoindole-4-carboxamide+%28NMS-P118%29%3A+a+Potent%2C+Orally+Available+and+Highly+Selective+PARP-1+Inhibitor+for+Cancer+Therapy&doi=10.1021%2Facs.jmedchem.5b00680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBusel%26aufirst%3DA.%2BA.%26aulast%3DCaprera%26aufirst%3DF.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DCirla%26aufirst%3DA.%26aulast%3DCorti%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Anello%26aufirst%3DM.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DKhvat%26aufirst%3DA.%26aulast%3DKrasavin%26aufirst%3DM.%2BY.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPezzetta%26aufirst%3DD.%26aulast%3DRainoldi%26aufirst%3DS.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DSola%26aufirst%3DF.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DMontagnoli%26aufirst%3DA.%26atitle%3DDiscovery%2520of%25202-%255B1-%25284%252C4-difluorocyclohexyl%2529piperidin-4-yl%255D-6-fluoro-3-oxo-2%252C3-dihydro-1H-isoindole-4-carboxamide%2520%2528NMS-P118%2529%253A%2520a%2520Potent%252C%2520Orally%2520Available%2520and%2520Highly%2520Selective%2520PARP-1%2520Inhibitor%2520for%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6875%26epage%3D6898%26doi%3D10.1021%2Facs.jmedchem.5b00680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Shalinsky, D. R.</span>; <span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Preclinical chemosensitization by PARP inhibitors</span>. In  <span class="citation_source-book">PARP Inhibitors for Cancer Therapy</span>; <span class="NLM_contrib-group">Curtin, N.; Sharma, R.</span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">260</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1007%2F978-3-319-14151-0_9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=225-260&author=D.+R.+Shalinskyauthor=N.+Curtin&author=R.+Sharma&title=PARP+Inhibitors+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-14151-0_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-14151-0_9%26sid%3Dliteratum%253Aachs%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26atitle%3DPreclinical%2520chemosensitization%2520by%2520PARP%2520inhibitors%26btitle%3DPARP%2520Inhibitors%2520for%2520Cancer%2520Therapy%26aulast%3DCurtin%26aufirst%3DN.%26pub%3DHumana%2520Press%26date%3D2015%26spage%3D225%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span><span class="refDoi"> DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lhG0ef9m8VhVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span><span class="refDoi"> DOI: 10.1038/nature03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+J.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&doi=10.1038%2Fnature03445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0lhG0ef9m8VhVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%2BJ.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921%26doi%3D10.1038%2Fnature03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3785</span><span class="NLM_x">–</span> <span class="NLM_lpage">3790</span><span class="refDoi"> DOI: 10.1200/JCO.2008.16.0812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1200%2FJCO.2008.16.0812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=18591545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGjs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3785-3790&author=A.+Ashworth&title=A+synthetic+lethal+therapeutic+approach%3A+poly%28ADP%29+ribose+polymerase+inhibitors+for+the+treatment+of+cancers+deficient+in+DNA+double-strand+break+repair&doi=10.1200%2FJCO.2008.16.0812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair</span></div><div class="casAuthors">Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3785-3790</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability.  This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically.  Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCA2, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase.  This provides the basis for a novel synthetic lethal approach to cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXrRHAispvD7Vg90H21EOLACvtfcHk0ljzNxBvdzgokw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGjs7rL&md5=ae9227ee9c2fd4367264e738921fec2c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.16.0812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.16.0812%26sid%3Dliteratum%253Aachs%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DA%2520synthetic%2520lethal%2520therapeutic%2520approach%253A%2520poly%2528ADP%2529%2520ribose%2520polymerase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancers%2520deficient%2520in%2520DNA%2520double-strand%2520break%2520repair%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3785%26epage%3D3790%26doi%3D10.1200%2FJCO.2008.16.0812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings</span> <span class="citation_source-journal">Mol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span><span class="refDoi"> DOI: 10.1016/j.molonc.2011.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.molonc.2011.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=21821475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=387-393&author=T.+Helleday&title=The+underlying+mechanism+for+the+PARP+and+BRCA+synthetic+lethality%3A+clearing+up+the+misunderstandings&doi=10.1016%2Fj.molonc.2011.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings</span></div><div class="casAuthors">Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-393</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Poly (ADP-ribose) polymerase (PARP) inhibitors effectively kill tumors defective in the BRCA1 or BRCA2 genes through the concept of synthetic lethality.  It is suggested that PARP inhibitors cause an increase in DNA single-strand breaks (SSBs), which are converted during replication to irreparable toxic DNA double-strand breaks (DSBs) in BRCA1/2 defective cells.  There are a no. of recent reports challenging this model.  Here, alternative models that are not mutually exclusive are presented to explain the synthetic lethality between BRCA1/2 and PARP inhibitors.  One such model proposes that PARP inhibition causes PARP-1 to be trapped onto DNA repair intermediates, esp. during base excision repair.  This may in turn cause obstruction to replication forks, which require BRCA-dependent homologous recombination to be resolved.  In another model, PARP is directly involved in catalyzing replication repair in a distinct pathway from homologous recombination.  Exptl. evidence supporting these novel models to explain the PARP-BRCA synthetic lethality are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPUCIzO2NudrVg90H21EOLACvtfcHk0ljzNxBvdzgokw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyqtL%252FO&md5=1b64dde39e08d863e774de91a0fbe1e9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2011.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2011.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DThe%2520underlying%2520mechanism%2520for%2520the%2520PARP%2520and%2520BRCA%2520synthetic%2520lethality%253A%2520clearing%2520up%2520the%2520misunderstandings%26jtitle%3DMol.%2520Oncol.%26date%3D2011%26volume%3D5%26spage%3D387%26epage%3D393%26doi%3D10.1016%2Fj.molonc.2011.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Biomarkers of PARP inhibitor sensitivity</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1007/s10549-011-1375-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1007%2Fs10549-011-1375-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=21301956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A280%3ADC%252BC3MvitVOqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=283-286&author=N.+C.+Turnerauthor=A.+Ashworth&title=Biomarkers+of+PARP+inhibitor+sensitivity&doi=10.1007%2Fs10549-011-1375-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers of PARP inhibitor sensitivity</span></div><div class="casAuthors">Turner Nicholas C; Ashworth Alan</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research and treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">283-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqvWEtOUv36LJzI8owOhpDfW6udTcc2eaYGbY_maq-nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvitVOqsQ%253D%253D&md5=9d5a04417162585c252a39156f6650f4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1375-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1375-8%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBiomarkers%2520of%2520PARP%2520inhibitor%2520sensitivity%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D127%26spage%3D283%26epage%3D286%26doi%3D10.1007%2Fs10549-011-1375-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Trapping of PARP1 and PARP2 by clinical PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5588</span><span class="NLM_x">–</span> <span class="NLM_lpage">5599</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F0008-5472.CAN-12-2753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=23118055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=5588-5599&author=J.+Muraiauthor=S.+Y.+Huangauthor=B.+B.+Dasauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+H.+Doroshowauthor=J.+Jiauthor=S.+Takedaauthor=Y.+Pommier&title=Trapping+of+PARP1+and+PARP2+by+clinical+PARP+inhibitors&doi=10.1158%2F0008-5472.CAN-12-2753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-yin N.; Das, Benu Brata; Renaud, Amelie; Zhang, Yiping; Doroshow, James H.; Ji, Jiuping; Takeda, Shunichi; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5588-5599</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">These findings indicate that PARP inhibitors in clin. trials not only block catalytic function but also trap PARP enzymes on DNA, illuminating the mechanistic basis for their cytotoxic activity in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW3m55HXn9ObVg90H21EOLACvtfcHk0lg4CVoIsVYssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsF2jsLjE&md5=81c590b6a4fbb9efc9c64f7de5e89524</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2753%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DDas%26aufirst%3DB.%2BB.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DTrapping%2520of%2520PARP1%2520and%2520PARP2%2520by%2520clinical%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D5588%26epage%3D5599%26doi%3D10.1158%2F0008-5472.CAN-12-2753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">De Lorenzo, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="refDoi"> DOI: 10.3389/fonc.2013.00228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.3389%2Ffonc.2013.00228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=24062981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt1yqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=228&author=S.+B.+De+Lorenzoauthor=A.+G.+Patelauthor=R.+M.+Hurleyauthor=S.+H.+Kaufmann&title=The+elephant+and+the+blind+men%3A+making+sense+of+PARP+inhibitors+in+homologous+recombination+deficient+tumor+cells&doi=10.3389%2Ffonc.2013.00228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells</span></div><div class="casAuthors">De Lorenzo Silvana B; Patel Anand G; Hurley Rachel M; Kaufmann Scott H</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Poly(ADP-ribose) polymerase 1 (PARP1) is an important component of the base excision repair (BER) pathway as well as a regulator of homologous recombination (HR) and non-homologous end-joining (NHEJ).  Previous studies have demonstrated that treatment of HR-deficient cells with PARP inhibitors results in stalled and collapsed replication forks.  Consequently, HR-deficient cells are extremely sensitive to PARP inhibitors.  Several explanations have been advanced to explain this so-called synthetic lethality between HR deficiency and PARP inhibition: (i) reduction of BER activity leading to enhanced DNA double-strand breaks, which accumulate in the absence of HR; (ii) trapping of inhibited PARP1 at sites of DNA damage, which prevents access of other repair proteins; (iii) failure to initiate HR by poly(ADP-ribose) polymer-dependent BRCA1 recruitment; and (iv) activation of the NHEJ pathway, which selectively induces error-prone repair in HR-deficient cells.  Here we review evidence regarding these various explanations for the ability of PARP inhibitors to selectively kill HR-deficient cancer cells and discuss their potential implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiyQIXPBx6kVm8bhe6roZYfW6udTcc2eYTxfoRdUnlurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt1yqtA%253D%253D&md5=3dc80d23dca912a20c717677a3e31ed8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00228%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLorenzo%26aufirst%3DS.%2BB.%26aulast%3DPatel%26aufirst%3DA.%2BG.%26aulast%3DHurley%26aufirst%3DR.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DThe%2520elephant%2520and%2520the%2520blind%2520men%253A%2520making%2520sense%2520of%2520PARP%2520inhibitors%2520in%2520homologous%2520recombination%2520deficient%2520tumor%2520cells%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D228%26doi%3D10.3389%2Ffonc.2013.00228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Murai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span> </span><span class="NLM_article-title">Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1535-7163.MCT-13-0803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=24356813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=433-443&author=J.+Muraiauthor=S.+Y.+Huangauthor=A.+Renaudauthor=Y.+Zhangauthor=J.+Jiauthor=S.+Takedaauthor=J.+Morrisauthor=B.+Teicherauthor=J.+H.+Doroshowauthor=Y.+Pommier&title=Stereospecific+PARP+trapping+by+BMN+673+and+comparison+with+olaparib+and+rucaparib&doi=10.1158%2F1535-7163.MCT-13-0803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib</span></div><div class="casAuthors">Murai, Junko; Huang, Shar-Yin N.; Renaud, Amelie; Zhang, Yiping; Ji, Jiuping; Takeda, Shunichi; Morris, Joel; Teicher, Beverly; Doroshow, James H.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks.  We recently reported that several PARP inhibitors have an addnl. cytotoxic mechanism by trapping PARP-DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacol. concns.  Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP-DNA trapping.  Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clin. PARP inhibitors, olaparib and rucaparib, using biochem. and cellular assays in genetically modified chicken DT40 and human cancer cell lines.  Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP-DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP-DNA complexes.  The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2.  Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient.  BMN 673 is also approx. 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents Me methane sulfonate (MMS) and temozolomide.  Our study demonstrates that BMN 673 is the most potent clin. PARP inhibitor tested to date with the highest efficiency at trapping PARP-DNA complexes.  Mol Cancer Ther; 13(2); 433-43. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8p5YTwAneh7Vg90H21EOLACvtfcHk0lg4CVoIsVYssw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmtr4%253D&md5=513c544d1cb5c2203e7696af76201afd</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0803%26sid%3Dliteratum%253Aachs%26aulast%3DMurai%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%2BY.%26aulast%3DRenaud%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DStereospecific%2520PARP%2520trapping%2520by%2520BMN%2520673%2520and%2520comparison%2520with%2520olaparib%2520and%2520rucaparib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D433%26epage%3D443%26doi%3D10.1158%2F1535-7163.MCT-13-0803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span> </span><span class="NLM_article-title">Trapping poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1124/jpet.114.222448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1124%2Fjpet.114.222448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25758918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=446-457&author=J.+Shenauthor=M.+Aoyagi-Scharberauthor=B.+Wang&title=Trapping+poly%28ADP-ribose%29+polymerase&doi=10.1124%2Fjpet.114.222448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Shen, Yuqiao; Aoyagi-Scharber, Mika; Wang, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-457</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage.  The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.  Several clin.-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.  Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells.  In this article, we review the available data on mol. interactions between these clin.-stage PARP inhibitors and PARP proteins, and discuss how their biol. differences might be explained by the trapping mechanism.  We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7H8kc8UmXLVg90H21EOLACvtfcHk0ljaqk9bm4eD-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D&md5=36ceb95db0a63ab9ce002906df555482</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.222448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.222448%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DTrapping%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D446%26epage%3D457%26doi%3D10.1124%2Fjpet.114.222448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of poly(ADP-ribose) polymerase inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">–</span> <span class="NLM_lpage">4584</span><span class="refDoi"> DOI: 10.1021/jm100012m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+poly%28ADP-ribose%29+polymerase+inhibitors.+From+concept+to+clinic&doi=10.1021%2Fjm100012m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584%26doi%3D10.1021%2Fjm100012m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Optimization of phenyl-substituted benzimidazole carboxamide poly (ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3142</span><span class="NLM_x">–</span> <span class="NLM_lpage">3153</span><span class="refDoi"> DOI: 10.1021/jm901775y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901775y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3142-3153&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=J.+Gongauthor=S.+Thomasauthor=V.+B.+Gandhiauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+H.+Parkauthor=E.+H.+Fryauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=F.+G.+Buchananauthor=G.+T.+Bukofzerauthor=L.+E.+Rodriguezauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Optimization+of+phenyl-substituted+benzimidazole+carboxamide+poly+%28ADP-ribose%29+polymerase+inhibitors%3A+identification+of+%28S%29-2-%282-fluoro-4-%28pyrrolidin-2-yl%29phenyl%29-1H-benzimidazole-4-carboxamide+%28A-966492%29%2C+a+highly+potent+and+efficacious+inhibitor&doi=10.1021%2Fjm901775y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901775y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901775y%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DFry%26aufirst%3DE.%2BH.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBuchanan%26aufirst%3DF.%2BG.%26aulast%3DBukofzer%26aufirst%3DG.%2BT.%26aulast%3DRodriguez%26aufirst%3DL.%2BE.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DOptimization%2520of%2520phenyl-substituted%2520benzimidazole%2520carboxamide%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitors%253A%2520identification%2520of%2520%2528S%2529-2-%25282-fluoro-4-%2528pyrrolidin-2-yl%2529phenyl%2529-1H-benzimidazole-4-carboxamide%2520%2528A-966492%2529%252C%2520a%2520highly%2520potent%2520and%2520efficacious%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3142%26epage%3D3153%26doi%3D10.1021%2Fjm901775y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardberg, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yip, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzpatrick, P. A.</span><span> </span><span class="NLM_article-title">Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from tetrahydropyridophthalazinone</span> <span class="citation_source-journal">Acta Crystallogr., Sect. F: Struct. Biol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1107/S2053230X14015088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1107%2FS2053230X14015088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25195882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=1143-1149&author=M.+Aoyagi-Scharberauthor=A.+S.+Gardbergauthor=B.+K.+Yipauthor=B.+Wangauthor=Y.+Shenauthor=P.+A.+Fitzpatrick&title=Structural+basis+for+the+inhibition+of+poly%28ADP-ribose%29+polymerases+1+and+2+by+BMN+673%2C+a+potent+inhibitor+derived+from+tetrahydropyridophthalazinone&doi=10.1107%2FS2053230X14015088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone</span></div><div class="casAuthors">Aoyagi-Scharber, Mika; Gardberg, Anna S.; Yip, Bryan K.; Wang, Bing; Shen, Yuqiao; Fitzpatrick, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1143-1149</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2), which are involved in DNA damage response, are targets of anticancer therapeutics.  BMN 673 is a novel PARP1/2 inhibitor with substantially increased PARP-mediated tumor cytotoxicity and is now in later-stage clin. development for BRCA-deficient breast cancers.  Here, in co-crystal structures, BMN 673 was anchored to the nicotinamide-binding pocket via an extensive network of H-bonding and π-stacking interactions, including those mediated by active site water mols.  The novel di-branched scaffold of BMN 673 extended the binding interactions toward the outer edges of the pocket, which exhibited the least sequence homol. among PARP enzymes.  The crystallog. structural analyses reported here therefore not only provide crit. insights into the mol. basis for the exceptionally high potency of the clin. development candidate BMN 673, but also new opportunities for increasing inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3neiOqbsUprVg90H21EOLACvtfcHk0ljaqk9bm4eD-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsV2qt77I&md5=6d75628ad833fa618eac02e72f326666</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS2053230X14015088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X14015088%26sid%3Dliteratum%253Aachs%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DGardberg%26aufirst%3DA.%2BS.%26aulast%3DYip%26aufirst%3DB.%2BK.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DFitzpatrick%26aufirst%3DP.%2BA.%26atitle%3DStructural%2520basis%2520for%2520the%2520inhibition%2520of%2520poly%2528ADP-ribose%2529%2520polymerases%25201%2520and%25202%2520by%2520BMN%2520673%252C%2520a%2520potent%2520inhibitor%2520derived%2520from%2520tetrahydropyridophthalazinone%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2014%26volume%3D70%26spage%3D1143%26epage%3D1149%26doi%3D10.1107%2FS2053230X14015088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">de Bono, J.; Mina, L. A.; Gonzalez, M.; Curtin, N. J.; Wang, E.; Henshaw, J. W.; Chadha, M.; Sachdev, J. C.; Matei, D.; Jameson, G. S.; Ong, M.; Basu, B.; Wainberg, Z. A.; Byers, L.; Chugh, R.</span><span> </span><span class="NLM_article-title">First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 31–June 4</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Abstract 2580.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&conference=ASCO&author=J.+de+Bono&author=L.+A.+Mina&author=M.+Gonzalez&author=N.+J.+Curtin&author=E.+Wang&author=J.+W.+Henshaw&author=M.+Chadha&author=J.+C.+Sachdev&author=D.+Matei&author=G.+S.+Jameson&author=M.+Ong&author=B.+Basu&author=Z.+A.+Wainberg&author=L.+Byers&author=R.+Chugh&title=First-in-human+trial+of+novel+oral+PARP+inhibitor+BMN+673+in+patients+with+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBono%26aufirst%3DJ.%26atitle%3DFirst-in-human%2520trial%2520of%2520novel%2520oral%2520PARP%2520inhibitor%2520BMN%2520673%2520in%2520patients%2520with%2520solid%2520tumors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Wainberg, Z. A.; Rafii, S.; Ramanathan, R. K.; Mina, L. A.; Byers, L. A.; Chugh, R.; Goldman, J. W.; Sachdev, J.; Matei, D.; Wheler, J. J.; Henshaw, J. W.; Zhang, C.; Gallant, G. J. A.; de Bono, J. S.</span><span> </span><span class="NLM_article-title">Safety and antitumor activity of the PARP inhibitor BMN 673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA mutation carrier cancer patients</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 30–June 3</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>Abstract 7522.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&conference=ASCO&author=Z.+A.+Wainberg&author=S.+Rafii&author=R.+K.+Ramanathan&author=L.+A.+Mina&author=L.+A.+Byers&author=R.+Chugh&author=J.+W.+Goldman&author=J.+Sachdev&author=D.+Matei&author=J.+J.+Wheler&author=J.+W.+Henshaw&author=C.+Zhang&author=G.+J.+A.+Gallant&author=J.+S.+de+Bono&title=Safety+and+antitumor+activity+of+the+PARP+inhibitor+BMN+673+in+a+phase+1+trial+recruiting+metastatic+small-cell+lung+cancer+%28SCLC%29+and+germline+BRCA+mutation+carrier+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26atitle%3DSafety%2520and%2520antitumor%2520activity%2520of%2520the%2520PARP%2520inhibitor%2520BMN%2520673%2520in%2520a%2520phase%25201%2520trial%2520recruiting%2520metastatic%2520small-cell%2520lung%2520cancer%2520%2528SCLC%2529%2520and%2520germline%2520BRCA%2520mutation%2520carrier%2520cancer%2520patients%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorlick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keir, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billups, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyalin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurmasheva, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, P. J.</span><span> </span><span class="NLM_article-title">Synergistic activity of PARP inhibition by talazoparib (BMN 673) with Temozolomide in pediatric cancer models in the pediatric preclinical testing program</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1158%2F1078-0432.CCR-14-2572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25500058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=819-832&author=M.+A.+Smithauthor=C.+P.+Reynoldsauthor=M.+H.+Kangauthor=E.+A.+Kolbauthor=R.+Gorlickauthor=H.+Carolauthor=R.+B.+Lockauthor=S.+T.+Keirauthor=J.+M.+Marisauthor=C.+A.+Billupsauthor=D.+Lyalinauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghton&title=Synergistic+activity+of+PARP+inhibition+by+talazoparib+%28BMN+673%29+with+Temozolomide+in+pediatric+cancer+models+in+the+pediatric+preclinical+testing+program&doi=10.1158%2F1078-0432.CCR-14-2572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program</span></div><div class="casAuthors">Smith, Malcolm A.; Reynolds, C. Patrick; Kang, Min H.; Kolb, E. Anders; Gorlick, Richard; Carol, Hernan; Lock, Richard B.; Keir, Stephen T.; Maris, John M.; Billups, Catherine A.; Lyalin, Dmitry; Kurmasheva, Raushan T.; Houghton, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">819-832</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Inhibitors of PARP, an enzyme involved in base excision repair, have demonstrated single-agent activity against tumors deficient in homologous repair processes.  Ewing sarcoma cells are also sensitive to PARP inhibitors, although the mechanism is not understood.  Here, we evaluated the stereo-selective PARP inhibitor, talazoparib (BMN 673), combined with temozolomide or topotecan.  Exptl. Design: Talazoparib was tested in vitro in combination with temozolomide (0.3-1,000 μmol/L) or topotecan (0.03-100 nmol/L) and in vivo at a dose of 0.1 mg/kg administered twice daily for 5 days combined with temozolomide (30 mg/kg/daily x 5; combination A) or 0.25 mg/kg administered twice daily for 5 days combined with temozolomide (12 mg/kg/daily x 5; combination B).  Pharmacodynamic studies were undertaken after 1 or 5 days of treatment.  Results: In vitro talazoparib potentiated the toxicity of temozolomide up to 85-fold, with marked potentiation in Ewing sarcoma and leukemia lines (30-50-fold).  There was less potentiation for topotecan.  In vivo, talazoparib potentiated the toxicity of temozolomide, and combination A and combination B represent the MTDs when combined with low-dose or high-dose talazoparib, resp.  Both combinations demonstrated significant synergism against 5 of 10 Ewing sarcoma xenografts.  The combination demonstrated modest activity against most other xenograft models.  Pharmacodynamic studies showed a treatment-induced complete loss of PARP only in tumor models sensitive to either talazoparib alone or talazoparib plus temozolomide.  Conclusions: The high level of activity obsd. for talazoparib plus temozolomide in Ewing sarcoma xenografts makes this an interesting combination to consider for pediatric evaluation.  Clin Cancer Res; 21(4); 819-32. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRSU7OIbk0urVg90H21EOLACvtfcHk0lgPZcgOvw4-fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGgsL4%253D&md5=eb7b7d7224fa3700fd624d6074712a69</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2572%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DLyalin%26aufirst%3DD.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26atitle%3DSynergistic%2520activity%2520of%2520PARP%2520inhibition%2520by%2520talazoparib%2520%2528BMN%2520673%2529%2520with%2520Temozolomide%2520in%2520pediatric%2520cancer%2520models%2520in%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D819%26epage%3D832%26doi%3D10.1158%2F1078-0432.CCR-14-2572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Stewart, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goshorn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benavente, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twarog, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caufield, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahrami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlström, Å.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsurkan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatfield, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiagarajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirinifard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sablauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelat, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, M. A.</span><span> </span><span class="NLM_article-title">Targeting the DNA Repair Pathway in Ewing Sarcoma</span> <span class="citation_source-journal">Cell Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">829</span><span class="NLM_x">–</span> <span class="NLM_lpage">840</span><span class="refDoi"> DOI: 10.1016/j.celrep.2014.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1016%2Fj.celrep.2014.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=25437539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVantbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=829-840&author=E.+Stewartauthor=R.+Goshornauthor=C.+Bradleyauthor=L.+M.+Griffithsauthor=C.+Benaventeauthor=N.+R.+Twarogauthor=G.+M.+Millerauthor=W.+Caufieldauthor=B.+B.+Freemanauthor=A.+Bahramiauthor=A.+Pappoauthor=J.+Wuauthor=A.+Lohauthor=%C3%85.+Karlstr%C3%B6mauthor=C.+Calabreseauthor=B.+Gordonauthor=L.+Tsurkanauthor=M.+J.+Hatfieldauthor=P.+M.+Potterauthor=S.+E.+Snyderauthor=S.+Thiagarajanauthor=A.+Shirinifardauthor=A.+Sablauerauthor=A.+A.+Shelatauthor=M.+A.+Dyer&title=Targeting+the+DNA+Repair+Pathway+in+Ewing+Sarcoma&doi=10.1016%2Fj.celrep.2014.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA Repair Pathway in Ewing Sarcoma</span></div><div class="casAuthors">Stewart, Elizabeth; Goshorn, Ross; Bradley, Cori; Griffiths, Lyra M.; Benavente, Claudia; Twarog, Nathaniel R.; Miller, Gregory M.; Caufield, William; Freeman, Burgess B. III; Bahrami, Armita; Pappo, Alberto; Wu, Jianrong; Loh, Amos; Karlstrom, Asa; Calabrese, Chris; Gordon, Brittney; Tsurkan, Lyudmila; Hatfield, M. Jason; Potter, Philip M.; Snyder, Scott E.; Thiagarajan, Suresh; Shirinifard, Abbas; Sablauer, Andras; Shelat, Anang A.; Dyer, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">829-840</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ewing sarcoma (EWS) is a tumor of the bone and soft tissue that primarily affects adolescents and young adults.  With current therapies, 70% of patients with localized disease survive, but patients with metastatic or recurrent disease have a poor outcome.  We found that EWS cell lines are defective in DNA break repair and are sensitive to PARP inhibitors (PARPis).  PARPi-induced cytotoxicity in EWS cells was 10- to 1,000-fold higher after administration of the DNA-damaging agents irinotecan or temozolomide.  We developed an orthotopic EWS mouse model and performed pharmacokinetic and pharmacodynamic studies using three different PARPis that are in clin. development for pediatric cancer.  Irinotecan administered on a low-dose, protracted schedule previously optimized for pediatric patients was an effective DNA-damaging agent when combined with PARPis; it was also better tolerated than combinations with temozolomide.  Combining PARPis with irinotecan and temozolomide gave complete and durable responses in more than 80% of the mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXVo1kI7i2vLVg90H21EOLACvtfcHk0lgPZcgOvw4-fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVantbbN&md5=ed18f79a51857f793b95d25af21270ff</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DStewart%26aufirst%3DE.%26aulast%3DGoshorn%26aufirst%3DR.%26aulast%3DBradley%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DL.%2BM.%26aulast%3DBenavente%26aufirst%3DC.%26aulast%3DTwarog%26aufirst%3DN.%2BR.%26aulast%3DMiller%26aufirst%3DG.%2BM.%26aulast%3DCaufield%26aufirst%3DW.%26aulast%3DFreeman%26aufirst%3DB.%2BB.%26aulast%3DBahrami%26aufirst%3DA.%26aulast%3DPappo%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLoh%26aufirst%3DA.%26aulast%3DKarlstr%25C3%25B6m%26aufirst%3D%25C3%2585.%26aulast%3DCalabrese%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DB.%26aulast%3DTsurkan%26aufirst%3DL.%26aulast%3DHatfield%26aufirst%3DM.%2BJ.%26aulast%3DPotter%26aufirst%3DP.%2BM.%26aulast%3DSnyder%26aufirst%3DS.%2BE.%26aulast%3DThiagarajan%26aufirst%3DS.%26aulast%3DShirinifard%26aufirst%3DA.%26aulast%3DSablauer%26aufirst%3DA.%26aulast%3DShelat%26aufirst%3DA.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BA.%26atitle%3DTargeting%2520the%2520DNA%2520Repair%2520Pathway%2520in%2520Ewing%2520Sarcoma%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D9%26spage%3D829%26epage%3D840%26doi%3D10.1016%2Fj.celrep.2014.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Flack, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardinelli, G.</span><span> </span><span class="NLM_article-title">Reporting and evaluating absolute-structure and absolute-configuration determinations</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1143</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span><span class="refDoi"> DOI: 10.1107/S0021889800007184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1107%2FS0021889800007184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsl2isbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2000&pages=1143-1148&author=H.+D.+Flackauthor=G.+Bernardinelli&title=Reporting+and+evaluating+absolute-structure+and+absolute-configuration+determinations&doi=10.1107%2FS0021889800007184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Reporting and evaluating absolute-structure and absolute-configuration determinations</span></div><div class="casAuthors">Flack, H. D.; Bernardinelli, G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1143-1148</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A discussion, with ∼34 refs.  Detailed practical and numerical information is provided for undertaking and evaluating abs.-structure and abs.-configuration detns.  The interpretation of numerical values of x, the Flack parameter, and its std. uncertainty u are explained in terms of the inversion-distinguishing power.  Also, the conditions to obtain reliable values of x(u) are detailed.  Further explanatory material is provided on the use of right-handed axes, valid intensity data, the application to macromol. structures, the dangers of polar-dispersion errors, Euclidean normalizers of space groups, the detection and reporting of mol. symmetry, enantiopurity and optical activity in soln.  New CIF data names are introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6yJBh7Ya8arVg90H21EOLACvtfcHk0lh9xjx_2t5TXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsl2isbY%253D&md5=b69fce3ec144b7ad60344bcf1c164afe</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1107%2FS0021889800007184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889800007184%26sid%3Dliteratum%253Aachs%26aulast%3DFlack%26aufirst%3DH.%2BD.%26aulast%3DBernardinelli%26aufirst%3DG.%26atitle%3DReporting%2520and%2520evaluating%2520absolute-structure%2520and%2520absolute-configuration%2520determinations%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2000%26volume%3D33%26spage%3D1143%26epage%3D1148%26doi%3D10.1107%2FS0021889800007184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Integration, scaling, space-group assignment and post-refinement</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span><span class="refDoi"> DOI: 10.1107/S0907444909047374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=10.1107%2FS0907444909047374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=20124693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=133-144&author=W.+Kabsch&title=Integration%2C+scaling%2C+space-group+assignment+and+post-refinement&doi=10.1107%2FS0907444909047374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Integration, scaling, space-group assignment and post-refinement</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Important steps in the processing of rotation data are described that are common to most software packages.  These programs differ in the details and in the methods implemented to carry out the tasks.  Here, the working principles underlying the data-redn. package XDS are explained, including the new features of automatic detn. of spot size and reflecting range, recognition and assignment of crystal symmetry and a highly efficient algorithm for the detn. of correction/scaling factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGW7t3Bb1P_rVg90H21EOLACvtfcHk0lh9xjx_2t5TXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D&md5=eb1db34f3c959b4921771eb9f57b2159</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047374%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DIntegration%252C%2520scaling%252C%2520space-group%2520assignment%2520and%2520post-refinement%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D133%26epage%3D144%26doi%3D10.1107%2FS0907444909047374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Litton, J. K.; Blum, J. L.; Im, Y. H.; Martin, M.; Mina, L.; Roche, H.; Rugo, H. S.; Visco, F.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Eiermann, W.</span><span> </span><span class="NLM_article-title">A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRCA)</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 29–Jun 2</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>Poster TPS1107.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&conference=ASCO&author=J.+K.+Litton&author=J.+L.+Blum&author=Y.+H.+Im&author=M.+Martin&author=L.+Mina&author=H.+Roche&author=H.+S.+Rugo&author=F.+Visco&author=C.+Zhang&author=N.+A.+Lokker&author=D.+L.+Lounsbury&author=W.+Eiermann&title=A+phase+3%2C+open-label%2C+randomized%2C+parallel%2C+2-arm+international+study+of+the+oral+PARP+inhibitor+talazoparib+%28BMN+673%29+in+germline+BRCA+mutation+subjects+with+locally+advanced+and%2For+metastatic+breast+cancer+%28EMBRCA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26atitle%3DA%2520phase%25203%252C%2520open-label%252C%2520randomized%252C%2520parallel%252C%25202-arm%2520international%2520study%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520talazoparib%2520%2528BMN%2520673%2529%2520in%2520germline%2520BRCA%2520mutation%2520subjects%2520with%2520locally%2520advanced%2520and%252For%2520metastatic%2520breast%2520cancer%2520%2528EMBRCA%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Turner, N. C.; Balmaña, J.; Fasching, P. A.; Hurvitz, S. A.; Telli, M. L.; Visco, F.; Wardley, A. M.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Robson, M. E.</span><span> </span><span class="NLM_article-title">A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)</span>, <span class="NLM_conf-name">ASCO</span>, <span class="NLM_conf-loc">Chicago, IL</span>, <span class="NLM_conf-date">May 29–Jun 2</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>Poster TPS1108.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&conference=ASCO&author=N.+C.+Turner&author=J.+Balma%C3%B1a&author=P.+A.+Fasching&author=S.+A.+Hurvitz&author=M.+L.+Telli&author=F.+Visco&author=A.+M.+Wardley&author=C.+Zhang&author=N.+A.+Lokker&author=D.+L.+Lounsbury&author=M.+E.+Robson&title=A+phase+2+study+%282-stage%2C+2-cohort%29+of+the+oral+PARP+inhibitor+talazoparib+%28BMN+673%29+in+patients+with+germline+BRCA+mutation+and+locally+advanced+and%2For+metastatic+breast+cancer+%28ABRAZO%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DA%2520phase%25202%2520study%2520%25282-stage%252C%25202-cohort%2529%2520of%2520the%2520oral%2520PARP%2520inhibitor%2520talazoparib%2520%2528BMN%2520673%2529%2520in%2520patients%2520with%2520germline%2520BRCA%2520mutation%2520and%2520locally%2520advanced%2520and%252For%2520metastatic%2520breast%2520cancer%2520%2528ABRAZO%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Case, D. A.</span>; <span class="NLM_etal"></span>AMBER 10; <span class="NLM_publisher-name">University of California</span>: <span class="NLM_publisher-loc">San Francisco, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+A.+Case&title=AMBER+10"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26jtitle%3DAMBER%252010%26pub%3DUniversity%2520of%2520California%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PJT','PDB','4PJT'); return false;">PDB: 4PJT</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i155"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01498">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52348"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01498">10.1021/acs.jmedchem.5b01498</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR spectra including <sup>1</sup>H NMR, <sup>13</sup>C NMR, HMBC, and HSQC for (8<i>S</i>,9<i>R</i>)-<b>47</b>; optical rotation measurement for (8<i>S</i>,9<i>R</i>)-<b>47</b> and (8<i>R</i>,9<i>S</i>)-<b>47</b>; single-crystal structure information for (8<i>S</i>,9<i>R</i>)-<b>47</b> and (2<i>S</i>,3<i>R</i>)-<b>60a</b>; SMILES strings for the compounds shown in <a class="ref internalNav" href="#tbl1">Tables 1</a>–<a class="ref showTableEvent internalNav" href="#tbl3">3</a>; enantiomeric purity analysis for the compounds shown in <a class="ref internalNav" href="#tbl3">Table 3</a>; and mouse body weight in xenograft model studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01498/suppl_file/jm5b01498_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01498/suppl_file/jm5b01498_si_001.pdf">jm5b01498_si_001.pdf (1.18 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01498&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-1%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01498%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01498" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679916c92b803c82","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
